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DALE Disability adjusted life expectancy
DALY(s) Disability adjusted life year(s)
DfID (UK) Department for International Development
EQ5D EuroQol five dimensional questionnaire on health-related
quality of life
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YLD(s) Year(s) of life lost from disability
YLL(s) Year(s) of life lost from premature death
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What are DALYs?
Disability adjusted life years (DALYs) are used to calculate life years
lost from a wide range of diseases and injuries, adjusted for assump-
tions about the severity of mental or physical disability as well as age
and discounted over time.  Thus DALYs are one way of measuring the
loss from living a shorter life with disease rather than living a longer
life without disease.  At present DALYs are a tool of estimation using
secondary data, rather than one developed for primary data collection.
Why were DALYs developed?
DALYs were developed to help shape the of health policies of interna-
tional institutions such as the World Bank and World Health
Organisation.  Their introduction was designed to broaden the usual
focus of these institutions from measuring disease in terms of mortal-
ity and morbidity to including an estimate of the impact of morbidi-
ty.  As the focus of the institutions was international, the DALY was
intended to enable many forms of comparison: across diseases, coun-
tries, curative/preventive care as well as different time periods.
Once calculated, the two prime purposes of DALYs were: as an
input to the calculation of the global burden of disease and as an out-
come measure for use in cost-effectiveness analysis.  Both were intend-
ed to influence the:
● prioritisation of health care spending within and across countries
for curative and preventive care;
● flow of funds within health research and development;
● identification of disadvantaged groups for targeting health inter-
ventions;
● composition of training for clinical and health practitioners;
● methods for assessing performance in health projects and health
systems.
How are DALYs constructed?
DALYs have evolved over time and are still under development.  The
Mark 1 version was presented in the World Bank’s 1993 ‘World
Development Report’ and the Mark 2 (superseding Mark 1) was out-
lined in the WHO’s and World Bank’s ‘Global Burden of Disease’
9
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series.  Both versions are calculated as weighted combinations of the
following four components.
Life expectancy: Where DALYS are used to measure the burden of a
disease, this is based on the ‘standard expected years of life lost’
approach.  It imposes an ideal length of life expected on each popula-
tion and measures the burden of a disease in terms of life lost from that
point.  The idealised standard chosen was the highest national life
expectancy at birth observed globally.  This was in Japan, with females
having a life expectancy at birth of 82.5 years and males 80 years, after
accounting for the riskier behaviour of men.  However, in cost-effec-
tiveness analysis we need to measure the impact of an intervention, i.e.
the different qualities and quantities of life experienced by patients
with and without treatment.  In those cases it is recommended that
DALYs are calculated using the relevant national life expectancy, if
mortality is stable and the intervention lasts no more than one year.  If
these conditions do not hold, then either a cohort approach or a
dynamic population model will be needed.
The value of life at different ages: Each year of life lived is weighted
differently according to the age of a person.  The highest values are
given to 20-40 year olds and the lowest values to those younger than
five or older than 90.  The shape of the age weighting function was
chosen because it reflected two views:
● people aged 20-40 are more likely to be looking after young chil-
dren or elderly relatives and therefore poor health during these
years would be particularly detrimental to others;
● because people’s productivity (reflected in the value of wages)
tends to be higher during this age range.
The value of future time: Each year of future life is discounted at an
annual rate of 3 percent so that each additional year is, from the per-
spective of the present, worth a little less than the preceding year.
Therefore, at the age of 40, an additional year of life is worth 0.3 com-
pared with 0.5 at the age of 20 and 0.1 at the age of 60.  This pattern
of values is argued to reflect individuals’ preferences for benefits soon-
10
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er rather than later, as well as the small risks of death in any particular
year and the diminishing marginal utility of additional life years.
The value of avoiding disability: The impact of disease on disability is
weighted between zero (representing healthiness) and 1 (representing
death), which is an inversion of the scale used by quality adjusted life
years (QALYs).  This part of the DALY has evolved most over time.
The weights for the Mark 2 version were developed using technical
descriptions of 22 conditions (e.g. blindness, active psychosis).  A
small group of international health professionals were asked to rate
and discuss the value of each condition in two ways, by considering
the value of extending the lives of healthy people compared with:
● extending the life of people with the specified condition;
● curing the disability of people with the specified condition.
The median point from this group was the weight adopted for the
condition.  An arbitrary cutting of the 0-1 scale into seven unequal
sizes was used to group the 22 conditions and then used to place sev-
eral hundred other diseases into each category (for which each was
assigned the mid-point value of the category).  To move from these
severity weights to a disability weight for a disease involved multiply-
ing the severity weight by the proportion of incident cases of a disease
expected to suffer disability at each level of severity.
How have DALYs been used?
The table below shows the four main ways in which DALYs have been
used to date by the original developers and others.  The main differ-
ences are that the original developers apply DALYs globally rather
than locally, to a wider range of diseases, and that they are more con-
sistent in the assumptions they use for weighting DALYs.
The most frequent use for DALYs by both groups has been as an
indicator of the burden of disease.  There are a few cost-effectiveness
analyses and none for interventions amongst people from high-income
countries.  The sectoral analyses have combined national burden of
disease estimates with cost-effectiveness analyses for a limited number
of interventions.  These have been used to plan the provision of a min-
imum package of essential health services in over 20 low/middle
11
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income countries and the results have often formed the basis of World
Bank loans for health sector development.
What are the principal criticisms of DALYs?
Disagreement with the presence and contribution of each weighted
component:
● The use of an idealised life expectancy in calculating the burden of
a disease is not relevant to national planning and fosters, rather
than reduces, inequity between countries.  In effect, older people
in richer countries are accorded more weight than younger people
in poorer countries.
● The value of living a healthy life at different ages during a person’s
lifetime may have become confused with the value of time and the
greater likelihood that older people are disabled.  Therefore the
impact of disability at different ages may have been double counted.
● As the developers of DALYs rejected human capital theory for
valuing age, it is inconsistent of them to draw on the same theory
for valuing future time.  The arbitrary choice of a 3 percent annu-
al discount rate has little empirical evidence to justify it and is
unlikely to reflect globally held preferences.
EXECUTIVE SU M MARY
Type of use By DALY developers By others
Burden of World Health Organisation/ National (e.g. Australia) and
disease World Bank global burden sub-national (e.g. regions in
of disease exercise the UK) burdens of disease;
individual diseases
Cost- The World Bank health Cost-effectiveness analysis
effectiveness sector priorities review for of alternative treatments in
analysis low/middle income specific low-income
countries countries
Sectoral Mexico (country) Turkey (country)
analysis Tanzania (district)
Planning WHO (1996) report on NIH post-hoc justification
health R&D investing in health R&D of R&D spending
How DALYs have been used
● The two ways used to lead health professionals to choose weights
for conditions are based on unacceptable ethical principals.  Also,
forcing a consistency in answers between the two approaches
means that even the preferences of the few professionals selected
were sometimes ignored.
In practice one of the main problems in using DALYs is the way
that analysts report results.  Few report the assumptions used or test
the sensitivity of results to the assumptions.  This hampers compara-
bility between studies and lends support to calls for the time and age
weights to be taken out of the baseline disability weighting formula.
Disagreement about whose values are, and should be, represented:
● The limited focus of DALYs on disease and some aspects of dis-
ability, means that many benefits of interventions that improve
health and welfare are not measured.  It also means that the only
way that co-morbidity within a person is included is by adding up
weights for each disease separately.  Unfortunately this means that
the benefits expected from an intervention may not be realised
because it is not linked to the reality of disease and illness within
people.
● There has been a strong reaction against the view that people expe-
riencing disease are unable to give a truthful account of their con-
dition and that the biomedical models of disease and preferences
of English speaking health professionals should be used exclusive-
ly to determine global resource allocation.
● The DALY approach ignores decades of research showing that the
understanding and experience of disease and sickness depends fun-
damentally on context.  Therefore disability weights are unlikely to
be universal and assuming that they are they could lead to ineffi-
cient interventions being provided.
● The DALY relies on data that are known to be gender biased and
much gynaecological morbidity is missing from the estimates of
burden of disease.
● DALYs are not counted as lost prior to a live birth and therefore
the unborn have no claim on resources (unless the health of the
mother is affected).  There are also concerns that DALYs may
13
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14 affect the rights of a person to be born if they are known to have a
higher probability of being physically or mentally challenged.
● Those with less ability to return to full health have a lower claim
on resources, a group which is more likely to include the poor.
Concerns about the quality of data: The quantity of guesstimates used
in calculating DALYs requires more open reporting of the sources of
data and their reliability, and at least some sensitivity analysis based on
the levels of uncertainty.
Are DALYs more widely applicable than EQ5D quality adjusted life
years (QALYs)1?
DALYs have been applied more widely and more consistently across
more countries and diseases than EQ5D QALYs because the original
developers of the DALY have made the estimates.  However, when
others use DALYs there are many differences in the way they calculate
them.  For example, age and future time may or may not be included,
different disability weights may be used, and even the standard expect-
ed years of life lost may not be used – and yet they are still called
DALYs!  The EQ5D QALYs have been used more widely in assessing
the effectiveness and efficiency of health interventions because this
tool has been operationalised for primary data collection, e.g. in clin-
ical trials, whereas DALYs have not.
Neither of these instruments evolved from studying conceptions of
health in the countries targeted for their use but instead are based on
the values of the researchers who developed the instruments, with the
EQ5D developers having a wider range of disciplines and countries
represented.   Therefore neither is likely to represent a universally held
view of health, and the ‘centres’ of the instruments are more likely to
represent views held by well-educated, wealthy, white, middle-class
professionals from Europe and North America.
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1 QALYs can be calculated using many methods.  I chose the EQ5D approach for
comparison because it one of the few generic measures based on population derived
preferences for health states in relation to death and because it is the only health index
developed from the beginning for use in more than one country.
Are DALYs better than EQ5D QALYs as an outcome measure in
economic evaluation?
Evidence on the validity, reliability and sensitivity of the EQ5D is con-
siderable and shows that the instrument reaches acceptable standards.
There is almost no published evidence for DALYs which, coupled with
a lack of openness in their design, means that it is difficult for
researchers to conclude that this is an acceptable measure.  EQ5D
QALYs are more inclusive than DALYs because they can:
● include the impact of side-effects;
● account for the impact of co-morbidities;
● involve the patient in measuring their own health state; and
● reflect the values of the general public in particular countries rather
than of a small group of ‘experts’.
These criticisms could change only: if DALYs were operationalised
and tested for primary data collection; if they were redesigned to meas-
ure health rather than disease; and if the reporting of methods and
results were improved.
In countries where the EQ5D has not been tested, or is not con-
sidered relevant, the DALY may be the only option available and
therefore used.  However, the reliability and validity of the outcome
measure must still be questioned and the results subjected to more rig-
orous sensitivity analysis than is happening currently, particularly as
the disability weights have not been evaluated for any intervention and
are unable to distinguish alternative interventions.
As DALYs and QALYs share the same basic idea of combining the
impact of mortality and morbidity into one measure designed for
resource allocation decisions, they also share (and are unlikely to shed)
some of the same criticisms.  For example, discrimination against the
aged and those less likely to return to full health such as the perma-
nently disabled and the poor, and that ‘health’ rather a broader notion
of human welfare is used to allocate resources.
DALYs or QALYs for decision-making?
As DALYs only partially reflect the impact of disease on people’s lives,
they offer at best a limited picture of the size of the problem.  They are
useful if the intention is to eradicate a disease or to ascertain the scale
15
EXECUTIVE SU M MARY
of resources required for palliative care.  However, estimates of the
burden of disease are not a sufficient basis for resource allocation, as
they say nothing about how interventions are likely to reduce the
problem, or about the opportunity cost of treating one problem rather
than another.  Therefore increasing spending in this area of research is
unlikely to be an efficient use of resources for decision-makers.
Cost-effectiveness analysis can be used by decision-makers at dif-
ferent levels, each of which leads to different conclusions about the
current relevance of using QALYs relative to DALYs.
International decision-making: DALYs offer a quick, broad-brush
approach to estimating the impact of interventions for different dis-
eases in different regions of the world based on expert views.  DALYs
are therefore of more interest to international decision-makers such as
the WHO and World Bank.  QALYs have never been used in this con-
text and so provide no data, however rough.
National decision-making: In high-income countries, DALYs offer no
advantages over the existing QALY measures.  In middle-income
countries where there is some development in QALY research, either
they or DALYs might be relevant.  In low-income countries, where the
World Bank ties loans to the calculation of DALYs and where little
research funding exists for the development of nationally applicable
measures, it is less likely that locally relevant QALYs will be developed
for decision-making.
Recommendations
1. Everyone using DALYs should evaluate the impact of assumptions
on their results routinely.
2. Move DALYs away from disease to a health or welfare based meas-
ure and to a people-centred measurement and valuation process.
3. The current assumptions about the impacts of interventions on
DALYs need to be explained, justified and also tested.
4. Testing the assumptions about the impacts of interventions on
DALYs requires that a measurement tool is operationalised and
tested for validity, reliability and equivalence across countries.
16
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This process needs to be culturally fair for results to be meaning-
ful to local populations and in low-income countries it is likely
that external agencies will need to help fund this process.
5. In high-income countries researchers should not adopt DALYs to
assess the effectiveness of health technologies.
6. For national decision-making in middle-income countries it is
time to invest in the development of locally appropriate measures
of health and welfare for use in economic evaluation of health
technologies.
7. Measures used globally should not claim universality if the devel-
opment of the measure did not access a range of local views first.
If the idea of universality is considered relevant, research should
begin by investigating conceptions of health to more accurately
identify the ‘centre’ of universality prior to developing and testing
tools for international measurement.
8. Stop funding more of the same burden of disease studies in low-
and middle-income countries and provide more decisional studies
based on the cost-effectiveness of interventions.
17
EXECUTIVE SU M MARY
Disability-adjusted life years (DALYs) were introduced in 1993amid the pages and policy directives of the World Development
Report ‘Investing in Health’ (World Bank, 1993).  DALYs are a meas-
ure of life years lost from disease, adjusted for assumptions about dis-
ability as well as the impact of age and future time.  They were
launched to widen the measurement of disease from the presence of
morbidity and mortality, usually cited by the World Bank, to include
the impact on disability in a commensurable way with mortality.  The
World Development Report was ground breaking for two reasons:
● it was the first attempt to assess the global burden of disease by
region of the world in this way; and
● it was the first attempt to bring together results from various cost-
effectiveness analyses of health interventions by disease using one
outcome measure (DALYs) to recommend global health policies.
This monograph outlines the construction, uses and criticisms of
DALYs and hence summarises the current state of thinking about this
relatively new measure.  The monograph highlights the range of val-
ues underlying the development and use of the measure.  I reflect on
the impact that DALYs have had on the types of agendas set and deci-
sions made about which interventions ameliorate disease in high-,
middle- and low-income countries.
The integration of quantity of life with aspects of its quality in one
measure is not new.  Indeed DALYs have been argued to perform a
similar function to quality adjusted life years (QALYs) (Bevan et al.,
1999) and have even been described as a ‘variant’ (Williams, 1999) or
‘clone’ of the QALY (Bobadilla, 1996).  A simplified schematic com-
parison of DALYs and QALYs is given in Figure 1, which shows that
DALYs lost and QALYs lived could be considered the obverse of each
other.  Where a change in health is measured for one disease following
an intervention, DALYs averted would equal QALYs gained, if quali-
ty of life were measured and valued in the same specific way by each
measure.
In making a comparison between QALYs and DALYs, it is difficult
to write about QALYs as if they are one measurement method.  Rather,
they are an approach.  Examples of techniques to calculate the ‘Q’ part
in QALYs include:
18
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19● generic pre-scored questionnaires, such as the EQ5D2 (Brooks,
1996) or Health Utilities Index (Torrance et al., 1996), which have
valuation matrices for attaching weights to different health states;
or
● scenario approaches to valuing descriptions of specific disease
states, e.g. using time trade-off to place a value on having a partic-
ular treatment for breast cancer (Ashby et al., 1994).
However, because of the difficulty in running time trade-off exer-
cises, the valuation matrix approach appears to be increasingly popu-
lar for assessing the impact of medical technologies3.
This monograph concentrates on DALYs and includes the findings
of a thorough review of the literature4.  Section 2 explains in detail
1  I NTRODUCTION
2 It is called the EQ5D because it was developed by the EuroQol group and this version
had five dimensions.  The nomenclature was developed to avoid confusion with earlier
versions of the instrument that had six dimensions.
3 However, readers should be aware that the valuation matrix for pre-scored
questionnaires for calculating the ‘Q’ of QALYs is based on the results of a valuation
approach such as the TTO.  The difference when compared with the ‘scenario’ approach
is that: the values are not attached to any particular disease; and the values do not have
to be ascertained each time a disease/health state is measured.
4 Appendix 1 outlines the search and selection criteria used for this literature review.
QALYs / DALYs
1 QALY =
0 DALY
DALYs lost from disease
QALYs gained or DALYs averted
(with intervention)
QALYs
(no intervention)
1 DALY =
0 QALY Life expectancy
Figure 1 Relationship between QALYs and DALYs
20 what DALYs are as well as how and why they are constructed.  It shows
that DALYs incorporate assumptions about life expectancy, time and
age-group preferences within their calculation, and that the focus is on
disease rather than health.  It also shows the crucial role that health
professionals have played in their development.
Section 3 moves on to show how DALYs have been used in prac-
tice, distinguishing between use by their original developers and by
others.  In a relatively short time the DALY appears to have become
one of the most talked about approaches to measuring health across
the globe.  Indeed the 1993 World Development Report and its
accompanying volume (Jamison et al., 1993) have been described as
‘probably the most important document in international health that
has appeared in at least a decade’ (Hinman, 1997 p8).  The DALY’s
impact on decision-making in international organisations is undisput-
ed (Laurell and Arellano, 1996; Bobadilla and Cowley, 1995).  Within
a year of their introduction, DALYs had been used as the outcome
measure in cost-effectiveness analyses for sector-wide decision-making
in the health sectors of eight countries including Mexico, Mauritius,
Turkey and Indonesia (Bobadilla and Cowley, 1995) and applied in
many more countries as a measure of the burden of disease.  The speed
of uptake reflected:
● the need to take decisions, even when information was not avail-
able;
● the power of the agencies developing, and requiring use of, the
tools;
● the paucity of experience in using or developing alternative,
QALY-based instruments in low- and middle-income countries.
Early reactions to the 1993 World Development Report (World
Bank, 1993) heralded important changes in thinking about interna-
tional health at the World Bank (Foege, 1994) whilst at the same time
reflecting views that the methods and assumptions used in DALYs
were controversial (Lancet, 1993).  Publication of some of the meth-
ods in 1994 (Murray and Lopez, 1994a) facilitated greater considera-
tion in the academic press of the construction and meaning of DALYs
and their use in analyses of burden of disease and cost-effectiveness by
people other than the developers.  In 1996 a revision to DALYs was
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produced (Murray and Lopez, 1996a), which took account of some of
the published discourse, and there has since been an increasing litera-
ture using and criticising DALYs as an outcome measure.
Section 4 of this monograph summarises the range of criticisms of
DALYs to date.  It focuses first on the four main methods of weight-
ing designed by Murray, and progresses to outline concerns about the
value systems embedded within the design of DALYs, as well as the
quality and cost of existing data.  The most persistent criticisms are
that:
● DALYs discriminate against people with disabilities;
● the minimisation of DALYs would increase inequalities of health
across populations;
● the DALY is too reductive a view of health;
● the DALY does not account for the context in which disease is
experienced;
● DALYs do not reflect either individual or societal preferences in
any one country;
● DALYs will not help identify the most efficient, welfare maximis-
ing interventions.
The last part of Section 4 outlines the debates raised concerning
uses of DALYs in decision-making.  In particular it is argued that the
tool has been most useful to international organisations like the World
Bank, but that using DALYs to measure the burden of disease is not
helpful in helping decide what to do about disease.  Indeed, as
Williams (1999) argues, spending vast amounts on estimating the bur-
den of disease is taking valuable research resources away from cost-
effectiveness analyses that could help decision-makers decide what to
do.
Like all methods for measuring and valuing the impact of treating
disease, understanding of the measurement process changes over time.
Section 5 briefly describes the range of on-going work and potential
approaches for the future.  It shows that, over time, there appears to
be greater convergence between the QALY and DALY methods as
DALYs adopt some of the characteristics of existing questionnaire
based approaches for QALYs, e.g. from the EQ5D.  Secondly there is
some consideration of separating out the measurement of perceived
21
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changes from the values attributed to those changes.  However, it
remains to be seen which ideas will be adopted.
The discussion in Section 6 reflects on the added value of DALYs
over other approaches for calculating QALYs, specifically EQ5D-con-
structed QALYs (readers who would like an introduction to the
EQ5D are directed to Appendix 2).  The answer will depend on who
is using the measure, where, for what purpose and from which view-
point.  In considering whether DALYs are more widely applicable than
QALYs, I argue that both have been applied in varied ways, although
the DALY has been applied in more countries.  However, as DALYs
have moved away from a strictly biomedical orientation, it is difficult
to argue that either of them has accessed universally held views of
‘health’.  DALYs have only sought the views of health professionals,
whereas QALYs constructed with the EQ5D have been used to meas-
ure, rather than estimate, change in health and have used random sam-
ples of the general population to provide the values of such changes to
an individual.
As the DALY has not been operationalised as a primary data col-
lection tool, it has not been used directly to measure change in ‘health’
and is a tool for estimation based on secondary data and a range of
assumptions.  Thus as an outcome measure for use in economic eval-
uation, DALYs are argued to provide a quick route to estimating the
partial impact of a disease or health intervention.   However, at pres-
ent there is no way to distinguish impacts of different interventions for
the same disease on the ‘D’ of DALYs because there are only two pos-
sible weights by disease: with or without an (unnamed) intervention.
Therefore, relative to questionnaire based approaches to measuring
QALYs, the DALY not only adds little but favours interventions that
have more side-effects or that people find it harder to adapt to, as well
as diseases that have more co-morbidities, as the benefits of such inter-
ventions are systematically overestimated.  Much of this problem aris-
es because the focus of DALYs is on disease rather than health or well-
being.
In this monograph I consider the advantages of DALYs relative to
QALYs in the context of high-, middle- and low-income countries, as
well as at the international, national and sub-national levels of decision
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making.  I argue that decision-makers in low- and middle-income
countries and at the international level are more likely to use DALYs
rather than QALYs because:
● DALYs are required to be used in order to agree health sector loans
with the World Bank;
● QALY approaches have hardly been used in these settings so there
are few alternative measures to DALYs; and because
● there has been little investment in research to develop locally-spe-
cific, health-related quality of life measures in these settings.
In high-income countries, especially those in which health-related
quality of life measures such as QALYs have been developed, there is
much less need for DALYs, although there is still an onus to develop
understanding of QALY gains for a wider range of interventions across
a wider range of disease areas to help sectoral decision-making.
The conclusions presented in Section 7 focus on the achievements
of DALYs to date with respect to their four principal uses as:
● an indicator of the burden of disease;
● a director of research and development;
● a measure of effectiveness; and
● a unit of benefit in cost-utility analysis for micro and sectoral eval-
uations.
I conclude that the use of DALYs in assessing the global burden of
disease has helped people think about the distribution of disease based
research funding across the globe.  The main concerns raised are about
the quality of data input, the method of dealing with co-morbidity,
that the context of disease experience is ignored and the implied equi-
ty weights emanating from the assumptions.  With respect to the use
of DALYs as an indicator of burden and measure of effectiveness or
benefit, I suggest that it would help clarify matters to separate actual
change in quantities from the values attached to the changing quanti-
ties.  This would clarify the impact of weighting for age and time pref-
erence; the impact of assuming ‘ideal’ life spans; and the desired dis-
tributions of benefits to ‘healthy’ people and people who are disabled
(i.e. suffering from any disease).  It would also allow alternative value
functions to be considered, and the impact of judgements to be under-
stood.
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I also question the usefulness of DALYs that focus on disease rather
than people, because it is people who experience disease, sickness and
interventions that change disease.  Useful decisional information
needs to incorporate both perspectives.  However, to move to max-
imising QALYs, rather than minimising DALYs, may still lead to a
sub-optimal allocation of resources, even from the viewpoint of effi-
ciency, as the desired objective function may be broader than or dif-
ferent from what QALYs are measuring.  The likelihood of this may
well increase with the number of countries included, as views about
the constituents of health and well-being have not yet been investigat-
ed in the process of developing internationally used measures of
‘health’.  Existing measures will therefore increasingly impose values
on, rather than reflect values of, new populations.
Finally, I also highlight the disparity between the demand for and
supply of decisional information for health sector prioritisation by
comparing the large and increasing quantity of data produced on bur-
den of disease globally with the fact that only 107 economic evalua-
tions were published between 1984-97 that had anything to do with
low- or middle-income countries.  An average of one publication per
country is hardly a sufficient basis for global policy making.  Thus, if
cost-effectiveness analysis is to be used, far more resources should be
targeted to the use of DALYs in economic evaluation rather than to
burden of disease exercises.
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2.1 What is the DALY?
DALYs are the present value of future years of lifetime lost through
premature mortality, plus the present value of the adjustment to years
of future lifetime to allow for the average severity (frequency and
intensity) of any mental or physical disability caused by a disease or
injury.  This shows that DALYs are a measure of something lost rather
than something gained, so that DALYs lost are not desired themselves,
but rather their reduction.  ‘Popular’ explanations have even described
DALYs lost as ‘the enemy’ (McNamee citing Feacham, 1993, p105).
2.2 The founding principles of DALYs
In 1994, Murray outlined four principles on which he argued DALYs
were based (Murray, 1994, p4-5):
● to the extent possible, any health outcome that represents a loss of
welfare should be included;
● the characteristics of the individual affected by a health outcome
that should be considered in calculating the burden of disease
should be restricted to age and sex, being the only two character-
istics which mean the same in all cultures;
● the measure treats like health outcomes as like;
● time is the unit of measure for the burden of disease.
However, whilst not counted among the founding principles, it is
clear that four other views have also dominated thinking:
● a desire to ‘decouple epidemiological assessment from advocacy so
that estimates of the mortality or disability from a condition are
developed as objectively as possible’ (Murray, 1996, pp1-2).  This
resulted from research showing that claims concerning adult and
child mortality by disease when summed exceeded total deaths in
each age group by 200-300 percent (Murray and Lopez, 1994a);
● that ‘it is better to make an informed estimate of disability flowing
from a particular condition than to have no estimate at all’
(Murray and Lopez, 1994b, p55), to ensure that under- or unre-
searched diseases do not drop off research or policy agendas;
● that ‘health research and action agendas are global not national’
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and that ‘the health profiles and the agendas for health research
and health policy for the developing world and the developed
world are converging’ (Murray, 1998).  Both beliefs underpin
views that facilitate the construction of global outcome measures
and global policy agendas;
● that international agencies have a critical role in influencing
national health policies in developing countries, in terms of: aid-
ing the expensive and time intensive process of priority setting;
allaying ‘the problems of inertia’; and in facilitating long-term
commitments to research (Murray, 1990, p310).
2.3 The architecture of DALYs
DALYs have evolved over time and there are now two markedly dif-
ferent versions.  Whilst what I shall call the DALY Mark 2 version has
superseded the Mark 1, both are referenced and used in the literature
and a Mark 3 version being developed appears to draw on some of the
ideas of the original version.  Therefore, I will draw out comparisons
of the Mark 1 and Mark 2 versions in four ways, through which the
construction of DALYs can be viewed.  This section will show in detail
how the DALY is constructed for a single individual of given age and
sex.  Individual DALYs then have to be summed up for the whole pop-
ulation to calculate total DALY burdens or treatment impacts.
The four pillars of DALYs involve different methods of weighting for:
● life expectancy;
● age;
● future time;
● disability.
These are discussed in turn in the remainder of this section of the
monograph.
2.3.1 Life expectancy
The method for calculating life expectancy in burden of disease esti-
mates is based on the ‘standard expected years of life lost’ method.
This imposes an ‘ideal’ length of life expected on each population and
measures the burden of a disease in terms of life lost relative to that.
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27The idealised standard chosen was the highest national life expectan-
cy observed globally.  This was in Japan, where females were shown to
have a life expectancy at birth of 82.5 years and males 80 years5.  The
difference was estimated as the biological difference in gender, after
accounting for men behaving badly6.
The main reason for adopting a standardised life expectancy across
the world was to avoid the problem of valuing deaths differently across
the world.  If each country’s life expectancies for current birth cohorts
were used as the base for calculations of disease burden, a 40 year old’s
death in Nairobi, Kenya would be worth less (in terms of DALYs lost)
than a 40 year old’s death in London, because life expectancy in England
is higher (Murray, 1994, p7).  The implication for basing allocation of
World Bank resources on burden of disease calculations in this simple
example would be to give money to the English and not the Kenyan per-
son, which was not desired.  The ‘standard expected years of life lost’
approach was preferred7 for measuring the burden of disease because it
combined the cohort expectation approach in treatment of deaths at
older ages with the egalitarian nature of potential years of life8.  The
method of calculating life expectancy remained the same for Mark 1 and
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5 The standard life expectancies at each age are given in Murray (1996, p17).  These
life expectancies were chosen because of the need to make international comparisons to
aid the World Bank’s decisions about where to lend money for reforming health sectors.
6 Including, for example, men smoking and drinking more than women as well as
engaging in more risky behaviours and taking more hazardous employment (Murray,
1996, p17-18).
7 Compared with three alternative approaches: potential years of life lost, period
expected years of life lost and cohort expected years of life lost.
8 This allows life expectancies for each age cohort to be calculated and is particularly
useful where age specific mortality rates are changing (mostly mortality is falling over
time, although more recently mortality in some sub-Saharan Africa countries has
increased, attributed to HIV/AIDS).  However mortality has to be estimated as we do
not know the future, and a range of projection models exist to do this.  The problem
with period expected life lost is that current mortality rates are applied as the ‘ideal’ or
highest possible age of death and where mortality changes over time this can lead to odd
results as reference standards change (Murray, 1996, p13).  The difference between
period expected and cohort expected years of life lost on the one hand and potential
years of life lost on the other is that in the former more weight is given to deaths at older
ages because expectation of remaining life does not fall to an arbitrary zero at a particular
age (using standard expected years of life lost it falls to zero at 82.5 for women).  A full
discussion of the arguments is given in Murray (1996, pp10-16).
28 Mark 2 DALYs.  The tables of life expectancy at each age used to calcu-
late DALYs are reproduced in Murray (1994, p9; and 1996, p17).
2.3.2 Weighting age
Age weights were introduced into DALYs to reflect beliefs that years
of life vary in value depending on an individual’s age.  Two justifica-
tions have been given (Murray, 1994 and 1996).  First, it was argued
that human capital theory allows the value of individuals to be calcu-
lated in the same way as the value of machines and that measures of
productivity, including wages, can be a good approximation of this.
Such indicators show an inverted U-shaped relationship of value
across time.  Secondly, age weights attempt to capture the belief that
social roles, and in particular the level of ‘welfare inter-dependence’,
vary with age.  For example, people between the ages of 20 and 50 are
more likely to have young children or elderly relatives dependent on
them and therefore it can be judged that it is more important to be
alive and healthy during these times than before or after.  Latterly
Murray (1996, p56) cited evidence from Bussbach et al. (1993) that
students and elderly people prefer to be healthy at particular ages.
A continuous age weighting function was chosen for both Mark 1
and Mark 2 DALYs, to ease the computational burden that would
have accompanied a discrete weighting system, of the form:
C xe-ßx
where:
ß and C = constants
x = age in years
e = base for natural logarithm (approx 2.718)
The shape of the age function is given in Figure 2, when C =
0.1658 and ß = 0.04.  It can be seen that the relative value rises until
around the age of 25 and then falls9.  This suggests that adding 10
years of life to a 10 year old is worth more than adding 10 years of life
to a 50 year old.
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9 Note that Barendregt et al. (1996, p441) showed that the combined effect of
discounting and age weighting extended the ‘hump’ of the graph in Figure 2 and
therefore added further value to life years in age groups 27-38.
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The only difference between Mark 1 and Mark 2 DALYs is the size
of the constant C, which equals 0.16523 in Mark 1 DALYs and
0.1658 in Mark 2 DALYs.  The purpose of the constant is to ensure
that the total number of DALYs lost without age weighting equals the
total number of DALYs lost after accounting for age weights.10  The
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Figure 2 Relative value of a year of life lived at different ages
incorporated into DALYs
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Source: Murray (1996, p60).
10 As Murray (1994, p10) states, the size of the constant would change if either the age
weighting function changed (e.g. by changing ß) or if the age and sex pattern of the
global burden of disease in real populations changed.  Therefore if the burden of disease
was calculated at a different point in time or for a specific country, the size of the
constant should change.  This quickly becomes a complex exercise and WHO has
adopted the pragmatic approach of using 0.1658 in all country and regional estimates
of the burden of disease and for cost-effectiveness analysis (Evans D, personal
communication).  This means that total age-weighted DALYs will not equal total non-
age weighted DALYs in such cases.
30 choice of value for ß (which controls the shape of the age weighting
function) as 0.04 was made on the basis of:
● ‘a modified Delphi method’11 with a group of public health
‘experts’;
● the judgement that ‘only a narrow range of ß provides reasonable
age patterns between 0.03 and 0.04’;
● the conclusion that ‘results are largely insensitive to the specific ß
chosen but are sensitive to the difference between equal and
unequal weights’;
● ‘an informal polling of the advisory board’ (all quotes are from
Murray, 1996, p10).
2.3.3 Weighting future time
The concept of pure time preference is drawn on to justify reducing
the weight of successive increments of future time; i.e. an individual
would prefer a benefit today rather than in one year’s time (assuming
there is no risk or uncertainty12).  However, in addition to this,
Murray (1996) also draws on two further reasons why individuals are
likely to have a positive rate of time preference: a 1 percent annual risk
of personal death; and a diminishing marginal utility to additional life
years.  The latter argument is linked to additional life years increasing
the capacity of an individual to access utility through consumption.
The arguments concerning moving from individual to social rates
of time preference are premised on similar bases.  Pure time preference
is discussed with reference to the possibility that one generation may
be more concerned with the welfare of future generations than an indi-
vidual is in their own private day to day transactions; and that groups
of individuals today may be more willing to save if they join together
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11 The Delphi technique is an approach used for establishing and developing
consensus.  It is usually based on experts being sent a self-completion questionnaire,
analysing the responses, feeding back a summary of the group’s views and asking
respondents to re-evaluate their own views given the results.  If a substantial amount of
disagreement remains (e.g. rankings are still disparate) a further round of feedback may
ensue (Bowling, 1997, pp362-3).
12 When this assumption is relaxed, the effect is to decrease or increase the rate of time
preference depending on whether future income becomes more or less valuable relative
to current income, which depends on whether marginal utility is convex or concave.
31rather than if they remain on their own.  Risks of death, rather than
being attributed to an individual, are considered in relation to societies
as a whole with respect to extinction of an individual society (through
war or natural disaster) and of the human race (through a cataclysmic
event) – both of which are considered to be much smaller than 1 per-
cent per year but still with a positive risk.  The same argument con-
cerning expectations of future economic growth is given.  However,
Murray outlines an additional argument called the ‘disease eradication
paradox’.  This is based on the case where a disease is conceived as hav-
ing a stable and infinite incidence and the possibility of an interven-
tion to eradicate it.  He argues ‘society would necessarily redirect all its
resources to disease eradication programmes and reduce all other
investments in all curative and preventive programmes to zero’ and
that, therefore, a discount rate high enough to counteract such exces-
sive sacrifice by current generations is needed.
In choosing the rate at which to discount, Murray writes about his
struggle between, on the one hand, using a positive (albeit low) dis-
count rate to capture the uncertainty that increases with time and the
need to reduce problems of excessive sacrifice and, on the other hand,
using a zero discount rate that ignores the cumulative effect of small
future uncertainties (with an option of counteracting the excessive sac-
rifices through arbitrary delineations of budgets for current and future
generations).  A positive discount rate of 3 percent per year is used in
both Mark 1 and Mark 2 DALYs, a rate which Murray felt was likely
to represent ‘the lower limit of acceptability for those economists who
are persuaded by opportunity cost arguments… and the upper limit
for public health practitioners who are willing to accept a positive rate
of discount’ (Murray, 1996, p54)13.  The discount rate was introduced
into the DALY formula for both Mark 1 and Mark 2 as a continuous
discounting function of the form:
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13 In a final section, Murray (1996, p54) also raises the possibility of discounting the
expected benefits of preventive interventions differently for communicable and non-
communicable diseases, suggesting that the discount rate in the latter case should
perhaps be lower.  The main argument propounded is that the annual decline of
communicable disease has been much faster and therefore the future benefits from
prevention are likely to be smaller and more uncertain.
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where:
r = discount rate expressed as a decimal (e.g. 0.03)
e = base for natural logarithm
t = time
In estimating the burden of disease, DALYs Mark 2 are presented
with a discount rate of 0 percent as well as 3 percent.
2.3.4 Weighting disability
The broad approach adopted was to weight the impact of disease
between zero (representing healthiness) and 1 (representing death)14.
It is this area that has been subject to greatest change between the
Mark 1 and Mark 2 DALYs.
Whilst both Mark 1 and Mark 2 DALYs used the same name, ‘dis-
ability adjusted life years’, and the conception of disability is in both
cases argued to arise largely from the work of the International
Classification of Impairments, Disabilities and Handicaps
(ICIDH)15, what is covered has changed over time.  Thus, in 1994,
Murray wrote ‘we have chosen to measure disability, not handicap16’
(p11), whilst for the Mark 2 DALYs he stated that the underlying con-
2  TH E CONSTRUCTION OF DALYS
14 Note that this is an inversion of the quality adjusted life year (QALY) type scales for
which zero represents death and 1 healthiness.
15 Where impairment is defined as ‘any loss or abnormality of psychological,
physiological, or anatomical structure or function’.  ‘Disability has to do with
compound or integrated activities expected of the person or body as a whole, such as are
represented by tasks, skills and behaviour. It is defined as any restriction or lack
(resulting from an impairment) of ability to perform an activity in the manner or within
the range considered normal for a human being.  Handicap relates to the social
consequences of deficiencies in organs and activity performance.  It is defined as a
disadvantage for a given individual, resulting from an impairment or a disability that
limits or prevents the fulfilment of a role that is normal (depending on age, sex and
social and cultural factors) for that individual’ (Reynolds Whyte and Ingstad, 1995,
pp6-7).
16 Disability in the ICIDH (WHO, 1980) concerns the loss of functional capacity
emanating from an impaired organ (mental, sensory, internal or externally visible body),
whereas handicap concerns the social and cultural consequences of a disability (or
impairment to an organ).
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struct ‘lies somewhere between disability and handicap’ and ‘is best
described as an average level of handicap’17 (Murray, 1996, p34).
One of the most significant changes between DALY Marks 1 and
2 is the way in which the impact of disease on disability is described.
Table 1 shows the classifications of disability used originally.  It can be
seen that the top four classes are measured in terms of ability to func-
tion for work, leisure, procreation and education.  The bottom two
classes measured quite different abilities involving managing aspects of
a home environment and basic activities of daily living.  Mark 2
DALYs moved away from this to specific definitions of individual dis-
ease states and conditions.  Boxes 1 and 2 show the range and opera-
tionalisation of disease states and conditions considered.  The main
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17 This is an interesting claim, as Murray previously adopted the position that
disability and not handicap allowed ‘like outcomes to be treated as like’.  Using
handicap, it was argued, would exacerbate inequalities as different expectations are held
in different social contexts (Murray, 1994, p12).
Table 1 Classifications of disability used in Mark 1 DALYs
Class 1 Limited* ability to perform at least one activity in one of the
following areas: recreation, education, procreation or occupation
Class 2 Limited* ability to perform most activities in one of the
following areas: recreation, education, procreation or occupation
Class 3 Limited* ability to perform activities in two or more of the
following areas: recreation, education, procreation or occupation
Class 4 Limited* ability to perform most activities in all of the
following areas: recreation, education, procreation or occupation
Class 5 Needs assistance with instrumental activities of daily living
such as meal preparation, shopping or housework
Class 6 Needs assistance with activities of daily living such as eating,
personal hygiene or toilet use
Note: *Limited ability was arbitrarily defined as 50 percent of full activity.
Source: Murray (1994, p12).
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● Largely physical manifestations 
 e.g. blindness, deafness, below-the knee amputation
● Neuro-psychiatric conditions 
 e.g. unipolar major depression, active psychosis, Down’s syndrome
without cardiac malformation, mild mental retardation
● A condition with social/group interaction consequences 
 e.g. vitiligo on face
● Pain 
 e.g. severe migraine, angina, severe sore throat
● Sexual/reproductive functioning 
 e.g. erectile dysfunction, infertility, recto-vaginal fistula
Box 1 The ‘indicator conditions’ chosen to reflect different
dimensions of non-fatal outcomes in Mark 2 DALYs*
reason given for the change in descriptions was that the original, Mark
1, classification was not appropriate for children as they would, by def-
inition, be considered disabled because of their dependency on others.
Other than considering the literature, no description of the processes
used to arrive at the descriptions of disease or health states for either
version of DALYs is given, except that definitions of the indicator con-
ditions used in constructing Mark 2 DALYs were revised following
testing by ‘students and fellows from a number of countries at the
Harvard School of Public Health’ (Murray, 1996, p36).
The methods for determining weights for DALYs Mark 1 and
Mark 2 are also very different, although the idea that the severity
weight is a combination of the perceived intensity of disability and the
Note: *The remaining conditions, not categorised in the above manner,
include paraplegia, quadriplegia, severe anaemia, fracture of radius in a stiff
cast, dementia, watery diarrhoea, two standard deviations below weight-for-
height, rheumatoid arthritis.
Source: Murray (1996).
35
time spent in the disabled condition remains the same in both ver-
sions.  Little explanation was given about the processes involved for
the Mark 1 DALY.  We are told that weights were chosen ‘based on the
word definitions and the set of disabling sequelae in each class.  De
facto, they used a magnitude estimation method18 to choose a number
between 0 and 1 for each of the six classes.  Their votes were averaged
to generate the final class weights’.  The values were given by a group
of ‘independent ‘experts’’ (public health practitioners) ‘who had not
been involved in the estimation of the incidence, duration or mortal-
ity of any disease’ (Murray, 1994, p13).
A protocol was developed for the process of eliciting values for the
indicator conditions of Mark 2 DALYs (see Murray, 1996, pp90-96).
The person trade-off (PTO) approach was used in a deliberative group
process, based on two thought experiments, which are described in
Box 3.  Each individual within the group was asked:
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Blindness
Maximum visual acuity with the best possible correction is less that 3/60.
(A person is unable to distinguish the fingers of a hand at 3 metres, or has
less than 5 per cent of remaining vision as compared to a normally sighted
individual).
Dementia
An individual with multiple cognitive deficits that include memory
impairment and aphasia (difficulty producing the names of individuals and
objects) and apraxia (impaired ability to execute motor activities despite
intact motor abilities, sensory function, and comprehension of the
required task).
Box 2 Examples of the descriptions given for ‘indicator
conditions’
Source: These definitions and all others used are given in Murray (1996, pp94-
96).
18 Later Murray states this was a rating scale (Murray, 1996, p34).
36 ● from the viewpoint of a decision-maker purchasing interventions
and for each indicator condition19, to make two individual choic-
es: to trade quantity of life for healthy or disabled individuals
(PTO1) and to trade off quality of life for improvements in
‘healthy’ versus disabled individuals (PTO2);
● to reflect on any differences between their own values (including a
rank ordering exercise) and to arrive at one internally consistent
weight to reconcile any differences in the disability weight implied
by the two PTO questions.  To do this, each participant was given
a ‘PTO1-PTO2 equivalence table’ (Murray, 1996, pp97-8).  This
allowed the experts to make their decisions based on Murray’s
expectations of the relationship between PTO1 and PTO2;
● to participate in a group discussion which focused on who had the
highest and lowest values in the group for each condition for
PTO1 and PTO2, and why;
● to reconsider their own values in private and make changes if they
wished to.
The final value selected for the group composite disability weight
was the median PTO value for each condition20.  Murray and Lopez
(1997a, p379) reported that the correlation coefficients between vari-
ous group exercises exceeded 0.9, indicating a high degree of agree-
ment between them.
The group of people providing the disability weights for the DALY
Mark 2 had been invited to an ‘international consensus meeting on
disability weights’ which was convened at the WHO in Geneva in
August 1995.  The group included individuals from each region of the
world, of whom 60 percent were male and 40 percent female21.  They
were also described as health providers from ‘diverse cultural back-
grounds’ (Murray, 1996, pp38-39) with knowledge of, but not suffer-
ing from, any of the conditions (Murray, 1996, p93).  The critical role
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19 In considering each indicator condition, raters were asked to ‘evaluate the average
individual with the condition described taking into account the average social response
or milieu’ (Murray, 1996, p38).
20 Unfortunately no data have been published on the mean, standard deviation or any
other information to describe the distribution of values.
21 We are not told the total number of people, although we are told that the process
was designed for a group of 8-12 health providers (Murray, 1996, p36).
THOUGHT EXPERIMENT 1 (PTO1)
You are a decision maker who has only enough money to buy one of two
mutually exclusive health interventions.
Either 
Choose intervention A which will: 
Extend the life of 1,000 healthy individuals for exactly one year, at
which point they will all die.
If you do not purchase this, they will all die today.
Or 
Choose intervention B which will:
Extend the life of n (≥ 1,000) blind individuals for one year.
If you do not purchase this, they will all die today.
THOUGHT EXPERIMENT 2 (PTO2)
You are a decision maker who has only enough money to buy one of two
mutually exclusive health interventions.
Either
Choose intervention A which will:
Extend the life of 1,000 healthy individuals for exactly one year, at
which point they will all die.
If you do not purchase this, they will all die today.
Or 
Choose intervention B which will:
Cure the disability of n blind individuals, who will live exactly one year
with or without the intervention. 
With the intervention they will live in perfect health, without the
intervention they will continue to live for one year with the given dis-
abling condition.
Box 3 Two types of thought experiment given to raters of the
‘indicator conditions’ used to elicit disability weights for Mark 2
DALYs
Source: Adapted from Murray (1996, p91).
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38 of the facilitator at the consensus meeting was highlighted, in terms of
needing to encourage participants constantly to take the exercise seri-
ously and carefully, as well as to challenge individuals about their cho-
sen values, in an attempt to elicit reliable and valid assessments.
Following the derivation of weights for each indicator condition
by the above group, the spectrum of disease states or conditions
between death and no disability or disease was divided arbitrarily into
seven disability classes (Murray, 1996, p40).  The weights were divid-
ed, as shown in Table 2, and disability weights for each disability class
were fixed at the midpoint.  Next, the individual disability classes and
the 22 ‘benchmark’ indicator conditions were used in the mapping of
disease states through their disabling sequelae for several hundred
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Table 2 Revised disability classes and weights (DALYs Mark 2)
Disability Severity Mid- Indicator conditions
class weights point*
1 0.00-0.02 0.01 Vitiligo on face, weight-for-height
less than two standard deviations
2 0.02-0.12 0.07 Watery diarrhoea, severe sore throat,
severe anaemia
3 0.12-0.24 0.18 Radius fracture in a stiff cast,
infertility, erectile dysfunction,
rheumatoid arthritis, angina
4 0.24-0.36 0.30 Below-the-knee amputation,
deafness
5 0.36-0.50 0.43 Recto-vaginal fistula, mild mental
retardation, Down’s Syndrome
6 0.50-0.70 0.60 Uni-polar major depression,
blindness, paraplegia
7 0.70-1.00 0.85 Active psychosis, dementia, severe
migraine, quadriplegia
Note: *Weight applied by class to distribution of disability in the global bur-
den of disease exercise, version 5.
Source: Adapted from Murray (1996, pp40-41).
39other ‘conditions’, which did not have individual descriptions.
The same group that provided the weights for the indicator con-
ditions was also asked to use a rating scale to decide the distribution
of people with each ‘condition’ in its treated and untreated form by
broad disability class and, once again, views were amended following
a group discussion.  In this exercise, many pieces of information were
considered: ‘where treatment was judged to change the distribution of
severity by class, and not simply the incidence, duration or case-fatal-
ity rate of a condition, the group developed a separate distribution for
the treated form of a condition’ (Murray, 1996, p41).  A single dis-
ability weight for each condition was constructed by multiplying the
per cent in each class by the mid-point severity weight for the range
defining that class.  An illustrative example is given in Table 3.  The
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Table 3 Estimated proportion of incident cases developing a
disability and the distribution of these disabilities by severity
class: an illustrative example in Latin America and the Caribbean
Age Percentage Percent distribution by severity classa of
group of incident those developing a disability
(years) cases
developing 1 2 3 4 5 6 7
a disability 0.01b 0.07b 0.18b 0.30b 0.43b 0.60b 0.85b
0-4 100 35 15 15 15 10 5 5
5-14 100 35 15 15 15 10 5 5
15-44 100 35 15 15 15 10 5 5
45-59 100 35 15 15 15 10 5 5
60+ 100 35 15 15 15 10 5 5
Notes: a Distributions across the seven disability classes sum to 100 percent.
Data on these distributions may come from a variety of sources in a specific
country, and will vary by location and condition.  If not available, they
would have been estimated by the expert group.
b Weight for time spent in each disability class (the mid-point of the disabili-
ty class).
Source: Based on an example in Murray and Lopez (1994b, p59).
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1. Descriptions of 22 indicator conditions devised.
2. Weighting of named indicator conditions using two person trade-off
(PTO) questions with a small group (n<13) of international health
providers.
3. Each provider required to make values from PTO exercises consistent
with expectations.
4. Values of individual experts shown to group, with discussion of reasons
for highest and lowest values.
5. Chance for experts to re-assign their individual values of indicator con-
ditions.
6. Median value of group assigned to each indicator condition, and all
indicator conditions ordered on a scale between 0 and 1.
7. Arbitrary slicing of the 0-1 disability scale into seven categories (each
category containing between 2-5 of the 22 indicator conditions).
8. Seven category rating scale was used, by the same small group of inter-
national health providers, to agree (following group discussion) the
distribution across the seven categories of each condition in treated
and untreated groups of people for:
● the indicator conditions;
● ‘several hundred other conditions’a.
9. All conditions should have had separate information on the duration
of time spent in each disability class for each condition that was used
to calculate the final weightb.
10. Distributions of a condition were converted to a single disability
weight by multiplying the percentage in each part of the category scale
by the mid-point severity weight for that classification for the relevant
distribution range decided for that condition (treated and untreated).
Box 4 Summary of steps used to weight disease states in Mark 2
DALYs
Notes: a Values for a total of 237 sequelae are given in Annex 3 of Murray and
Lopez (1996a, pp412-416).  Murray and Lopez (1996, p202) also point out
that the disabling sequelae were selected in consultation with disease ‘experts’
who collaborated on the global burden of disease exercise.
b At times steps 8 and 9 were done together in a composite step by the group
of raters when information was not available.
41implied disability weight in this example, assuming equal time was
spent in each disability class, would be 0.201522.  However, given the
gaps in knowledge of the distribution of some conditions by severity
of disability, the group often had to make a combined judgement con-
cerning the distribution and time spent with each form of the condi-
tion (Murray, 1996, p41).  Box 4 summarises the steps used to weight
disease states in Mark 2 DALYs.
2.4 How to calculate Mark 2 DALYs
DALYs for a specific condition are the sum of years of life lost (YLL)
plus years of life lived with disability (YLD):
DALYs [r, K, ß] = YLLs + YLDs
where:
r = discount rate expressed as a decimal
K = age weighting modulation factor
ß = parameter from the age weighting function
To reflect the base case recommended and used by Murray and Lopez
(1996a,b) this would mean that r = 0.03, K = 1 and ß = 0.04.  The
notation DALYs [0.03, 1, 0.04] provides a quick way for evaluators to
highlight any key changes in the assumptions of the DALYs they cal-
culate.
The method used to calculate DALYs differs according to the pur-
pose of analysis.  The following two sections exemplify these differ-
ences by first showing the calculation of DALYs when estimating the
burden of disease and then showing the different DALY calculation
method that is used in cost-effectiveness analysis of a health interven-
tion.  Both examples focus on calculating DALYs for one individual.
2.4.1 Estimating the burden of one case of disease using DALYs
The relevant formulas were outlined by Murray (1996, pp65-6) and
are shown in Appendix 3.  Homedes (1995) usefully exemplified the
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22 Note therefore that, with the same assumptions about duration, the maximum
disability weight is 1.0x0.85 and the lowest is 1.0x0.01.
42 calculation of Mark 1 DALYs for an individual, using four illustrative
case studies.  Using a similar approach but a different example, I show
how Mark 2 DALYs can be calculated for an individual.
Imagine that a woman becomes sick with bipolar depression at age
35, has it for 10 years and dies as a result.  How many DALYs [0.03,
1, 0.04] have been lost?  To calculate this we need to estimate the
numbers of DALYs lost due to both her premature mortality, YLLs,
and the disability she experiences while suffering from the condition,
YLDs, and then sum them.  The expected time horizon for this
woman is shown below, by age:
Time horizon without treatment:
Depression Death
Age 35 45
The calculation of YLDs focuses on the period during which she is
living with depression, from 35-45 years.  By substituting the follow-
ing values into the general equation shown in Appendix 3, the YLD
based DALYs can be calculated:
K = 1 
C = 0.1658
r = 0.03
a = 35
ß = 0.04
L = 10
D = 0.6 (from Murray and Lopez, 1996a, p415)
The number of DALYs lost due to disability23 from age 35 is then
6.95.
The calculation of the YLLs requires two steps, in this example.
First to calculate the life lost from age 45 onwards, and secondly to
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23 The formula for this specific example in Excel for YLDs is
=0.6*(1*0.1658*EXP(0.03*35)/(0.03+0.04)^2)*(EXP(-1*(0.03+0.04)*(10+35))*(-
(0.03+0.04)*(10+35)-1)-EXP(-1*(0.03+0.04)*35)*(-(0.03+0.04)*35-1))+((1-
1)/0.03)*(1-EXP(-1*0.03*10)).
43discount this value to age 35 so that all DALYs can be added up from
age 35 onwards (if the woman had died immediately at age 35, this
latter step would not be necessary).  The first step requires a straight-
forward substitution of values into the general YLL equation shown in
Appendix 3 using the following values:
K = 1 
C = 0.1658
r = 0.03
a = 45
ß = 0.04
L = 38.72 (the life expectancy at age 45, using the tables provided
in Murray, 1996)
The DALYs lost from the age of 45 onwards, due to lost years of
life24 are then 20.66.  The conversion of this to DALYs calculated at
age 35 uses the following formula:
DALYs at age x = (DALYs at age x+s)e-rs
where:
s = number of years to be discounted
r = discount rate expressed as a decimal
Therefore, substituting in the appropriate values:
DALYs at age 35 = 20.66 x e(-0.03x(45-35)) = 15.31
Therefore, from the time of onset of disease at age 35, the total
number of YLLs lost due to premature death equals 15.31.  Adding
this to the years of life lost with disability (YLDs = 6.95), gives the
total number of DALYs lost of 22.26.
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24 The formula in Excel for YLLs in this example is 
=(1*0.1658*EXP(0.03*45)/(0.03+0.04)^2)*(EXP(-1*(0.03+0.04)*(38.72+45))*(-
(0.03+0.04)*(38.72+45)-1)-EXP(-1*(0.03+0.04)*45)*(-(0.03+0.04)*45-1))+((1-
1)/0.03)*(1-EXP(-1*0.03*38.72)).
To move from this calculation for an individual to the total num-
ber of DALYs lost in a community due to bipolar depression would
require calculating the DALYs lost to each individual with bipolar
depression, using the approach shown above, and then adding them all
up.  With full knowledge, this would give the most detailed figures.
However, in reality the calculations tend to work from a population
level down, given assumptions e.g. about proportions of the popula-
tion with the disease.
2.4.2 Estimating the DALYs averted for one case for use in cost-
effectiveness analysis
It is important to note that, for calculating DALYs averted as part of a
cost-effectiveness analysis, the ‘standard expected years of life lost’
approach is not used.  What is needed is the difference between years
lived with and without the intervention being studied.  Standard
expected years of life lost measures neither.  Therefore, in cost-effec-
tiveness studies the relevant national life expectancy is recommended
as a good approximation of life expectancy, provided that mortality is
stable and interventions have a duration of less than one year (Murray,
1996, p20, citing Preston, 1993).
If, however, underlying mortality is changing over time, each new
birth cohort will experience a different life expectancy and the current
local life expectancy becomes a less accurate representation of future life
for interventions that impact on particular age groups.  Therefore a
cohort life expectancy is recommended as the basis for estimating
change with and without an intervention (Murray, 1996, p20).
However, the situation quickly becomes more complex if the evaluation
considers an intervention lasting several years that changes age-specific
mortality rates.  Not only is a great deal more information required (age
specific mortality rates and the impact of the interventions on mortal-
ity at each age) but a move to a population model is also required to
capture the dynamic nature of the impact of the intervention.
For ease I will use the same example as above.  The first step is to
use local life tables rather than the standard expected life tables to cal-
culate YLLs without treatment (in this example the estimation of
YLDs will be the same as above because the 10 years alive with dis-
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ability is a given).  The YLLs will therefore differ by country/life table
used.  In this example I use Chile, where the remaining life expectan-
cy for women at age 35 is 44.13 years and at 45 is 34.73 years25.  I
also use WHO’s approach and assume the Global Burden of Disease
value of the constant (see footnote 10).  The YLLs at age 45 are 19.97,
which when discounted to age 35 values becomes 14.80 YLLs.
Therefore the total DALYs lost as at age 35 without treatment are 6.95
(YLDs) plus 14.80 (YLLs), which equals a total of 21.75 DALYs26.
Now imagine if this woman received treatment for her depression
at age 35, and that she does not die at age 45 but lives for her expect-
ed life span, in the treated state.  Her new time line is shown below.
Time horizon with treatment:
Depression treated Death
Age 35 79.13
How many DALYs would be averted by the intervention?  A
DALY weight for the treated form of the disease is given in Murray
and Lopez (1996b, p415)27 as 0.302 (a fall of 0.298 from the untreat-
ed DALY weight of 0.6, as used in the example in Section 2.4.1).
Using the YLD formula from Appendix 3 with the values: K = 1; C =
0.1658; r = 0.03; a = 35; ß = 0.04; L = 44.13; D = 0.302; the DALYs
now associated with her condition28 equal 7.94.  This means the total
number of DALYs [0.03, 1, 0.04] averted following treatment of the
woman is 21.75 – 7.94 = 13.81.  As Fox-Rushby and Hanson (2001)
45
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25 These are the female life expectancies at ages 35 and 45 respectively using the
Chilean life tables from the United Nations, 1982 Model Life Tables.
26 See Fox-Rushby and Hanson (2001) for full calculations.
27 Note that whilst we are given this value we do not know what the treatment is.  Also,
the value is meant to represent the ‘average’ response of people to treatment of bipolar
depression.  In an average, some people will be better, and may have a 100 percent
recovery with no need for further treatment and no remission.  Others may not recover
at all following treatment.
28 Using the Excel formula: =0.302*(1*0.1658*EXP(0.03*35)/(0.03+0.04)^2)*(EXP(-
1*(0.03+0.04)*(44.13+35)))*(-(0.03+0.04)*(44.13+35)-1)-EXP(-1*(0.03+0.04)*35)*(-
(0.03+0.04)*35-1))+((1-1)/0.03)*(1-EXP(-1*0.03*44.13)).
46 show, changing the age and discount weights would alter the DALYs
averted from treatment at age 35 as follows:
DALYs averted [0.03, 1 0.04] = 13.81
DALYs averted [0.03, 0, 0] = 13.76
DALYs averted [0, 1, 0.04] = 25.07 
DALYs averted [0, 0, 0] = 27.40
Therefore, in this example, discounting (at 3 percent rather than 0
percent) has a much bigger impact on the DALY calculation than does
the choice of age weights.  Once the DALYs averted from an inter-
vention have been calculated for an individual, the total for the com-
munity can be summed and then compared with the difference in
costs between providing the treatment and not providing it, to yield
the incremental effects for an incremental cost-effectiveness ratio29.
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29 Because this compares treatment versus no treatment, the incremental cost-
effectiveness ratio will equal the average cost-effectiveness ratio.  It equates, in this
instance, with the approach forwarded by Murray et al. (2000).  However, note that this
approach takes no account of the impact of any other existing treatments because the
comparison is with no treatment. 
47The range of proposed uses of DALYs outlined by Murray and col-leagues (Murray, 1994; Jamison in Murray and Lopez, 1996a;
Murray, Salomon and Mathers, undated) include:
● setting health service priorities for curative and preventive care;
● setting priorities for health research and development;
● identifying disadvantaged groups and targeting health interven-
tions;
● providing a comparable measure of output for intervention, pro-
gramme and sector evaluation and planning;
● generating a forum for informed debate of values and priorities;
● allocating training time for clinical and health practitioners;
● assessing the performance of health systems30;
● comparing geographical and secular variation in health31.
One of the frustrations that developers of health-related quality of
life measures have had is that their measures are not always used for
the purposes for which they were intended (Rosser, 1990).  Criticisms
of their use in inappropriate ways cannot be a criticism of the measure
per se, but of its use.  Therefore, this section distinguishes uses by the
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30 Most recently, the World Health Report (WHO, 2000) has used DALYs and
disability adjusted life expectancy as part of an assessment of the performance of
countries’ health care systems.  Disability adjusted life expectancy was combined in an
index along with measures of: the distribution of health in the population; the overall
responsiveness of the country’s health care system; the distribution of responsiveness; the
distribution of financial contribution (WHO, 2000, p27); and were then compared
with health expenditure per capita (WHO, 2000, p43).  The results were widely
reported in the popular press, and government officials were charged with finding out
why their country ranked where it did.
31 A series of related papers by Jamison and colleagues have outlined the role of the
findings from the World Development Report (World Bank, 1993) in the broader
context of health sector reform (Aiyer et al., 1995; Jamison et al., 1995; Jamison, 1997).
They have consistently advocated that the main areas for improvements include:
strengthening the household’s capacity to improve health; improving national spending
on health; and promoting diversity and competition in the financing, organisation and
provision of health services (particularly with reference to extending the coverage of
health insurance).  Also see Musgrove (1995) for an outline of how the emphasis on cost
per DALY averted is related to choices for alternative funding mechanisms.
48 original developers32 and by others in each of the four principal areas
in which DALYs have been used:
● estimates of the burden of disease;
● individual studies of cost-effectiveness;
● ‘sectoral’ planning;
● directing research and development effort.
3.1 Estimates of the burden of disease
There have been a number of iterations in calculating the global bur-
den of disease.  The third attempt was the basis of the World
Development Report (World Bank, 1993) that covered 109 categories
of ICD933, disaggregated by: eight regions of the world, five age
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32 Separating out the developers of the DALY from ‘others’ is quite difficult given the
breadth of multi-authored papers.  For the purposes of this review I have included three
authors; Christopher JL Murray, Alan D Lopez and Dean T Jamison.  Murray was sole
author of the two main papers which outline the conceptual basis of the DALY but has
jointly edited the Global Burden of Disease series with Lopez, within which is the most
comprehensive presentation of data on DALYs.  Jamison was selected because he was the
project manager of the World Development Report in 1993 (within which was the
inaugural presentation of DALYs) and the lead author evaluating the cost-effectiveness
analysis in the Health Sector Priorities Review (Jamison et al., 1993) which was
presented in the World Development Report (World Bank, 1993).  Any papers
authored, or co-authored by these three were included for review within this section.  I
also include any papers in the collected volumes edited by Murray and Lopez (1996a-
c).  Christopher Murray is currently the Executive Director of the Evidence and
Information for Policy Cluster of the WHO and was Professor of International Health
Economics and Director of the Burden of Disease Unit at Harvard University during
the original launch of DALYs.  His academic background encompasses medical training
at Harvard and a DPhil in Economics from Oxford University.  Alan Lopez’s academic
background includes mathematics followed by postgraduate degrees in statistics and
medical demography.  He has worked at the WHO since 1980 and is currently co-
ordinator of the Epidemiology and Burden of Disease Unit there.  Dean Jamison read
philosophy and later engineering sciences at Stanford University, followed by a PhD in
economics at Harvard.  He is currently a Professor of Social Research Methodology and
Director of the Program on Global Health and Education at the University of
California, Los Angeles.  He has also spent many years as a senior economist in the
research department at the World Bank.
33 This is the 9th revision of the International Classification of Disease, which is used
to code and classify mortality data from death certificates.  The 9th revision covers the
period 1979-1998.
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groups, gender and cause.  The fourth iteration, presented in Murray
and Lopez (1994a) added the disease categories ‘other neoplasm’ and
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Table 4 Top 10 causes of DALYs [0.03, 1, 0.04] (percent of total)
in descending order, 1990
Developed regions of the world Developing regions of the world
Disease or DALYs % of Disease or DALYs % of
injury (’000s) total injury (’000s) total
Ischaemic heart 15,950 9.9 Lower respiratory 110,506 9.1
disease infections
Unipolar major 9,780 6.1 Diarrhoeal 99,168 8.1
depression diseases
Cerebrovascular 9,425 5.9 Conditions arising 89,193 7.3
disease during the
perinatal period
Road traffic 7,064 4.4 Unipolar major 41,031 3.4
accidents depression
Alcohol use 6,446 4.0 Tuberculosis 37,930 3.1
Osteoarthritis 4,681 2.9 Measles 36,498 3.0
Trachea, 4,587 2.9 Malaria 31,705 2.6
bronchus and
lung cancers
Dementia and 3,816 2.4 Ischaemic heart 30,749 2.5
other disease
degenerative
and hereditary
central nervous
system disorders
Self-inflicted 3,768 2.3 Congenital 29,441 2.4
injuries abnormalities
Congenital 3,480 2.2 Cerebrovascular 29,099 2.4
abnormalities disease
Source: Murray and Lopez (1996a, p262).
50 ‘skin disease’.  The fifth iteration34 was published in 1996 (Murray
and Lopez, 1996a-d, 1997b-e; Lancet, 1997).
The results show, for example, that in 1990 the top cause of
DALYs lost in developed regions of the world was ischaemic heart dis-
ease, whereas for the developing regions it was lower respiratory infec-
tions.  Table 4 shows the much larger proportion of DALYs lost due
to infectious disease in developing compared with developed regions.
One other finding was the larger than expected contribution of road
traffic accidents to total DALYs lost for developed countries.
The results have also shown the percentage contribution of DALYs
lost by age group.  Figure 3 shows that the distribution of DALYs lost
by age differs dramatically across regions.  In Sub-Saharan Africa 52
percent of the burden is due to mortality and morbidity in the 0-4 year
age group, whereas in the established market economies more than 50
percent of the burden is in the 45+ age group.  41 percent of all
DALYs lost globally occurred in the 15-44 year age group, which has
resulted in a call for ‘global health action to promote health and to
prevent disease and injury among young adults’ (Murray and Lopez,
1996a, p156).
Table 5 gives an idea of the greatest level of detail attained in the
global burden of disease exercise, showing the spread of cardiovascular
disease by age and sex for the established market economies.  It can be
seen that roughly 50 percent of the burden of cardiovascular disease is
due to ischaemic heart disease, and that men lose 30 percent more
DALYs to cardiovascular diseases than women.  65 percent of the bur-
den of cardiovascular disease occurs in the over 60s, particularly in
women.
The loss of DALYs has also been attributed to risk factors.  In
developing countries malnutrition is the main risk factor causing
DALY loss, followed by poor water supplies, sanitation and hygiene.
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34 Of the ten volumes, three have been published to date.  The categories of this disease
burden exercise: dropped pelvic inflammatory disease, detailed categories of diarrhoeal
disease, and eclampsia; and added dengue, Japanese encephalitis, and detail of two
conditions arising during the peri-natal period including low birth weight and birth
asphyxia/birth trauma; separated out schizophrenia, obsessive-compulsive disorders and
panic disorder; and also separated out ten categories of congenital abnormalities.  It also
included several risk factors such as indoor air pollution.
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In the developed regions, tobacco and alcohol were the main risk fac-
tors.  Murray and Lopez called for intensification of the expanded pro-
gramme of immunisation in developing countries and for reducing the
DALYs caused by addictive substances in developed regions (Murray
and Lopez, 1997e, p1441).  Murray and Lopez have also provided a
series of projections of DALYs, by cause, to 2020.  An aging popula-
tion, the spread of HIV, the increase in DALYs due to tobacco and the
decline in death from communicable diseases were judged to be the
main causes of the expected change in patterns of disease (Murray and
Lopez, 1997d).
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Figure 3 DALYs lost by age and region, 1990
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53Perhaps not surprisingly, the most frequent use of DALYs by peo-
ple other than the original developers of the measure is the citation of
results from the different global burden of disease exercises.  There has
been a profusion of organisations using or discussing DALYs, includ-
ing national agencies such as Rehabilitation International35, the UK
Public Health Laboratory Service36, the World Resources Institute37
and the US National Institutes of Health (NIH).  Sub-national organ-
isations such as departments of health in cities as well as directors of
public health have also used DALYs in their reporting38.  Other
DALY-using groups include aid wings of governments39, charities40,
commercial companies (Friedman, 2000) and teachers41.  The cita-
tions in the DALY literature fall into two principal categories: those
that accept the results and use the figures to call for greater funding of
specific disease based interventions, research and training42; and those
that question the estimates of DALYs lost for specific diseases.
Calls for increased expenditure on interventions and research have
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35 See www.rehab-international.org/measuringquality.htm
36 See www.phls.co.uk/whoweare/corpplan.htm 
37 See www.igc.org/wri/wr-98-99/dalys.htm 
38 For example, see
WWW.STAFFHEALTH.CO.UK/HADocs/REPORTS/PUBLIC%20HEALTH/HEA
LTH/NEXT-PAGE.HTM and
http://PHPH.DHS.CO.LA.CA.US/PH/REPORTS/PHLAUCLA/PHLAUCLA.HTM
39 See, for example, the UK Department for International Development’s strategy
paper ‘Better Health for Poor People’ (1999), which uses DALYs and the global burden
of disease estimates for targeting development (p11), even though the DALY is not yet
considered suitable as a performance measure.
40 E.g. United Cerebral Palsy of Prince George’s and Montgomery Counties,
http://www.ucppgmc.com
41 Taylor (1997, p156) cited the work as a ‘fascinating and plausible reference book’,
that he would draw on for senior undergraduate and graduate level health geography
courses.
42 See for example Gupta et al. (1994), who believe that the global burden of disease
does not under-report cancer deaths in India (contrary to Murray and Lopez’s view), and
Meerding et al. (1998) who considered the main causes of disability by age in The
Netherlands compared with the global burden of disease results.
54 been particularly noticeable in the areas of mental health43, infectious
diseases such as HIV/sexually transmitted diseases (Van Dam, 1995),
tuberculosis (Prabhakar, 1996; Squire, 1997), otitis media (Berman,
1995,) and malaria (Foster and Phillips, 1998).  Fèvre and Barnish
(1999) have pointed to the role DALYs and other economic indicators
of the burden of disease may play in attracting resources for combat-
ing disease, in their case malaria, even though others have argued that
the advocacy is now decoupled from DALYs and the epidemiology
(Andrews et al., 1998a).  A more unusual use has been by Jonsson
(1998), who attempted to link estimates of DALY loss due to diabetes
to costs of illness.  He concluded that any increase in incidence, and
therefore prevalence, would have a considerable economic impact.
Following a summary of injuries and non-communicable diseases
among children in developing countries, Deen et al. (1999) called for
more attention to be paid to the area, and for country estimates of the
burden of disease and the cost-effectiveness of intervention strategies
to be made.
Estimates of DALYs lost have been questioned in two ways.  One
approach has been to provide alternative measures of impact alongside
DALY estimates.  For example:
● Ramaiah et al. (1997) developed a disease specific questionnaire to
quantify the effect of lymphatic filariasis on domestic and occupa-
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43 See for example: Eisenberg (1997a) ‘the nations of the world must make a major
commitment to upgrade the quality of mental health services’; Blue and Harpham
(1994 p12) ‘sufficient evidence … now exists to warrant a greater emphasis being placed
on common mental disorders’; Shore (1999 p336) who concludes that ‘the next task for
research is to prove what clinicians experience everyday in their work with individual
patients – that modern treatment of psychiatric disorders is worth the money and is
even, in many cases, a bargain’.  Andrews (2000) argued that using burden of disease
figures alone, mental health services would warrant a three-fold increase in spending
relative to other health services in Australia.  However, he also argues that spending
should be related to the cost-effectiveness of interventions but notes the absence of data.
Therefore he outlines four alternative ways of splitting the budget for mental health
care, assuming that half of all care is emergency rather than a discretionary service.
Bremberg (1998) also used the global burden of disease results to focus on the mental
health of children ‘since this is the leading cause of DALYs lost in this age group’.
Finally, see a published series of supportive letters by Appelby et al. (1997) and
Eisenberg (1997b).
55tional activities and physical movement.  They found that 66 per-
cent of all patients reported limitations in occupation and 56 per-
cent of women reported limitation in travel and domestic activi-
ties, and that the most severe restriction was amongst those
patients with acute episodes of adenolymphangitis.  This, they sug-
gested, provided evidence that DALY estimates were likely to be
too low because previously there had been no data on functional
impairment and disability and they had shown that it was high;
● Guerrant et al. (1999) studied the physical fitness, activity and
cognitive development of a longitudinal cohort of 26 children
aged 6.5-9 years in Goncalves, a shantytown near Fortaleza, Brazil.
They argued that potentially there was a substantial impact from
early childhood diarrhoea and, if confirmed, there would need to
be significant revisions to estimates of DALYs lost from diarrhoea
and DALYs averted by interventions in cost-effectiveness analy-
ses44;
● Andrews et al. (1998b) have been among the few to suggest that
DALYs lost as a result of mental disorders may have been overesti-
mated.  They showed that mental disorder had particularly high
levels of co-morbidity and that therefore the measured global bur-
den of disease was likely to overestimate any potential gains for
treating this burden of disease, and especially for affective disorders
and substance abuse.
Such criticisms of DALY estimates were foreseen.  Indeed
Mansourian (1996, p334) suggested that one of the advantages of
using DALYs is that it would help highlight the data most urgently
needed.
The second approach to criticising the burden of disease estimates
has been to question the categorisation by cause.  For example:
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44 Kale (1998), rather than providing new estimates of burden, drew on Remme’s work
(Remme, 1998) to claim that the global burden of diseases underestimates DALYs lost
from onchocerciasis.  The two main reasons given were the reductive measure of benefits
(which does not account for the social costs of disfigurement from river blindness) and
the definition of blindness adopted (which assumes only those with 3/60 sight are blind,
whereas Kale argues that due to the environment even those with more sight than that
can be treated as practically blind).
● the burden of blindness has been considered to be underestimated
because it ‘is limited by the categorisation of the major causes of
blindness within children within other groups of disorders such as
malnutrition, communicable disease, perinatal disorders and con-
genital abnormalities’ (Rahi et al., 1999, p387);
● Hyder and Morrow (1999) show the impact of assuming that
DALYs lost begin at the age of death rather than at the age of dis-
ease onset.  They argue that this causes the DALY to underestimate
the burden of HIV and any other disease with a strong secular
trend.
Appendix 4 outlines eight studies that provide new estimates of
burdens of disease using DALYs45.  Four of these studies included
communicable diseases, two non-communicable diseases, one covered
all types of diseases and one focussed only on providing a new set of
disability weights for The Netherlands.  Four of the studies were fund-
ed, at least partly, by national governments and two by research organ-
isations, with the other two not stating the source of funding.  Only
three papers focussed on a specific country (The Netherlands,
Australia and UK), as the majority considered globally distributed
populations such as the world’s poor, or endemic malarial areas.
The main reasons for using DALYs in these studies were the desire
to use a single outcome measure (Martens et al., 1995) and to make
comparisons with other diseases (Chan, 1997) but also because the
impact of the global burden of disease exercise led researchers to
believe that DALYs were more likely to be used in the future to influ-
ence policy (Stouthard et al., 1997; Hollinghurst et al., 2000).
Hollinghurst et al. (2000) took a more unusual slant as they calculat-
ed ‘avoidable’ DALYs based on considering whether effective treat-
ment was available.  The eight papers were split between using Mark
1 and Mark 2 DALYs.  It is noticeable that, despite desires for com-
parison, the assumptions and sources of data used in the construction
of these DALYs differ significantly between studies.  Even for those
presenting base case DALYs [0.03, 1, 0.04], the sources of data either
differed or were unclear.
56
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45 These papers were found using the search strategy set out in Appendix 1.
573.2 Cost-effectiveness analysis
One of the most extensive uses of DALYs in cost-effectiveness analysis
was provided by Jamison et al. (1993) and reported in the World
Development Report (World Bank, 1993).  Using the DALY Mark 1,
a comparative analysis of 50 specific health interventions in 24 disease
areas was presented for developing countries.  The results were an
amalgam of conclusions from the ensuing chapters of the book even
though it was recognised that the methods of assessing cost and effec-
tiveness of intervention varied by chapter, thus complicating compar-
isons, but they were accepted as ‘reasonable first approximations’.
Nevertheless Jamison stated that ‘our concern is with generalization –
with addressing trends and findings that are important for a suffi-
ciently large number of countries that they assume significance for the
developing world as a whole’46 (Jamison, 1993).  The broad policy
conclusions drawn were that:
● there is no strong tendency for primary prevention or public health
interventions to have a superior cost-effectiveness;
● virtually no cost-effective interventions require more specialised
facilities than those available at district hospitals;
● a broad array of interventions are likely to make economic sense,
whatever the income level of the country;
● governments should plan to expand those services with costs below
$75 per DALY averted, for which a list was provided.
Appendix 5 reviews the 16 papers found47 that used DALYs as an
outcome measure in cost-effectiveness analyses.  It can be seen that 11
of these were published after 1997.  The majority focus on interven-
tions for communicable disease, and there is a preponderance of
papers about Sub-Saharan Africa.  These studies tended to be funded
by single agencies and most often by an international organisation or
a bilateral aid agency.  Nearly all papers compare the results of their
study with the ‘cut-off points’ used by the World Bank to signify good
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46 One reason for confidence in the results is that the World Development Report
claimed ‘differences in cost-effectiveness between one intervention and another are often
much larger than either the variation from one locale to another or the uncertainty of
the estimates’ (World Bank, 1993, p62).
47 These papers were found using the search strategy set out in Appendix 1.
or poor value for money.  They also compare their results with the
cost-effectiveness ratios for treating other diseases in different coun-
tries around the world.  Compared with the papers using DALYs for
burden of disease studies, summarised in Appendix 4, a greater pro-
portion of the cost-effectiveness analyses, in Appendix 5, focus on
‘hypothetical’ populations, but there is a similar split between those
using Mark 1 and Mark 2 DALYs.
With respect to the construction of DALYs, it is interesting to note
that, when the assumptions were made explicit, all used a discount rate
of 3 percent.  However, four papers chose to exclude the age weight-
ing, and in another six it was not clear what had happened.  When
using age weighting, 0.04 was always used.  With respect to disability
weights, the picture is different: two papers used only YLLs to calcu-
late DALYs and therefore the issue was not relevant; in eight cases it
was unclear whether weights had been applied or what rate was used
if they had; in two papers the weights applied were those developed in
Murray and Lopez (1996a); and in four cases the weights cited had
been drawn from other literature or assumptions of the authors.  There
is as much variation in the approaches taken to life expectancy: four
papers did not state the life expectancy used or the source of data; five
papers appeared to use the standard life expectancies presented in
Murray and Lopez (1996a), where life expectancy at birth is 80 years
or more; and the remaining seven used various estimates for local
cohorts.  It is important to note that those using the standard life
tables reproduced in Murray (1996) will overestimate the relative effi-
ciency of the interventions.
Of the 16 papers, eight did not present any sensitivity analysis con-
cerning assumptions involved in estimating DALYs.  Of those that
did, the variables most frequently examined were the discount rate, life
expectancy and case fatality rate.  The disability and age weights were
only examined once each.
3.3 Sectoral prioritisation exercises
The developers of the DALY combined burden of disease and cost-
effectiveness analyses to provide ‘sectoral analyses’.  The underlying
58
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59belief was that priorities for health sector spending ‘should go to those
health problems that cause a large disease burden and for which cost-
effective interventions are available’ (World Bank, 1993, p63).  This
had a significant impact on the proposals for governments to consider
adopting the ‘minimum’ and ‘essential’ packages of care recommend-
ed48.  The justification for the design, content and financing of an
essential package for national health services was outlined by Bobadilla
et al. (1994) for low- and middle-income countries49, based on the find-
ings of Jamison et al. (1993) and the global burden of disease exercise.
Whilst the mechanisms for undertaking the sectoral analysis are a little
vague in Bobadilla et al. (1994), Bobadilla and Cowley (1995) elucidate
the World Bank’s determination of an essential health services package
in practice.  Table 6 shows the steps planned.  It can be seen that, fol-
lowing an assessment of the burden of disease, broad judgements of the
cost-efficacy50 of interventions are made as a first stage process in select-
ing interventions and prior to any estimation of local costs.
There are several references testifying to the use of DALYs in pri-
oritisation exercises.  For example, Andrews et al. (1998a, p157) wrote
that ‘developing countries such as Mexico have successfully applied the
DALY based methodology to define priorities and essential packages
of care, and over 20 other countries are trialing this approach.  The
United States, Japan, the Netherlands, Sweden and most recently
Australia have begun or are planning national burden of disease stud-
ies’.  However, whilst the approach outlined in Table 6 was followed
in Mexico, Bobadilla and Cowley (1995) also show that countries with
higher mortality rates and lower incomes do not manage in practice to
48 An alternative, illustrative, model of resource allocation using DALYs for health
sector decision-making is given in Murray (1995a,b) and Murray et al. (1994).
49 Considering packages of interventions, rather than single interventions in isolation,
was considered particularly advantageous because of: the ability to consider jointness in
production as well as co-morbidities; potential synergies between treatment and
prevention; and the possibility of improving the use of specialised resources through
screening and referral.
50 Efficacy is distinguished from effectiveness, although without specific definition in
Bobadilla and Cowley (1995).  It would appear that the distinction is made between the
potential (efficacy) and actual effectiveness in practice, given a country’s different health
care scenarios.
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Table 6 Basic steps in designing a package of essential health
services in middle-income countries
Step Activity
1 Estimate the burden of disease due to premature mortality and
disability for approximately 100 diseases and injuries by age, sex
and geo-political region
2 Estimate the burden of disease for a selected list of proximate
risk factors, for example, inadequate water supply and
sanitation, protein energy malnutrition, tobacco consumption
and alcohol abuse
3 Select interventions that fulfil one of the five criteria: favourable
cost-efficacy; ability to address diseases, injuries or risk factors
with a high burden (about 1 percent or more of the total); high
supply or demand; high recurrent expenditure; ability to address
diseases of public concern.  Health interventions should include
three types: public health, community outreach, and clinical
(outpatient and hospital)
4 Estimate costs for the selected interventions and clusters of
interventions that are justifiably provided together.  This
includes making normative assumptions about technical
efficiency and desired quality of care
5 Assemble information on efficacy of interventions and estimate
the expected effectiveness for the country’s different health
scenarios
6 Define time frame and population coverage (current and
targeted) to estimate incremental cost per intervention per year
(including overheads and cost of limited diagnostic and health
services)
7 Congruent with the current model of care and constrained by
the financial resources available, construct a package of cost-
effective interventions that can be delivered in the same facilities
and through common mechanisms
Source: Bobadilla and Cowley (1995, pp553-554).
© John Wiley & Sons Limited.  Reproduced with permission.
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61work through all these steps.  For example, countries in East Africa
considered mortality only and a Ugandan study considered neither
burden of disease nor cost-effectiveness analysis specific to Uganda.
One of the most useful documents detailing this work is by Bobadilla
(1996), who reviewed the scope and methods of setting priorities in
World Bank lending projects.  He showed that all the large studies took
place in middle-income countries51 (mostly in Latin America and the
Caribbean) and that ‘none of the 19 countries undertook any analysis of
the types of disabilities and only two did any serious analysis of risk fac-
tors’52.  He highlighted that the most ambitious study took place in
Turkey at an estimated cost of over US$3 million, and that negotiations
had shown concern not to allow control to be in the hands of foreign uni-
versities and consultants.  In discussing the ownership of the process by
individual countries Bobadilla also commented that World Bank staff or
foreign consultants had written 17 out of 24 reports.
In the application of the DALY, Bobadilla stated (1996, p24) that
‘half of the countries made significant modifications, and one (Russian
Federation) used a different indicator.  Five countries did not discount
future health losses and all the countries that discounted used a three
percent rate.  Five countries did not apply any age weights’ and three
used a different disability scale.  He concluded that ‘only seven of the
19 study results are comparable in terms of the indicator and scope of
the study, five belong to the Latin American and Caribbean region’.
However, for nationally run studies, it is not surprising that there are
differences because, as Bobadilla (1996, p25) pointed out, ‘interna-
tional comparability of burden of disease studies should not be a pri-
mary concern of countries’.  He also showed that five countries used
no cost data, a further four had cost data on fewer than 20 interven-
tions, and only three focussed specifically on cost-effectiveness (for a
maximum of 35 interventions).
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51 Bobadilla (1996, p15) suggested that this was probably linked to the intensity of
World Bank lending rather than any other characteristics.
52 He also developed this point to suggest that the consequences of this were that no
country proposed any rehabilitation services (when analysis has shown this to be very
cost-effective), and that therefore resource allocation was significantly biased.  The lack
of consideration of risk factors was also argued to reduce the emphasis given to public
health and preventive activities (Bobadilla, 1996).
62 Few examples of sectoral prioritisation exercises are published53.
The findings of a four year project based in two districts in Tanzania
that set out to ‘test the hypothesis that burden of disease and cost-
effectiveness analysis should provide the basis for health services plan-
ning in low income countries’ (Finlay et al., 1995, p1083) are on the
point of being reported (The Economist, 2002).  This article suggest-
ed that using a combination of data on the burden of disease and on
the cost-effectiveness of interventions to plan the provision of an addi-
tional 80 cents spending per person resulted in major health improve-
ments: infant mortality fell by 28 percent and mortality of children
under five by 14 percent between 1999 and 2000.  It will be interest-
ing to read the full reports soon.
Parallel to the on-going debates about, and construction of, essen-
tial national health services is the development of the World Bank ini-
tiated ‘sector-wide approach’.   Cassels and Janovsky (1998) explain
that this approach is intended to move from the individual project-
based funding of most donor agencies to their contributing instead to
the funding of the entire health sector54.  Feacham justified the sector-
wide approach as a way for national governments to co-ordinate
donors, and ensure that there is a single set of disbursement, procure-
ment, evaluation and reporting procedures (Abbasi, 1999a, pp1207-
8).  To counterbalance donor agencies losing their power to complete-
ly determine their own priorities within countries, they were invited to
participate jointly (without a controlling interest) in the planning of
health sector activities as a whole.  Cassels and Janovsky (1998) drew
on around four years’ experience from four countries (Zambia, Ghana,
Pakistan and Bangladesh) to suggest that whilst the results looked
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53 Carter et al. (2000) reported the results of a priority setting exercise for cancer
control using programme budgeting and marginal analysis.  They used DALYs as the
outcome measure and the global burden of disease results from the study by Mathers et
al. (2000) that was commissioned for the Australian Ministry of Health.  At the same
conference, Oswald (2000) reported the results of a prioritisation exercise in two states
in the US based on Tengs et al. (1995) and a model of the population’s health and
demographic characteristics.  I also understand that, sometime in the future, WHO are
planning to calculate and report the cost-effectiveness of 100 interventions in 17 regions
of the world.
54 All private and public institutions that have a stake in health, including the
household (Cassels and Janovsky, 1998).
63promising, the sector-wide approach is quite varied in its implemen-
tation and therefore not a universally applicable model55.  However, it
appears that this is a framework within which the use of DALYs in cal-
culating the burden of disease and expected cost-effectiveness of health
interventions might be given substantial support.
3.4 Indicating the direction for health research and
development
The developers of DALYs have also been involved in the report
‘Investing in Health Research and Development’ (Ad Hoc Committee
on Health Research Relating to Future Intervention Options, 1996),
which used DALYs to consider the justifications for future research
and development.  Table 7 shows the broad approach adopted, with
three selected examples.  The Ad Hoc Committee report states that
only a few selected examples could be evaluated rigorously and that
many evaluations relied heavily on expert judgement and qualitative
analyses (p9).  The 17 recommendations in the report were aimed at
governments, industry and other investors, concerning the allocations
of funds to, and within, health research and development budgets.
The recommendations covered a wide range of specifications such as:
● reallocations of money (e.g. from HIV to TB);
● increasing the size of resources for developing and evaluating pack-
ages of care (e.g. for the ‘Mother-Baby package’);
● the development and evaluation of policy instruments (e.g. for
tobacco control);
● studying the impact of research on policy;
● establishing a forum to bring together governments, donors and
researchers56.
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55 But note that some Pakistani officials have been critical of the ‘problem of leadership
among donors’ because just having what might be a good idea does not mean it can be
implemented suddenly.  They complained that: systems in Pakistan were said not to be
geared up for such a change; the changes suggested were not based on the reality of the
situation on the ground; and that system-wide changes may take a long time to trickle
down to an impatient and poverty stricken populace (Abbasi, 1999b, p1133).
56 The Global Forum for Health Research was set up in January 1998 and reports of
its activities, in particular its re-direction of research, can be found in Global Forum for
Health Research (2000) and on the website www.globalforumhealth.org
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Two other organisations have also published work concerning the
use of DALYs in the prioritisation of research and development.
Oortwijn et al. (1998, p226) reported initial experiences with a new
model of priority setting for the US$21 million annual budget of the
Investigative Medicine Programme of the Dutch Health Insurance
Council57.  They concluded that four dimensions were important for
considering ‘relevance’.  The first was the burden of disease, for which
they cited the World Development Report as ‘playing a role’, despite
noting its ‘controversial’ method of measuring burden58.
The other, possibly better-known, example is the retort published
concerning the NIH, whose credibility had been questioned by advo-
cacy groups with respect to their choice of disease areas for research
funding (Varmus, 1997, 1999; Gross et al., 1999).  Following pres-
sure, an analysis ‘to determine whether the amount of funding the
NIH allocates to research on particular diseases is associated with
commonly available measures of the burden of disease’ was undertak-
en.  The DALY was among the outcome measures chosen by the NIH
because ‘it incorporates the social values placed on various aspects of
the physical, mental and social function’ (Gross et al., 1999, p1883).
Gross et al. found that the relation between NIH funding and DALYs
lost in ‘established market economies’ was statistically significant at the
99 percent level (Spearman’s rho = 0.62, p < 0.001), and that such a
relationship could not be found when NIH funding was related to
incidence or prevalence, although there was a positive association with
mortality (Spearmans’ rho = 0.4, p = 0.03).  Turning the tables on the
advocacy groups, it was pointed out that such groups can mislead pol-
icy makers if they only provide information using a single indicator to
measure the burden of disease, as the results are extremely sensitive to
the measure chosen.
57 This was described as the most important programme for health technology
assessment in the Netherlands, and is accessed predominantly by universities and
university hospitals.
58 The other dimensions included: searching Cochrane reviews; the HARMET and
Eur-ASSESS European projects which aim at developing consensus in methods for
economic evaluation; and implementation of results.
There is a growing critical literature focussing on the constructionand use of DALYs.  The aim of this section is to outline the range
of criticisms raised in the literature to date.  Many criticisms have
focussed on the specific assumptions concerning approaches to
weighting DALYs and I begin with these.  This is followed by various
concerns raised about: whose values are, and should be, represented;
the existence and quality of data; and how helpful DALYs are for deci-
sion-making in the health sector.  The range of criticism is summarised
in Box 5.  It is particularly noticeable that the majority of critiques
centre on notions of value.  Perhaps this is because, as Sundby (1999
p280) stated:
‘the initial presentation of the concepts as a tool in a World
Bank policymaking document, already demonstrates that it is
difficult to separate the critique of the methodology itself from
its application in a politicised debate on health reform’.
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4  CRITIQUES OF DALYS
1. The appropriateness of weights in DALYs for:
● life expectancy
● age
● future time
● disability
2. Whose values are, and should be, represented?
● conceptions of ‘health’, ‘disease’ and ‘disability’
● the role of ‘experts’
● the universality of disability weights
● gender bias
● human rights
● integrating equity
3. Quality of data
4. DALYs’ usefulness for decision-making:
● costly and time-consuming to construct 
● international versus national priorities
● burden of disease versus cost-effectiveness analysis
Box 5 The range of critiques of DALYs
674.1 Alternative views about the weights in DALYs
4.1.1 Life expectancy
Two aspects of life expectancy have been questioned: the choice of an
‘ideal’ standard for life expectancy; and the size of the difference
between male and female life expectancy.  In choosing to use DALYs
to calculate the burden of disease, Bowie et al. (1998, p41) question
the relevance of using Japanese life expectancies for national or region-
al priority setting in the UK.  They argue that using Japanese life tables
would give more weight to the elderly relative to the young than if
British life tables were used.  This highlights the potential differences
in the needs or desires of national and international decision-makers
and also reflects the concern that any one intervention is unlikely to
have a major impact on overall DALYs because of all the other con-
tributors to mortality and disability.  However, Musgrove (2000,
p111) suggests that national decision-makers should use the ‘standard
expectation of life’ approach because ‘if all the diseases contributing to
the burden were controlled to the extent that they are in Japan, life
expectancy would rise to 80 or more years, just as in that country’59.
Williams (1999 p4) develops Bowie et al.’s criticism and considers
the implication of assuming a hypothetical standard for life expectan-
cy for cross-country comparisons.  Whilst acknowledging the appeal-
ing moral position, he criticises the ‘strong political judgement’ on two
grounds.  First he queried whether such a ‘fiction’ should be intro-
duced as part of the composite measure of DALYs.  He suggested that
it would be clearer if two sets of calculations were made, so that
DALYs using actual and hypothetical life expectancy could be com-
pared.  This would allow people to see the impact of the political
judgement made for international comparisons, and would presum-
ably be more acceptable for national level data analysis.  Williams’ sec-
ond concern focussed on the implications of the current decision to
base DALYs on a life expectancy of 80/82.5 (male/female) in all coun-
tries.  He wrote that it
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59 Presumably this would also entail ‘interventions’ to include the same diet, level of
exercise and occupation – i.e. almost ‘becoming’ Japanese.
68 ‘is equivalent to applying an equity weight greater than 1 to each
year of life lost in a country where life expectancy at a given age
is less than the standard.  This implied equity weight will be larg-
er the greater the ratio of the standard life expectancy to the actu-
al life expectancy.  If the actual were 20, but the standard were 40,
then each actual year carries an equity weight of 2.  When these
figures are 30 and 50 respectively, the implied equity weight is
1.6.  But when applied to the model life tables that are used in
the global burden of disease calculations, this process generates
some very peculiar results concerning intergenerational equity,
both within and between countries.’ (Williams, 1999, p5)
Using Figure 4, Williams shows these implied equity weights for
four different regional model life tables, when life expectancy at birth
is 50 years.  It shows that that those who survive into older ages are
accorded more weight to the remaining years of their lives than are
younger people in every region, and particularly in the ‘East’ and
‘South’ regions60.  Figure 5 takes this data one stage further, dividing
the ‘East’ life tables into ‘poor’, ‘middle-income’ and ‘rich’ countries
on the basis of life expectancy61.  This shows that old people in rich-
er countries are given more weight than young adults in poor coun-
tries, which he imagined was ‘an unintended and unwanted side-
effect’ in a measure purportedly trying to avoid the impact of inequal-
ities in life expectancies.
Anand and Hanson (1997, p690) criticise the choice of 2.5 years
difference in life expectancy between males and females as arbitrary.
First they highlight the significant disagreement regarding the relative
contributions of biological, environmental and social factors leading
to biological-genetic differences.  Secondly, they criticise the generali-
sation of Murray’s method, based on projecting an observation of nar-
rowing gender gaps among higher income quintiles in urban Canada,
across time and space.  Most specifically they argue that the actual gap
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60 Note that these are the equity weights implied as a direct result of using a
hypothetical standard for life expectancy.  As such they are different from the age
weights imposed additionally which were outlined in Section 2.3.2.
61 As Williams argues that life expectancy is closely correlated to real income per head
(Williams, 1999, p5).
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is likely to be wider, and that therefore the reduction effects a move-
ment of resources away from women if burden of disease estimates are
used for decision-making.  However, although Murray has argued that
the biological difference in mortality lies somewhere between 1.9 and
3.2 years (Murray, 1996, p18), he has also questioned the inequity of
the difference in length of life between men and women, as well as
suggesting that the biological difference could just be added as one
more contributor to the burden of premature death (Murray and
Acharya, 1997, p712).
4.1.2 Age weights
Debate concerning the age weights in DALYs has centred on: ques-
tioning the conceptual basis of weighting by age; potential double
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Figure 4 Implied age weights when female life expectancy at
birth is 50, for different regional patterns
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© John Wiley & Sons Limited.  Reproduced with permission.
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counting introduced by age-weighting; and the evidence for an ‘appro-
priate’ rate.
Four arguments have been put forward that question the concep-
tual basis behind weighting life years by age:
● a principal of ‘universalism of life’ has been invoked to argue that
the value per life year should be common to all people regardless
of their age (Anand and Hanson, 1997, p694)62;
● using notions of dependency discriminates against those with
fewer dependencies and social ties.  However, as much of health
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Figure 5 Implied weights for ‘East’ only with differing life
expectancies at birth
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62 This assumes no diminishing marginal utility of additional life years (Donaldson et
al., 2002)
71care is given to an individual rather than on the basis of other peo-
ples’ dependence on them, such principles are irrelevant as an eth-
ical base for allocating health care resources (Brock, 1998, p78);
● principles are used inconsistently.  For example, to weight by age
because it captures different social roles raises the question: why
stop there, why not also weight according to, for example, a per-
son’s occupation or tax bracket or productivity (Anand and
Hanson, 1997, pp691-2; Paalman et al., 1998, p17)?
● the one reason for stopping at age weighting is because an indi-
vidual can expect to move through all the life stages whereas this
would not be the case if ethnic, income or gender groups were used
for weighting (Brock, 1998, p78).  However Murray did not draw
out this reasoning.
A number of authors are concerned about the possibility of dou-
ble-counting the impact of age or are at least worried that the issue has
not been worked through clearly from concept to method, results and
interpretation.  Bowie et al. (1998, p42) raise the question ‘is the
weight sought a function by age or individual’s social responsibilities?’
and worry also about the interaction between age weighting and dis-
counting.  Anand and Hanson (1997) ask for the exact question that
was posed to the TB programme managers63 and cited as part of the
evidence for the values given to preventing a death at different ages.
They wonder whether information had been elicited in a sufficiently
careful way to be sure that the values reflect an intrinsic value of time
lived at different ages and asked ‘how do we not know that it is not
reflecting their view of income levels and productivity through the life
cycle?’ (p692).  If this were the case, then selecting people with a dif-
ferent expected pattern of lifetime earnings would probably alter the
findings.  Like Tsuchiya (1999, p268), they also question whether the
value of living a healthy life at different ages was considered separate-
ly from the likelihood of disability.  If, for example, the programme
managers were properly informed about other adjustments in the
DALY formula (for example reductions in human function) the values
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63 This included 116 people from developing countries who had attended a
tuberculosis training course over a period of five years Murray (1996).
72 given in age-weighting would also reflect expectations of future dis-
ability and hence double count the impact of disability.
Questions concerning the evidence basis for age weights can be
considered in the light of Tsuchiya’s recent literature review (Tsuchiya,
1999).  She found some limited empirical evidence showing that peo-
ple do value health benefits differently depending on the age of the
recipient of health care.   However, she also concluded that the evi-
dence to suggest a particular rate for efficiency-based age weights is
extremely limited.  Given these contentions, and the suggestion that
age weighting is not used consistently in cost-effectiveness analysis
even by one of the developers of DALYs (Paalman et al., 1998, p17),
it is not surprising that there have been calls for age weighting to be
dropped, at least from the base case DALYs (Barendregt et al., 1996).
Williams (1999) suggests that age weights could be treated as an
optional extra.
4.1.3 Weighting future time
The questioning of weighting future time lived has focussed on why
discount and, if so, at what rate and with what functional form?64
Some critics have focussed on the nature of the good, for example
stating that health is not commensurate with money as health can-
not be re-invested elsewhere and so it should not be considered as a
financial flow and therefore should not be discounted (DfID, undat-
ed).  Some have focussed on the inconsistency of arguments used.
For example, Anand and Hanson (1997, p89) have claimed that
Murray’s rejection of the human capital approach as a basis for age-
weighting also implies a rejection of the view that health is com-
mensurate with money and that therefore any of the arguments pre-
sented concerning future consumption are irrelevant in any justifi-
cation of discounting.
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64 The only views reviewed here are those raised in the context of evaluating DALYs.
Other relevant arguments made in this area, but not yet directed specifically at DALYs,
are the possibility of adopting alternative functional forms for discounting future life
years saved (Cairns and van der Pol, 1997) and disentangling the effect of time
preference from the effect of the duration of health state (Dolan and Gudex, 1995).
73With respect to the social rate of time preference and inter-gener-
ational transfers, Anand and Hanson (1998, p309) disagree with the
use of a positive rate of discount because it can lead to forms of envi-
ronmental degradation as future lives are valued less than current lives.
Weighting the same life or disease differently by time period does not
accord with their ‘intuition or common language’.  They also question
why Murray feels uncomfortable with the implications of a zero dis-
count rate in recommending eradication of a disease, and wonder
whether feeling uncomfortable is a sufficient basis for a decision or an
excuse to fix results65.
As expected by Murray, the magnitude of the discount rate has
been questioned.  Sauerborn et al. (1998) criticise the choice of 3 per-
cent as arbitrary.  They draw on the mixed empirical evidence to ques-
tion the size of the discount rates, arguing that much more evidence
for 3 percent is needed given the profound impact it can have on the
ordering of burden of disease.  In particular they suggest that com-
munity-based studies in countries across the world should be used to
establish a rate rather than imposing a 3 percent discount rate across
all societies.  It would be interesting to establish whether a higher pri-
vate rate of time preference for health does occur in places where indi-
viduals face a higher annual probability of death and secondly whether
this is related to a higher social rate of time preference.
The functional form of the discounting element of DALYs has
been questioned in two ways.  First, Sauerborn et al. (1998), drawing
on existing literature (e.g. Gafni, 1995; Johanesson, 1992), question
whether the exponential function fully characterises an individual’s
time preference and suggest that it may depend on age but that more
research is required to determine this essentially empirical question.
Secondly, Elbasha (2000) has questioned the representation of time in
the DALY discounting formula as a continuous rather than as a dis-
crete variable.  Three reasons are given to justify a discrete approach:
the use of discrete time intervals is more common, especially in eco-
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65 However, contrast this with their own arguments based on ‘intuition’.  It would
appear that they feel uncomfortable with age weighting (Anand and Hanson, 1997,
p698).
nomic evaluations; it corresponds to the way that health and econom-
ic data are usually reported (i.e. specified time intervals such as an
hour, a day, a week, a month, a year); and discrete intervals are con-
sidered more plausible, because age standardisation formulas use dis-
crete weighting functions.  Elbasha reformulated both the age weight-
ing and the discounting formula in a discrete-time version, and com-
pared the estimates of DALYs lost due to cataracts in Africa in 1990.
The impact of the reformulation is greatest in diseases of short dura-
tion and for older people.  Thus DALYs as currently formulated are
argued to underestimate the burden of disease in these cases, although
it is not clear how the total burden for all diseases would change.
4.1.4 Weighting disability
The conceptualisation, measurement and valuation of disability is the
area that has been subject to greatest debate.  This section focuses on
questions raised about whether disability should or should not be
weighted, use of the PTO approach, the effect of the presence of co-
morbidity and whether ‘adaptive’ weights would be more appropriate.
Other issues concerning the definition of health and disability and
methods used to elicit values are discussed in the next section.
Several people have questioned the commensurability of death and
disability.  Anand and Hanson (1997, p689) take the softer critical
stance, noting the convenience of being able to combine imperfect
health and death in a single indicator, but stating that treating death
purely as another health state results in a significant loss of informa-
tion.  They suggested that DALYs should always be presented sepa-
rately as YLLs and YLDs (even if trade-offs between them could be
demonstrated).  This would have the advantage of allowing those who
believe that the two events were incommensurable (e.g. Field and
Gold, 1998, p17, drawing on Kamm, 1993) and that a life, whatever
its quality, is always preferred to death, to adopt different decisions
and to understand the impact of moving from one indicator to anoth-
er.
Arnesen and Nord (1999a, p1425) develop a stronger critique and
invoke the Declaration of Human Rights to argue that rights to life
extension should be equal for all people and not dependent on the
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75level of disability66 – the core positioning of the disability rights move-
ment that policy analyses should not make distinctions among lives
that are still worth living.  In an emotive illustration of this view,
Groce et al. (2000, p2) decry the alignment of people with disabilities
as lying somewhere between life and premature death.
The particular problem with the Mark 2 DALY’s approach to the
PTO, of forcing experts into adopting a particular view of the value of
disabled versus healthy lives, was set out in Arnesen and Nord (1999a).
For example, the first PTO question asks about the relative value of
extending the life of 1,000 sighted and 1,000 blind people (see Box 3
above).  An expert may reasonably conclude that these are of equal
value if they do not want to discriminate between the lives of disabled
and able-bodied people, such that the resulting disability weight
(1,000/1,000) = 1.  The second PTO question is different (see Box 3)
and does not require that a final weight of less than 1 is based on a sup-
position that the lives of disabled people are worth less than those of
the able-bodied.  Say an expert considers that relieving 5,000 people
of blindness is as valuable as prolonging the lives of 1,000 healthy
people.  In this case the health state ‘blindness’ would be given a dis-
ability weight of 0.2.  Therefore, quite logically, the PTO exercise
results in two different disability weightings for the same health state:
1 or 0.2 according to which question is being asked.  However, the
current methodology does not allow this positioning and the expert is
forced to make their valuations ‘consistent’.  Under the pressure of
such forced consistency, an expert might end up selecting PTO1 =
1,100 and PTO2 = 11,000, which together yield a disability weight-
ing of 0.09.  As Arnesen and Nord (1994, 1999a) state, ‘this weight-
ing, however, does not correspond to any actual preference of the
respondent’ and they conclude that the disability weightings are mere-
ly ‘artefacts’ threatening the validity of the entire global burden of dis-
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66 This was in response to receiving training in a workshop of European researchers
working with DALYs, as the trainees were told that they were expected to give a higher
value to saving healthy people than disabled people because if they were equal ‘it implied
that being disabled is as good as being non-disabled’ (Arnesen and Nord, 1999a,
p1424).
ease exercise.  They suggest that the first PTO question should simply
be dropped from the valuation exercise.
As part of any academic piece of research, it would have been inter-
esting to be able to access information on the extent to which these
issues were demonstrated.  Unfortunately none of this data has been
published.  Perhaps this criticism is keenly felt, given that a respondent
from one of the valuation exercises felt compelled to write about the
experience (Nygaard, 2000).  Not only did she indicate that people
had raised such issues during the meeting she attended but had ‘resis-
ted’ weighing the saving of lives of some against improving the health
of others.  She concludes that ‘the validity of valuations made in the
face of serious doubts and outright resistance and refusal to participate
are worth questioning’.  Secondly, she raises a related concern about
whether the use of average scores are a good representation of any one
individual with the disease as she hints that there may well have been
bimodal distributions of values.  These issues are compounded given
the arbitrariness of the classifying the seven categories of disability.
However, once again with no data presented on such issues, serious
questions are raised about the meaning of the disability weights and
what they represent.
Daniels’ (1998, p66) suggests that what is needed is a different
approach.  He suggests that ‘more complex methods that lead subjects
through a series of questions that import arguments and reasons’
should be the basis for making these trade-offs between quality and
quantity of life because complex philosophical exploration is more
likely to uncover evidence about why people weight as they do and not
simply uncover unconsidered tastes.  He states that:
‘if a good moral argument persuades us that our original belief
about what is right is in fact incorrect, we may be chagrined,
but we are (or should be) grateful as well.  We have been spared
doing what is wrong.’
Sauerborn et al. (1998, pp9-10) accepted combining quantity of
life and disability but suggested that the DALY could go further and
capture the possibility of weighting the impact that death or illness
(for specific diseases) may have in terms of the reduced chances of sur-
vival or quality of life on others (regardless of age).  Their suggestion
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77is particularly relevant for infectious diseases.  However, given the
paucity of accounting for co-morbidity in DALYs (Mansourian, 1996,
p334), it is unlikely that potential disease is likely to be considered yet.
One of the problems of not accounting for co-morbidity, pointed
out by Sayers and Fliedner (1997, p383), is that any future interven-
tion planned on the hypothesis of a single disease may fail to make the
anticipated impact because DALYs are not ‘logically linked to the real-
ities of disease and disability’.  Therefore there are concerns that use of
DALY weights will overestimate the impact that health services can
have because, once one cause of disease is eliminated, the DALY
approach assumes that all people with that disease are treated success-
fully and return to zero DALYs lost (or to the value of the treated state)
because it is implicitly assumed there is no co-morbidity.
That disability weights in DALYs deliberately do not account for
how well a person may have adapted to their condition has also been a
source of criticism.  For example, Anand and Hanson (1997, p694) sug-
gested that ‘compensated disability weights’ that capture the factors
affecting an individual’s capacity to cope with their disability (given their
circumstances) would be more appropriate.  These adaptive weights
would more closely reflect the true burden of disability as experienced
by the individual.  They suggested that indices of income or the provi-
sion of transport services may be usable for adjusting disability
weights67.  Rock (2000 p412) also criticises the use of pre-adaptive
weights because it causes over-emphasis on rehabilitation (rather than
on modifying the person’s physical or social environment) and on invest-
ment in people who do not have disabilities.  She argues that if the
DALY quantified ‘adaptation’, then interventions that extend the lives of
people with disabilities would become more cost-effective in compari-
son with those aimed at preventing disability.  Such measurement would
be more acceptable to governments pursuing policies of social inclusion.
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67 Murray and Acharya (1997, p713) clarify the impact of choosing adaptive or pre-
adaptive weights: using pre-adaptive weights will make prevention and rehabilitation
more attractive in cost-effectiveness analysis, but life extension for those with paraplegia
will appear to be less cost-effective.  Using the adaptive weights will make prevention
and rehabilitation much less attractive in cost-effectiveness analysis, but it will make life
extension more cost-effective.
Finally, Paalman et al. (1998, p18) queried the approach taken to
separate intensity and frequency of disability because this did not
allow for any interaction of the two variables.  Thus they suggest that
permanent or temporary inability to walk may be more or less than a
constant value multiplied by time.  Perhaps if adaptation occurs over
time it would suggest a diminishing or decreasing relationship
between intensity of, and time in, a disease state.
4.2 Whose values are, and should be, represented?
4.2.1 Conceptions of ‘health’, ‘disease’ and ‘disability’
The representation of DALYs averted as a measure of health gain and
a desirable goal has been debated.  Implicit in much of the criticism is
disagreement about who is making judgements about whom and with
what consequences.  Some stress that DALYs are a measure of disease,
and disapprove of its biomedical orientation towards conceptions of
health (Barker and Green, 1996, p181; Hanson, 1999, p12; Kindig,
1999, p17).  There is so much more to health than the absence of dis-
ease, for example the ability to call on support networks during sick-
ness or the ability to think clearly and work through problems that
might arise.  As Mooney and Wiseman, (2000, p371) state, ‘to assume
that the BOD [burden of disease] sums it all up, or that whatever else
is there is constant across the diseases in all these countries, is surely a
false premise’.
Others focus on the limitations of using disability as the basis for
the measure.  For example, Wasserman (2000) notes the appropriation
of the language of the International Classification of Impairments
Disability and Handicap (ICIDH) group by Murray and raises two
issues.  First Wasserman argues that it is the consequences of limita-
tions not the limitations themselves that determine the value of a non-
fatal outcome.  This view finds much support among those concerned
that the DALY weights take no account of context (AbouZahr and
Vaughan, 2000, p662; Hanson, 1999, p13; Brock, 1998, p73; Sayers
and Fliedner, 1997).  Secondly, Wasserman notes that even though the
DALY is described in the language of the ICIDH, the ‘disabilities’ are
actually described in terms of disease symptoms rather than common
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79activity limitations (such as difficulty walking or reading).  Perhaps
this discrepancy occurs because disability itself is never defined and is
assumed to be an illness (Groce et al., 2000, p2).
This links closely with the beginning of a fascinating critique by
Rock (2000), whose thesis juxtaposes the trial of Latimer68 and
DALYs to expose and compare implicit beliefs about disability.  She
begins her criticism with the observation that ‘the DALY regards dis-
ability as pathology – as disease in need of elimination …. it deems
time lived with disability as having less worth than time spent in ‘per-
fect health’’ (Rock, 2000, p408).  She states that, whilst there is no sin-
gle biomedical model of disability, ‘biomedicine does take the desir-
ability of a ‘normal’ body as its starting point, yet ‘perfectly normal’
bodies seem in short supply’ (p416).  She contrasts this with the pic-
ture conveyed by DALYs that ‘imagines ‘normality’ as limitless in
human populations, and universal but for injustice.  The DALY thus
portrays ‘premature’ death and observable pathologies as preventable
and even ‘unnatural’’ (Rock, 2000, p415).
Part of the reason for the focus on disease can be gleaned from the
view that an outcome measure should be able to measure the impact
of ‘health action’, which Murray and Lopez (undated, p9) defined as
‘any set of activities whose primary intent is to improve or maintain
health’.  This was exemplified by education.  Whilst more education is
related to improvements in health, they are not the primary aim of
education services, and therefore education would not be included as
a ‘health action’.  ‘Health’ is therefore defined, almost with circularity,
as what is delivered by health services which try to control disease.
Musgrove (1997, p2) is concerned about this limited focus of
DALYs, albeit from the opposite direction.  He argues that improving
people’s health (through disease control) leads to many benefits on top
of health itself, especially in children, such as increased opportunities
for education and production as well as better health in adulthood.
He therefore claims that measurement using DALYs under-represents
the benefits of health care, and particularly so in children.  He calls for
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because of her severe disabilities.
80 an understanding of the trade-offs between, for example, graduating
from another year of school versus being free of disease for three years.
Block et al. (2001, p1538) are of a similar view and stress the necessi-
ty of conceptualising the whole range of benefits, to allow a shift of
focus away from a sole concentration on the individual and their inter-
action with health services to a wider variety of actors and other ben-
efits.
One of the strongest criticisms of the descriptive basis of DALYs
can been seen in the response of the Dutch Disability Weights Project
group to eliciting weights for disease states in The Netherlands.  Their
approach was to systematise the description of disease states69 in terms
of levels of functioning using an adapted version of the EuroQol
group’s instrument the EQ5D70 (Brooks, 1996).  An example is given
below in Box 6.  This also shows that, even though this project group
gives the same title to a disease, the description of the disease differs
from that in the original DALY exercise71 and the dementia is also
described as severe72.
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69 They also changed the range of disease states considered, to include fewer tropical
diseases and more chronic diseases seen in affluent societies (Stouthard et al., 1997, p9).
70 See Appendix 2 for an introduction to the EQ-5D.  The adapted version referred to
here varies from the official EQ5D version in a number of ways: it is based on six, rather
than five, dimensions by adding a dimension on ‘cognitive functioning’; the levels of
severity in some dimensions are mixed, e.g. described as ‘no or some problems’, whereas
in the original version no problems and some problems are separate levels of severity; a
percentage figure is used to indicate severity in two dimensions, which is not done in
the EQ5D; and the wording of the ‘self care’ dimension is changed.
71 Dementia was described in the DALY exercise as ‘An individual with multiple
cognitive deficits that include memory impairment and aphasia (difficulty producing
the names of individuals and objects) and apraxia (impaired ability to execute motor
activities despite intact motor abilities, sensory function, and comprehension of the
required task).’
72 This was because the researchers did not believe it was possible for raters to assign a
single weight to the condition in its entirety because to achieve that it would be
necessary for all respondents to have an equal command of all the following
information: familiarity with all the sequelae; the contribution of each disability to total
morbidity burden due to the condition and therefore knowledge about the prevalence,
incidence and length of illness; and be able to arrive at an average weight for the entire
disorder.  Because researchers thought this was implausible (Stouthard, 1997, p13),
diagnostic categories were instead ‘staged’ by severity levels.
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The reason for Stouthard et al.’s (1997) departure from purely dis-
ease-based descriptions was that even though medical ‘experts’ were
thought to have a real insight into the consequences of disease, it was
considered ‘strongly unlikely that all the members of the panel would
have a comparable level of expertise’ and the move towards generic
descriptors was a way of standardising the information considered.
This idea has received some support from Nygaard (2000 p121)
who had participated in one of the WHO valuation exercises (with
just the disease based descriptors) and confessed that ‘I caught myself
using my own assessments of the various diseases, and not the ones
provided … and I believe this might also have been the case for other
participants.  Hence it is difficult to know what was actually valued’.
Whether this is more or less likely with the original DALY description
of disease states or with the Dutch approach is a moot point.
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DEMENTIA
Patients with severe dementia (permanent supervision required)
● Some problems in walking about (50 percent*) or confined to bed (50
percent*)
● Unable to wash or dress self
● Unable to perform usual activities (e.g. work, study, housework, family
or leisure activities)
● No pain or discomfort
● Moderately (50 percent*) or extremely (50 percent*) anxious or
depressed
● Extreme problems in cognitive functioning (e.g. memory, concentra-
tion, coherence, IQ)
Box 6 Example of the descriptive system used for dementia in
the Dutch Disability Weights Project
Note: *The percentages varied for the different indicator conditions.  However,
neither a justification for their inclusion nor an explanation of their intended
meaning was given in Stouthard et al. (1997).
82 4.2.2 The role of ‘experts’
Without ‘experts’ DALYs would have crumbled.  ‘Experts’ have been
involved at all stages, from their inception, through to their design,
estimation, valuation and interpretation.  ‘Experts’ have been used to
validate or refute numbers, conclusions and policies.  Musgrove (2000,
p111) wrote that the very tight deadline for producing estimates for
the World Development Report (World Bank, 1993) meant there
were no realistic options other than to include expert opinions.
However, their involvement in particular stages of the construction of
DALYs has attracted a lot of attention.  There has been no criticism of
their use in providing information about the distribution of mortality
or morbidity of disease or even of the distribution of severity of dis-
ease across populations73.  However, there has been particular criti-
cism about reliance on them for providing values concerning the
intensity of disease states, as well as for age weighting, discounting and
the concept of health adopted.
Many critics state that the ‘experts’ were not an appropriate group
of people to provide valuations of the impact of disease on disability
because:
● ‘experts’ do not necessarily have better judgement (Rock, 2000,
p414; Hanson, 1999, p20);
● ‘experts’ do not reflect societal preferences (Paalman et al., 1998,
p18; Bobadilla, 1996, p10); or at least the assumption that they do
has not been validated (Bobadilla, 1996, p10; Üstün et al., 1999,
p111);
● ‘experts’ lack personal experience (Paalman et al., 1998) and there-
fore their values are likely to differ from those of the general pop-
ulation and those of people experiencing the particular difficulty
(AbouZahr, 1999, p123; Nygaard, 2000, p118);
● ‘experts’ have ‘systematic biases’ (Brock, 1998, p75);
● there was no representation from an organisation of people with
disabilities (Groce et al., 2000);
● values of life with disability differ between able-bodied people and
people with disabilities (Groce et al., 2000);
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73 This does not mean there has been no disagreement with the estimates given!
● medical professionals inevitably see need in terms of medicine
rather than in social, economic or rehabilitation terms (Groce et
al., 2000);
● the choice of ‘experts’ had precluded national/local values (Morrow
and Bryant, 1994, p163).
Barker and Green (1996 p182) bemoan the fact that ‘we are not
told how these (‘experts’) were chosen; one might guess that every
effort was made to span the regions of the world in choosing ‘experts’
of various nationalities, but we do not know if a similar effort was
made too in terms of gender or class’.   Indeed several authors have
questioned why only 40 percent of the ‘experts’ were women (e.g.
Hanson, 1999, p12) and have pointed out that, given that the ‘experts’
were public health professionals sufficiently well known to receive an
invitation to an international consensus meeting in Geneva, it is
unlikely that they were from lower social classes.  In fact, AbouZahr
(1999, p123) goes further and claims that DALYs ‘can only be used by
people with a relatively high degree of literacy and understanding of
basic economic concepts.  It is therefore by definition, an exclusive
process driven by academic rather than experiential knowledge’.
Nygaard (2000, p122) agrees and also highlights the limitation
imposed by the need for panel members to speak English.
Nygaard’s (2000) paper is particularly interesting because it allows
us to consider how expert the ‘experts’ may feel.  She writes that in
practice when trying to make assessments of severity, ‘one soon realis-
es that the degree of severity, even for fairly objective dimensions of a
health condition, depends on contextual factors’.  She states that the
global burden of disease project recognised this and therefore asked
raters to consider the ‘average social response or milieu’ but she asks:
‘Is it possible to describe an ‘average social response or milieu’, there-
by including contextual issues, in a reliable way’?
If it is accepted that such values should not be predicated on
‘expert views’, then whose views should be solicited?  The majority of
papers suggest that either the general public (Williams, 1999, p6) or
people with disabilities or who are patients (Paalman et al., 1998, p18;
Hanson, 1999, p20) would be the most appropriate.  The main argu-
ments in favour of these alternatives are because the policy context
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84 focuses on society in general and because of the value given to personal
experience.  Nygaard (2000, p122), however, points to the problems
of using any of these views as a route to concluding that the whole
exercise is too difficult and that a single index should be abandoned.
Perhaps one of reasons for the strong reactions against the use of
‘experts’ has been the ‘express disavowal’ of including community pref-
erences (AbouZahr, 1999, p123).  Rock (2000, p412) questions why
Murray suggested that if people with disabilities report happiness it is
because they suffer from false consciousness, especially given that no
evidence was provided for such assertions (Wasserman, 2000).  Rock
(2000) went further and dissected Murray’s comparison of slavery and
disability, which she states ‘implies that people with disabilities are
unfairly trapped in their ‘diseased bodies’…(and) that people with dis-
abilities form a class of people who, like slaves, cannot provide valid
information about how they experience the world’.  Thus, all question
whether Murray’s ‘expert’ opinion on the role of ‘experts’ is sufficient.
4.2.3 The universality of disability weights
A number of researchers have voiced concerns over the assumption
that the weights assigned to disabilities can be applied meaningfully
across the world (Nygaard, 2000, p123; Sayers and Fliedner, 1997;
McMichael, 1995, p555; Groce et al., 2000, pp4-5).  There are ques-
tions both about why the assumption is made and how likely it is to
be true.
Wasserman (2000) cites two propositions of egalitarianism74 put
forward by Murray and suggests that ‘taken together, these proposi-
tions ensure that no personal or cultural characteristic of an individual
(wealth, religion, intelligence, race, beauty or socio-economic status)
shall be taken into consideration when determining the ‘burden of dis-
ability’ represented by his or her health status’.  This approach runs
counter to the conceptualisation of disability sponsored by the WHO
in the International Classification of Impairments, Disability and
Handicap, and does not even attempt to account for handicap, despite
any claims by Murray to the contrary (Wasserman, 2000).
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‘Why should we assume that one person’s perception of her quali-
ty of life is commensurable with another person’s, especially if the two
people are separated by language and culture?’ asks Wasserman (2000).
The burden of disease can only be judged in the context of the culture
of the individual, including the economic, family and social circum-
stances of the individual and as such it is likely to result in complex
population-wide heterogeneity (Sayers and Fliedner, 1997, p383).
The unpublished evidence cited by Murray that there was close agree-
ment between groups of health professionals on the values assigned to
the indicator conditions does not signify that real disability is uniform
across countries (Üstün et al., 1999, p112).
Indeed, most authors draw on evidence to suggest the contrary.
Brock (1998, p73), for example, considered that, in a setting in which
most labour was manual, limitations in physical functioning would be
likely to have greater importance than they would in a setting in which
most individuals are engaged in non-physical, knowledge-based occu-
pations, where certain cognitive disabilities are of greater importance.
He suggested such differences would be ‘magnified when summary
measures of population health are employed for international compar-
isons among very disparate countries’.
Groce (1999) litters her text with additional examples of diversity
and wonders why the DALY ‘ignores an entire body of research and
advocacy that has been developed over the past 20 years’ based on the
thesis that the impact of disablement is dependent on context.  Using
some of the same indicator conditions as the DALY Mark 2, Sadana
(cited in Hanson, 1999) asked 40 women aged between 17-54 in
Cambodia to give weights for disability for a range of health conditions
from the global burden of disease.  She found that most women gave
higher disability weights than the global burden of disease exercise
especially for those associated with stigma or shame for women (e.g.
vitiligo on the face and infertility) and that this was consistent across
education and age groups.  Whilst it should be noted that Sadana used
different methods to the global burden of disease exercise, she did con-
clude that it was important to assess community/population values.
Üstün et al. (1999, p111) appear particularly concerned about the
presumption of universality when the numbers were derived from a
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86 single PTO exercise carried out at the WHO in Geneva.  They sug-
gested (p115) that a further reason why DALY disability weights may
not be universal is that in addition to the description of disabling
effects of disease/conditions, valuations will also be driven by mood
and public opinion.  They called for ‘more systematic testing across
cultures and different informant groups, with other forms of measure-
ment’ and therefore asked groups of around 15 people from 14 coun-
tries75 the same questions.  The groups were comprised of:
● medical professionals (e.g. physician, psychiatrist, psychologist,
nurse);
● allied health professionals (e.g. social worker, case worker);
● policy makers or opinion leaders in the area of disability services;
● individuals with a disabling physical condition and their care-
givers;
● individuals with a disabling health condition related to alcohol,
drugs or mental health, and their care-givers.
Results showed that the conditions at the extreme ends of the
ranking exercise showed less variability between informants than for
the middle-ranked conditions, which focussed mainly on conditions
related to mental health.  Üstün et al. (1999) also found that differ-
ences between countries in disability weights were statistically signifi-
cant for 13 out of 17 conditions (but with no differences for quadri-
plegia, paraplegia, amputation below the knee, and mild mental retar-
dation).  Their main conclusions were that:
‘the relative burden of different health conditions, in terms of
disability, is fairly similar across the world …(but that)…there
are systematic, and in some cases, pronounced differences
between cultures and informant groups.  These differences are
large enough to shed doubt on the assumption of universality
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Canada Greece China
Japan Romania Egypt
Luxembourg Tunisia India
The Netherlands Turkey Nigeria
Spain
UK
87of the disability rankings, and subsequently on the weights,
and they are large enough to be investigated further in a sys-
tematic way’ (Üstün et al., 1999, p115).
Such differences have led to suggestions that cross-country com-
parisons would be vitiated and interpretations, at best, rendered mean-
ingless (Sayers and Fliedner, 1997).  Nygaard (2000, p123) went fur-
ther and suggested that it:
‘could lead to governments using their resources for pro-
grammes that give the biggest improvements (i.e. reductions)
in the burden of disease, as determined by the GBD [global
burden of disease] project, in order to score well in WHO
comparisons of national health improvements.  However,
national considerations might well indicate quite different
improvements in health and health care’.
4.2.4 Gender bias
It has been acknowledged that the use of the DALY methodology has
brought reproductive health (especially with regard to women) more
prominently onto the global health and development agenda76
(AbouZahr and Vaughan, 2000, p657).  Yu and Sarri (1997) have used
DALYs to document changing patterns of female diseases and causes
of death.  But, there has nevertheless been an interesting group of
papers published presenting a gender-based criticism of DALYs.  They
centre on: the types and implications of missing data; gender sensitiv-
ities in the construction of the DALY; and the problems of focussing
only on disease.
DALYs rely on existing reported data.  Therefore, if that informa-
tion is gender biased, then estimates of DALYs will be too.  Sundby
(1999, p281) argues that more health data are processed for men than
for women and that, when there are no gender disaggregations, the
norm is often the adult man.  Under-reporting can be a particular
problem in places, due to a ‘culture of silence’ (Sauerborn et al., 1998,
p8) especially if deaths result from induced abortion or suicide
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76 See Section 4.4 of this monograph for a summary of the critiques about using
estimates of burdens of disease to fix policy agendas.
(Hanson, 1999).  AbouZahr and Vaughan (2000, p659) note that
many reproductive health problems only surface when there are seri-
ous complications or through direct questioning.  Given that maternal
causes of ill health are such a large proportion of the overall burden of
disease, the imprecision of current estimates in maternal health under-
mine confidence in the estimates of women’s overall health burden
(Hanson, 1999).
Another type of under-reporting is built into the model of diseases.
A number of absences from the list of diseases captured by DALYs
were found by comparing the list with the definition of reproductive
health provided at the International Conference on Population and
Development (AbouZahr and Vaughan, 2000, p658).  These omis-
sions included gynaecological morbidity due to sexually transmitted
diseases, menstrual disorders, female genital mutilation, psychological
disabilities due to sexuality and reproduction and stillbirths.  It was
also noted that different forms of gender related violence are missing
such as forced sex and female infanticide (AbouZahr and Vaughan,
2000) as well as the impact of contraceptives on women’s lifetime
health (Sundby, 1999).
A particular problem, highlighted in the section on conceptions of
health, is the over-reliance on averting DALYs through medical inter-
ventions rather than broader multi-sectoral developments.  If DALYs
focussed on health rather than disease, resources would be more like-
ly to be directed to poverty alleviation than medical interventions, and
the increasing feminisation of poverty means that failure to address
this issue adversely affects women, and increasingly so (Sundby, 1999,
p282).  Curlin and Tinker (1995, p345) draw on the marginalisation
of older women, especially widows, in Bangladesh to highlight the
relationship between social exclusion and chronic diseases or malnu-
trition and have called for disease to be viewed in its social context.
Finally, there have been some interesting positions taken about
potential biases in the methods used to estimate DALYs, which might
underestimate the true relationship between gender and health.  For
example:
● many issues in reproductive health lie between health and social
well-being (e.g. empowerment and reproductive rights, circumci-
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sion, domestic violence, illegal abortion or lack of labour regula-
tions for working pregnant or lactating women) and are therefore
not captured in an approach that favours distinct diseases (Sundby,
1999, p283);
● the estimated gap between the burden of disease of women and
that of men is compressed in two ways: by accounting and adjust-
ing for the riskier behaviour of men; and because the additional
gains in life years receive less weight in women due to discounting
(Hanson, 1999, p22);
● given that one of the reasons justifying age weighting was welfare
interdependence, the age profile used to reflect value of women by
age may be underestimated relative to men as young girls in many
societies have extensive responsibilities for childcare and food
preparation, and it is not clear that women’s responsibilities for the
welfare of others decline as they reach old age (Sundby, 1999,
p283).
4.2.5 Human rights
The ethical positioning of the construction and use of DALYs has
been contested in two broad areas concerning human rights: the right
to life and the right to self-determination.  Debates around DALYs
and the right to life range across: the right of a foetus to be considered
alive; the right to be born; and the ‘rule of rescue’.
Lal (1994) contrasts studies implying very different values attached
to the life of a prematurely born infant (for whom death even after one
minute would mean a lifetime’s DALYs had been lost) and the value
attached by both QALYs and DALYs to the life of an unborn foetus
(who, if it died prior to birth, has no impact on DALYs lost).  He
shows that it matters crucially when a person comes into existence, as
once a person exists then all future DALYs and QALYs count but,
until that time, none do.  He comments:
‘the beginning of a person seems inherently vague, so it seems
wrong to attach great importance to the moment when it
occurs … if we doubt there should be a large difference
between the value of saving a premature baby and the value of
saving a foetus, that may make us doubt that the value of sav-
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90 ing a baby is really all the QALYs in the rest of her life’ (p7).
This view is part of a much wider debate but it does allow consid-
eration of how well the assumptions of QALYs and DALYs reflect
national or state laws on the right to life, whatever one’s position.  For
example, the UK’s current legal position allows pregnancies to be ter-
minated77 but only on certain grounds78, and it is clear that the posi-
tioning of DALYs lies with the ‘pro-choice’ rather than ‘pro-life’ (anti-
abortion) campaigners.
Considering the role that measuring DALYs has on determining
the cost-effectiveness of pre-natal testing, highlights the ethical judge-
ments being made about the quality and value of human life.  This is
particularly significant given recent announcements of the mapping of
the human genome.  If genetic tests will enable parents to identify foe-
tuses susceptible to disease or disability, then the tests may also have a
more ‘eugenic’ connotation for public policy.  It will mean that health
care professionals can identify children and adults who are currently
healthy but who have particular susceptibilities and assign a discount-
ed value to their lives.  With respect to the future birth of children, it
could mean that children likely to be born with disabilities have less
right to life79.
The ‘rule of rescue’ is the third argument raised in connection with
the right to life.  Glick (1994, p179) argues that when an identifiable
person’s life is threatened by a treatable condition we ‘will almost
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77 By a registered medical practitioner, in a hospital or licensed clinic (except in
emergencies).
78 Including where: the pregnancy has not exceeded its 24th week and the continuance
of the pregnancy would involve risk, greater than if the pregnancy were terminated, of
injury to the mental and physical health of the woman or of any existing children of her
family; the termination is necessary to prevent grave permanent injury to the physical
or mental health of the woman (no time limit); the condition of the pregnancy would
involve risk of grave physical and mental injury to the woman or to the life of the
woman, greater than if the pregnancy were terminated (no time limit); or there is
substantial risk that if the child were born it would suffer from such physical or mental
abnormalities as to be seriously handicapped (no limit). See
http://www.gn.apc.org/nac/newsite/reference.html
79 For example, there would be less reason to allocate health resources to a pregnant
woman with a child more likely to be disabled than not, other things being equal
(Wasserman, personal communication).
91invariably refuse to stand idly by’.  Because DALYs have been equated
with reflecting preferences in decision-making, then the DALY should
account for such rules.  As they do not, it is argued that prioritisation
exercises based on cost per DALY averted are likely to fail (Glick,
1994).  However, on this point, Musgrove (1994) draws the analogy
of doctors choosing how to allocate their time to a group of people
each considered a medical emergency.  Because this happens, it is
argued that it is not unethical per se to ask ‘How long will the saved
individual live as a result and in what condition?’ and thereby to
choose who to treat.  Nevertheless, he believes that, these questions
tend to arise for very ill patients who are already hospitalised, when it
is urgent to consider how much ‘life’ can really be ‘saved’ by further
interventions, taking into account both quality and duration.  In those
circumstances, he argues that ‘cost-effectiveness is a reminder that the
rule of rescue should not be invoked to justify every effort to keep a
disabled person alive for only a short while longer’.
Regarding rights to self-determination, Wasserman (2000) cites
the view that the great majority of people with disabilities regard their
lives as well worth living and to suggest otherwise is ‘disrespectful in
its exaggeration of their burdens and its disregard of their testimony’.
It also clearly contravenes notions of individual consumer sovereignty
if such values are used to control private decision-making within a
public health system.  Indeed a classical liberal positioning would lead
one to question the right of the state to choose on behalf of an indi-
vidual.  ‘If people knowing the risks choose a risky and legal activity
with a high probability of shortening their lives, and bear its financial
costs themselves, their decision is to be respected’ (Lal, undated, p3).
However, when individuals do not bear the costs themselves and are
subsidised by the state or others80, the issue becomes clouded.  This
becomes even more difficult if one purpose of state intervention is to
focus on equity, such that questions like ‘When should we allocate
resources to produce ‘best outcomes’ and when should we give people
fair chances at some benefit?’ are raised (Daniels, 1998, pp58-9).
Given that there are no principled solutions yet for these issues, it is
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92 not surprising that there is concern that the results from the global
burden of disease exercise are being used as a replacement for ethical-
ly sensitive deliberations across the world (Daniels, 1998).
4.2.6 Integrating equity81
Gilson (1998, p1892) argues that any health care allocations dispro-
portionally favouring disadvantaged social groups, such as the poor,
are acceptable with DALYs only to the extent that they maximise
aggregate health status gain given existing resources.  She contrasts this
with an equity-driven approach that promotes a broader basis for deci-
sion-making in three respects:
‘First, it requires consideration of the broader policy action
required to promote health equity.  Second, the concern for
equity also points towards the broader policy goals that might
be pursued through health policy.  Third, the pursuit of equi-
ty forces consideration of decision-making procedures in soci-
ety, and the extent to which they allow for broad representation
and so expand choice’ (Gilson, 1998, pp1893-4).
Pro-equity policies therefore emphasise ‘the need to redistribute
societal and health resources to address the particular needs of the poor
and other vulnerable groups such as the old and chronically ill’ (Gilson,
1998, p1894).  However, an allocation rule based on minimisation of
DALYs lost for a community will give less weight to saving the life of a
disabled person than of an able-bodied person.  In doing so, ‘the poli-
cy of giving priority to saving the able-bodied would be to compound
the disadvantage of the disabled: those who are already worse off
because of a disability would be made more worse off because of being
discriminated against in the allocation of heath care.  It heaps a handi-
cap on a person who is already worse off ’ (Sen, 1997, p217)82.
4  CR IT IQU ES OF DALYS
81 Clearly equity could relate to many factors such as age, gender, degree of disability
etc.  As much of this has already been covered, I focus primarily on equity of income.
82 See pages 214-218 of Sen (1997)for a formalisation of the argument, based on
ordinal comparisons, which shows that pursuit of DALYs increases inequality of
capabilities and that the converse (a compensatory policy of giving more care to disabled
people) will decrease inequality.
93Drawing on some of the arguments from the disability rights
movement, that DALYs discriminate against those unable to return to
perfect health, prompts consideration of whether this can also be said
of the poor.  If a poor person is less likely to return to full health than
a rich person (other things being equal), then resources based on max-
imising health will discriminate against the poor.  If so, then Gilson’s
critique is particularly strong, considering that it is the rich elite who
have been involved in developing and valuing DALYs.
Others have been at pains to argue how the two objectives of equi-
ty and efficiency can work together.  For example, Musgrove (1994)
argues that equity and cost-effectiveness are entirely compatible goals
in the global burden of disease exercise, given certain conditions83,
although he does point out the discrimination against older people
because they have less life remaining than young people, and against
people who live in less accessible places because of the greater margin-
al costs of their accessing health services.
One of the potential solutions to some of these issues is to create
an additional set of explicit equity weights.  To date there have been
three suggestions:
● using the concept of a ‘fair innings’ based on age, to replace the
weights implicit in the global burden of disease exercise Williams
(1999, p7);
● using weights related to income levels (DfID, undated);
● societal valuation could be reflected as a multiplication of: change in
utility from an intervention; weighting for the severity of the initial
condition; and a weight for ‘potential for health’84 (Nord et al., 1999).
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83 These include when: two people with the same health problem at the same age are
treated identically and the only distinction is the expected survival of men and women;
no account is taken of people’s income, because what is measured is health rather than
its consequences for productivity; there is no discrimination by race or other factors; and
no account is taken of co-morbidity or of the health risks that face a person beyond the
immediate problem for which the cost-effectiveness of treatment is considered.  Under
such circumstances, Musgrove (1994) argues that the health of an African child is not
judged to be less valuable than that of a child in a rich country.
84 This is designed to counter the discrimination between patients with different
capacities to benefit associated with QALYs and DALYs.  Basically, it devalues large
health gains relative to smaller health gains.
94 4.3 Quality of data
Early critics voiced concerns over the availability of the different
aspects of data required for the calculation of DALYs.  For example, in
his review of Murray and Lopez (1994a), McMichael (1995, p555)
felt that:
‘much of the assignment of a disability-time score to various
non-fatal illnesses has relied on guesswork, since there are few
systematic data available to assist in this Herculean task’.
Most critics concede (see for example, Sauerborn et al., 1998) that
Murray and Lopez are well aware of the deficiencies of data85 (proba-
bly more so than the critics) and that, as Paalman et al. (1998, p15)
wrote, it ‘is an ongoing exercise, and data are improving as time goes
by’.  Despite this, there appears to be a general feeling of unease as the
sources and implications of all the assumptions and estimations are
not clear (Sauerborn et al., 1998, pp1-2).  One improvement called for
by Paalman et al. (1998, p16) was for confidence intervals, or at least
upper and lower limits, to be attached to the estimates of global bur-
den of disease.  Alternatively, as ‘experts’ had often provided guessti-
mates for the range of required data along with an indication of how
reliable they felt their estimates were, it would have been interesting to
see such information presented.  Without this, the quality of all esti-
mates is assumed to be the same.
More recently, AbouZahr and Vaughan (2000, p662) have made a
number of recommendations for improving the quality of data in the
area of reproductive health.  In addition to developing descriptions
and measures of reproductive health as part of a cross-national research
agenda they suggested improving the underlying epidemiology by:
● setting up a series of country case studies bringing together and
analysing all the available information on reproductive health;
● standardising analysis of existing demographic and epidemiologi-
cal data collected in longitudinal studies;
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85 See for example, Lopez’s own critiques of cause of death statistics in Lopez (1987;
1990) and Ruzicka and Lopez (1990).  Musgrove (2000, p114) writes ‘it is probably safe
to say that every single issue raised by Paalman et al. (1998) was debated extensively, and
sometimes acrimoniously, within the Bank and WHO; arguments between orthodox
economists and public health specialists were often particularly sharp’.
95● funding longitudinal studies to detect the incidence of reproduc-
tive ill-health and the risk of subsequent complications.
4.4 The usefulness of DALYs for decision-making
4.4.1 Costly and time-consuming to estimate
A number of authors have commented on the resources required and
available to undertake the calculation of DALYs for burden of disease
exercises and cost-effectiveness analyses.  Concern has been voiced that
burden of disease exercises are ‘cumbersome’ (Hyder and Morrow,
1999) as well as being ‘expensive and time consuming, often taking
key ministry personnel away from vital day to day activities’ (DfID,
undated).  This mirrors concerns of Barker and Green (1996, p182),
who asked whether DALYs were worth the bother:
‘in some countries resources are so short that even the most
minimal health care programmes are beyond reach.  In that sit-
uation, can health planners feel justified in standing back and
carrying out the necessary research to construct DALYs?’
Others have gone further and suggested that the wide range of sci-
entific, analytical and technical capabilities required for policy analy-
sis ‘are rare in most ministries of health in less developed countries’,
and required much support and capacity building in such countries
(Mosley, 1994, p28).  There is evidence to suggest that, even when
exercises have been undertaken, policymakers in Uganda perceived the
burden of disease methods to be complicated and difficult to under-
stand86 (Kapiriri and Norheim, 2000).  Given these difficulties, it
increases the likelihood of Barker and Green’s (1996, p182) concern
that DALYs will be imported off-the-peg, so that global or regional
estimates will simply be applied to an individual country for decision-
making rather than estimated locally.
Budgets and resources obviously differ across countries.  In the
high-income setting of Australia it is interesting to note that the bur-
den of disease exercise was not believed to exceed a ‘modest’ one to two
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advocacy and resource mobilisation, and in providing criteria for resource allocation.
person years of available analytical resources (Vos and Mathers, 1998,
p516).  However, Vos and Mathers (1998) also felt that far more
resources needed to be invested in the cost-effectiveness analysis.
4.4.2 International versus national priorities
It is helpful to remember that the World Bank87 was the major funder
of the 1993 World Development Report (World Bank, 1993) that
launched DALYs globally.  The World Bank has become the leading
source of funding in the health sector amongst international agencies
(see Ugalde and Jackson, 1995, citing Buse; Reich, 1995, citing Walt,
1994, p494) alongside its role as a development institution.  Therefore
the desire for some form of international prioritisation exercise was a
key factor in the thinking and process of development of the global
burden of disease project and DALYs.
Subsequently there has been much emphasis given to extending
the global burden of disease framework to national settings to aid pri-
oritisation of national health expenditures (Bobadilla and Cowley,
1995; Lozano et al., 1995).  However, critics have questioned whether
the DALY approach can ever be used to reflect a nation’s priorities.
For example, Ugalde and Jackson (1995, p527) have argued that, as
the World Bank is not a democratic institution, its controlling inter-
ests lie with the largest stockholders, principally the US, UK, France,
Germany and Japan.  They question how such a bank can both prof-
it from and assist the developing world88.  Any prioritisation exercise
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87 In conjunction with the Rockefeller Foundation and Edna McConnel Clark
foundation.
88 It is important to note that the World Bank is not set up as a profit making
institution, although the International Bank for Reconstruction and Development has
earned a net income every year since 1948 (which the Board of Governers decides how
to allocate to the reserves, as surplus, or for distribution).  The International Bank for
Reconstruction and Development accounts for around three quarters of the World
Bank’s international lending and it is here that voting power is linked to members’
capital subscriptions.  The International Development Association accounts for the
remaining quarter of the World Bank’s lending and is directed at interest-free loans
(known as ‘credits’, but charged at a 1 percent rate of interest, to cover administration
costs) to those countries with a Gross National Product per person less than US$885
and who lack creditworthiness to borrow on market terms but who demonstrate good
policy performance (judged on more than 20 criteria).  Readers are directed to the
World Bank website for more information: www.worldbank.org
set up and supported by the World Bank, they argue, must necessari-
ly reflect (at least partially) the desire to profit from the future.  Others
have argued for democracy and accountability to national populations
rather than international organisations:
‘in my opinion, national priorities on the use of health care
resources should be based within each country, and be deter-
mined by open debate and a democratic process.  In this
debate, the global DALY weights might be one piece of infor-
mation.  Decision-makers, however, should be accountable to
the people of their own country for their decisions and not to
WHO or the World Bank or any other international organisa-
tion’ (Nygaard, 2000, p123)
It is important that national settings are considered aside from
global decision-making agendas not only for democracy and local
accountability but also because national settings have different epi-
demiological and economic needs that are not recognised in the gross
aggregation of world or regional data.  Thus the burden of disease as
well as the costs and effectiveness of interventions will differ and the
‘cultural, economic, political, environmental, infrastructural and
behavioural differences will all impact on the package finally chosen’
(Paalman et al., 1998, pp14-15).  So, Paalman et al. ask, how can
international prioritisation exercises set relevant national priorities
when the results of any prioritisation exercise are ‘location, time and
group specific’?  Murray et al. (1994, p189) imply that this is merely
a function of data availability and recommend moving towards cost-
effectiveness production functions as a way of understanding and
increasing the relevance of cost-effectiveness ratios produced in one
context to another.  Whilst this is certainly a useful way forward, it
does not necessarily question the nature of the production function
across countries and to do so would require research nationally rather
than simply the global application of models of production functions.
4.4.3 Burden of disease versus cost-effectiveness analysis
Separately there have been some particularly strong criticisms of the
use of DALYs in the burden of disease approach to decision-making.
The criticisms have mainly been directed at the approach rather than
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the DALY per se, but at times it is difficult to separate out the two
because the DALY focuses on disease.  Both Williams (1999; 2000)
and Mooney and Wiseman (2000) have called for an end to the use of
burden of disease exercises as a resource allocation procedure for health
services and for setting research priorities.  Both advocate the use of
economic evaluations based on available technologies, with Mooney
and Wiseman (2000) also calling for a more socially inclusive view of
outcomes.
Their argument stems from the premise that burden of disease
studies consider only part of the problem and have nothing to con-
tribute to the solutions.  Monitoring disease is mistaken, they argue,
and money should be re-directed to assessing the impacts of interven-
tions.  Williams (1999) argues that there ‘is no link, either in theory
or practice, between the total burden of disease and our capacity to
benefit’.  He highlights ‘the crucial difference between conceptualising
a problem in terms of totals and averages, and conceptualising a prob-
lem in terms of what can be done at the margin’.  The latter is where
information gathering should be concentrated and is what, he says, ‘we
so desperately lack’.  We should only be interested in interventions,
their effectiveness and cost, but that has nothing to do with total bur-
den of disease.  This view has also been accepted in a recent guide for
DfID staff (DfID, undated) that concluded:
‘just estimating DALYs lost through burden of disease is not
very helpful.  It tells us what we already know or suspect.  At
best it might be carried out periodically to assess overall health
progress.  At worst it may be an expensive luxury which poor
countries can ill afford’
Whilst Murray and Lopez have not viewed burden of disease
results as the sole input to decision-making, they have also noted the
forced reliance on estimates because of the paucity of evidence on the
cost-effectiveness/benefit of health sector interventions.  This is not a
good enough reason, argues Williams, and indeed continued funding
of burden of disease studies may become a self-fulfilling prophecy as
scarce research money is taken away from economic evaluations of
health interventions (Williams, 2000, p83).
Williams (1999) has accepted that burden of disease estimates
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could be an appropriate tool to consider how money for research and
development should be spent.  He writes ‘I can see some limited valid-
ity in this argument, in that we might not want to devote vast amounts
of research money searching for a way to eliminate a particular disease
if that disease were an insignificant contributor to the overall burden’
(p2).  However, he has three criticisms: first, that the argument falls if
the objective of the health system is also to alleviate symptoms or arrest
disease progression; second, that this approach does not account for
desires to reduce side-effects of drugs; and finally that it does not
account for the cost of the expected impact of the research in reduc-
ing overall burden.  He suggests (1999, p31) that:
‘(a) cheap and successful …(research programme)... attacking
a disease which does not impose a major burden in terms of the
health of the whole population, may nevertheless do more
good for population health than an expensive and unsuccessful
research effort directed at some disease which imposes an
enormous burden in whole population terms’.
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There have been a number of indications in the literature that theDALY is undergoing further development.  Bevan (1998, p1404)
and Arnesen and Nord (1999a, p1424) have written that a new ver-
sion of the DALY is expected to be launched in 2003.  Murray and
Lopez (undated, p15) and Murray, Salomon and Mathers (2000) have
outlined ongoing work surrounding the definition and valuation of
disability in five projects.  One has involved modifying and refining
the protocol for eliciting weights, using a convenience sample of inter-
national public health practitioners89.  The modified protocol has
been used amongst ten groups based in the US, Mexico, Brazil, the
Maghreb countries (Morocco, Algeria and Tunisia), Japan, the
Netherlands, and four multi-national groups of health care practition-
ers.  They have provided valuations for 15-22 disability states – with a
set common to all exercises – using a multi-method approach with
internal consistency checks and group discussions (Murray and Lopez,
undated, p15).
The Disability Weights Project for Diseases in the Netherlands90
(Stouthard et al., 1997; 2000) and the European Disability Weights
Project constitute further examples of DALY development.  The
European Disability Weights Project began in March 1998, following
completion of the Dutch project, and was funded by the European
Union.  The aims included:
● establishing a comprehensive list of the disability weights associat-
ed with the various diseases that constitute the major part of the
burden in Europe;
● improving, refining and validating the methodology for estimating
the disability weights;
● investigating the cross-national stability of the disability weights
(interpreting the differences if found);
● comparing the estimates of burden of disease across countries91.
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89 No details of the changes are given.
90 Also see http://www.bisociety.dms.it/Projects/BIOMED/Disability_weights.htm
91 See the website www.eur.nl/fgg/mgz/mgzprojects/BIOMED.html for the European
Disability Weights Project Newsletter.
101This project has partners in England92, Sweden93, Spain, Norway,
the Netherlands and Denmark.  Early correspondence on these proj-
ects highlighted dissatisfaction with the PTO questions as they
stood94 – see Box 3 earlier – (Arnesen and Nord, 1999b; Essink-Bott
et al., 1999) and the group has made changes, using only one person
trade-off question and dropping the requirement of forced consisten-
cy.
The final two related ways in which the measurement and valua-
tion of DALYs are being developed include: a multi-informant valida-
tion of the global burden of disease weights, in 14 countries (Murray
and Lopez, undated, p15); and the WHO multi-country survey of
health and responsiveness (Üstün et al., 2001).  Whilst Murray and
Lopez gave no details of changes to the descriptive system or to the
protocol for the first study, two were helpful in identifying the rough
direction.  AbouZahr and Vaughan (2000, p660) indicated that the
following domains had been selected for a pilot study to measure
health status in developing as well as developed country settings:
mobility; self-care; usual activities; pain/discomfort; anxiety/depres-
sion; cognition; sensory; energy/vitality; shame/embarrassment; par-
ticipation (or overall handicap in a given environment and socio-eco-
nomic context).  Nygaard (2000, p119) also indicated the likely adop-
tion of a modified EuroQol format ‘where the health condition is
defined by 5-8 psycho-social and physical dimensions …(at) five lev-
els of severity’, which she states ‘were put together by panels of ‘experts’
on different disease conditions, under the auspices of WHO, in order
to obtain consensus among a group of ‘experts’’.  Box 7 shows an
example of a new disease state piloted.  It can be seen that there has
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92 See http://spp3.bham.ac.uk/hsmc/HEF/hef%20research%209.htm for an outline
of this part of the project.
93 See
http://www.phs.ki.se/socmed/research/se/projects/estimating_disability_weights_.html
for the Swedish research project outline.
94 Arnesen and Nord (1999a, p1424): ‘In the new procedure, the devaluation of life
in disabled people was made explicit.  An international research group that intended
to use the procedure to establish disability weightings for Europe recently became
aware of the offensiveness and lack of validity of the method and is now finding a new
valuation method’.
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been a return to a dimension based description, but that the levels of
severity have been standardised, and that there are a total of 25,000
possible states using this example.  This approach draws heavily from
the framework of the EuroQol EQ5D questionnaire.
Sadana et al. (2000, p62) later outlined a whole range of potential
dimensions considered by WHO as a basis for separating out ‘health’
(e.g. pain) and ‘well-being’ (e.g. participation in usual activities).  It
was argued that these ideas were differentiated because ‘the ability to
engage in usual activities does not describe non-fatal health per se, but
limitations or performance in this area may be associated with a non-
fatal health state’ and they continued that ‘we would prefer to assess
non-fatal health directly’.
The state of play was set out recently in a series of discussion
papers which form part of the development of WHO’s survey of
health and responsiveness (Üstün et al., 2001; Murray et al., undated;
Salomon et al., 2001; Sadana et al., 2002;).  The domains that formed
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Description and dimensions of cervical cancer
Cervical cancer, marked by irregular bleeding, pelvic pain and malodorous
vaginal discharge*
X A few problems with moving around
X A few problems with self-care
XX Some problems with performing usual activities
XX Some pain and discomfort
XXX Much anxiety or depression
No cognitive problems
XXX Much shame and embarrassment
XX Some limitations to social participation
Box 7 Example of a new DALY disease state being piloted
Note: *The Xs represent the degree of severity of each dimension of the con-
dition on a scale of (blank) = no problems, to a maximum XXXX = severe
problems.
Source: Nygaard (2000, p119).
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the basis of the newly developed questionnaire based tool for survey
interviewing are outlined in Figure 6.
The questions chosen to represent each of these domains were
taken from existing survey tools, with many coming from the WHO
Disability Assessment Schedule (WHODAS II)95 domains.  This
questionnaire was piloted and then implemented in 71 surveys across
61 countries, using samples of between 5-10,000 respondents.
Within the exercise 11 health states were valued using a visual ana-
logue scale where 0 is death and 100 is perfect health96.  These states
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Figure 6 Domains for assessing health and related well-being
Health domains Health-related domains
● Vision ● Self-care Daily activities
● Hearing including eating
● Speech ● Usual activities Household 
● Digestion activities; work or
● Bodily excretion school activities
● Fertility ● Social functioning Interpersonal
● Sexual activity relations
● Skin & disfigurement ● Participation Societal 
● Breathing participation
● Pain including
● Affect discrimination and
● Sleep stigma
● Energy/vitality
● Cognition
● Communication
● Mobility and dexterity
Source: Üstün et al. (2001, p12).
95 The WHODAS II covers six domains of health; cognition, self-care, mobility,
interpersonal relations, daily activities at work and in the household, and social
participation and impact.  Further details can be found on the website
www.who.int/m/topics/whodas/en/index.html
96 Separate surveys using multiple methods for valuing health states (including PTO,
time trade-off and standard gamble) were also conducted on samples with high levels of
education.
104 included the respondent’s own health and ten other ‘health condi-
tions’, based on a seven domain health state description (including;
mobility, self-care, pain, affect, cognition, usual activities and vision).
Initial results concerning validity, reliability and cross-cultural compa-
rability97 are currently being produced.  The current commitment of
the WHO is to launch a World Health Survey to monitor health and
performance of health systems over time using a revised version of this
questionnaire instrument (Üstün et al., 2001, p59).
Finally, Murray et al. (2000) have made a tentative suggestion that
new summary measures of health could be developed if an approach
applied the principle of the veil of ignorance (Rawls, 1971) to choose
which of two populations (with differing characteristics) an individual
would prefer to be in.  Murray proposes that the population that the
individual chooses is considered healthier.  Nord (1999) offered an
operationalisation of this idea for gaining a weight for severe asthma.
He assumed two equal sized groups of people, some of whom are
healthy, some of whom have asthma, and some of whom have a fatal
disease, as outlined in Table 8.  Each person would be asked ‘Behind
a veil of ignorance, to which cohort, A or B, would you rather belong’?
This was described as a variant of the PTO and probability trade-off
based standard gamble technique98.  If the numbers in Table 8 repre-
sent the median point of indifference, such that 50 percent of respon-
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97 Of particular note within this exercise has been the attempt to make results across
countries comparable.  This stems from Murray’s repeated concerns that self-reports of
health are an unreliable basis for comparison because they do not reflect objective
physical measurement and because any valuation exercises are biased systematically
because people use scales differently in different countries (Murray et al., undated;
Saloman et al., 2001; Sadana et al., 2000).  ‘Calibration tests’, such as using vision charts
to test near and distant vision and tests of verbal fluency and recall, are being used as
‘objective’ measures used to adjust for ‘biases’ in self-reports.  ‘Standard case vignettes’
are also being valued to compare how the same health condition is rated by people in
different settings.   Clearly the practical, conceptual and statistical mechanics of these
approaches need to be evaluated when full details emerge.
98 The standard gamble technique offers respondents either (a) a certain outcome
health state I for t years; or (b) a probability p of full health for t years but with a
probability (1-p) of immediate death.  The probability p is varied until the respondent
is indifferent between (a) and (b), and this value of the probability p is used to weight
health state I.
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dents would rather be in cohort A and 50 percent would rather be in
cohort B, then the disability weight for suffering asthma from age 40
onwards would be calculated by dividing 5 by 20, i.e. 0.25, and sub-
tracting the result from 1 (assuming that ‘healthy’ is set to 1), i.e. 0.75
in this case.
Nord points out that the valuations made in this way could incor-
porate concerns that an individual has for their own risk of fatal dis-
ease versus asthma as well as the distribution of healthiness across the
population, and suggests that respondents need to be directed to think
in one of these directions.
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Table 8 Scenario for valuing different distributions of fatal and
non-fatal disease
Cohort Healthy Asthma (at specified Fatal Sum
level) from age 40 disease
A 80% 20% 0% 100%
B 95% 0% 5% 100%
106 The following discussion compares the relative merits of DALYsand QALYs and debates which might be a better tool.   I propose
that the answer will depend on who is using the measure, where, for
what purpose and from which viewpoint.  I pose three questions:
● are DALYs more widely applicable than QALYs?
● are DALYs better than QALYs as an outcome measure in econom-
ic evaluation?
● when are DALYs or QALYs more likely to feed into decision-mak-
ing?
Contemplating QALYs, I specifically consider the EQ5D
approach to their calculation99 because it is one of the few generic
measures which bases its index values on population derived prefer-
ences for alternative health states in relation to death and it is the only
health index developed from the beginning for use in more than one
country.
6.1 Are DALYs more widely applicable than QALYs?
The response to this question draws on how QALYs and DALYs have
been (and can be) applied in practice, as well as how widely held the
conceptual basis of either instrument is likely to be.  Section 3.1
showed that DALYs lost due to burden of disease were most consis-
tently applied by the original developers of the measure.  However
when others used them as an outcome measure in cost-effectiveness
analyses there was much variability in the assumptions and values
used.  Thus their use in cost-effectiveness analysis would appear to
suggest that a DALY is not a DALY is not a DALY.  DALYs differ in
the age weights and discount rates used, as well as the sources and
methods of deriving disability weights.  This latter re-scaling has some
resonance with Weinstein’s (1988) concerns about QALYs that disease
specific re-scaling of QALYs over-sensitises them for the purpose of
decision-making.  Thus both DALYs and QALYs have a potential for
variation in their application.
6  DISCUSSION
99 See Appendix 2 for a description of this instrument and the approach to deriving
the quality weights for QALYs.
107There may be more or less variation in the types of DALYs used in
practice compared with QALYs.  More variation might be expected
with DALYs because more assumptions are contained in the ‘base case’
that people might choose to change, for example the weights for age
and future time.  As many authors do not make their assumptions
explicit, this additional scope for variation causes problems for com-
parison.  Variation is less likely to occur in QALYs because assump-
tions for weighting time, for example, are generally presented sepa-
rately, e.g. as ‘QALY s discounted at x percent’.  However, less varia-
tion may occur in the way DALYs are calculated in practice because:
● a smaller range of people are calculating DALYs.  The WHO or
Harvard University global burden of disease groups and the World
Bank have been involved in the majority of applications to date;
● DALYs are used more frequently for national prioritisation exer-
cises undertaken at one point in time, whereas QALYs are more
frequently calculated in studies of the cost-effectiveness of individ-
ual health interventions over time;
● the focus of the DALY is on disease and disability rather than on a
broader concept of health or well-being;
● the DALY has only used one method of valuation and one set of val-
uations whereas EQ5D based QALYs have used several approaches
with a variety of general populations in different countries;
● the DALY burden calculations are based on an assessment of one
intervention rather than of a series of potential interventions100.
Whether DALYs or EQ5D QALYs cover a universal definition of
health or have a more universally held conceptual base is an interest-
ing question.  Both measures have been applied in several countries,
although only the DALY has been used as a global measure.  However,
wider application does not necessarily reflect universally held views.  If
DALYs focussed exclusively on disease rather than disability or some
aspects of handicap, it might be easier to argue that DALYs had
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100 However, it is curious that we do not know what the DALY based calculations for
treated and untreated populations include as the intervention.  It is also curious that
treatments and the effects of treatment are considered to be the same across the world,
with the only variation occurring in rates of treatment.
108 focussed on a conception of health used globally (albeit a very reduc-
tive conception) and practised widely in hospitals and health centres
across the world.  However, moving from descriptions of disease to
valuing the impact of disease on disability or handicap changes this.  It
also brings the DALY closer to the QALY.  Indeed it is interesting to
see how close to the EQ5D questionnaire layout the new question-
naires for operationalising the measurement of DALYs are.
It therefore becomes important to consider the approaches taken
in developing both instruments.  Most notably, neither instrument has
evolved from a study of conceptions of health in the countries within
which the instrument was designed for use.  At best they have relied
on a review of past literature.  Therefore the views of researchers pre-
dominate in the selection of the conception and description of health
adopted in both instruments (Fox-Rushby and Parker, 1994).  Indeed,
Murray states ‘I have chosen to measure disability not handicap’ (my
italics) (Murray, 1996a, p33).
Starting from researcher based interpretations of ‘health’, both
QALYs and DALYs then value descriptions of health/disease states.  The
DALY relies on ‘experts’ and the QALY more frequently on random sam-
ples of different lay populations.  Williams argues (1999, p53) that the
ability to develop local scoring systems is one of the strengths of the
EQ5D QALY101.  However, I doubt whether either approach, based on
only local valuations can ever be considered universal (or even widely
held) given that the conception and definition of health adopted in either
instrument did not attempt to access a variety of views across the globe
in the first place.
It is interesting to note that the EuroQol group, whilst supporting
the translation of the EQ5D into many languages, has moved to the
position where it argues that the translation guidelines it produces can
only be used to establish semantic equivalence and not, for example,
conceptual equivalence (Herdman et al., forthcoming).  Indeed mem-
bers of the EuroQol group have written about their concern that the
cross-cultural equivalence and universality of health-related quality of
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DALY, regional based scoring systems will be developed for that measure too and that
national valuations will also be possible.
life questionnaires is assumed rather than investigated (Herdman et
al., 1997).  They later offered an approach to help assess the extent of
equivalence of health-related quality of life measures (Herdman et al.,
1998).  The estimation of DALYs Mark 2 did not confront these issues
as the valuation exercises were developed only in English and the inter-
national ‘experts’ who provided values used English as the common
working language during valuation.  However, this does not imply
that conceptual interpretations were identical.  Secondly, given that
DALYs are now being operationalised as a survey tool, all the same
issues concerning translation, equivalence and testing will apply.
Unfortunately the WHO group appear to be concentrating on scale
rather than conceptual equivalence, which is the last form of equiva-
lence that should be tested (Herdman et al., 1997; 1998).
The extent to which either QALYs or DALYs represent universal
conceptions of health is likely only to be an accident … or is it?  In a
series of essays written from a universalist’s perspective, Wa Thiong’o
(1993) suggests that what is written about or propounded as ‘univer-
sal’ or ‘global’ is often highly questionable.  He writes, ‘I am suspicious
of the uses of the word and the concept universal.  For very often, this
has meant the West generalising its experience in history as the uni-
versal experience of the world’ (p26).  Maybe what is required, as he
suggests, is a movement of what is considered to be ‘the centre’.  A
more representative view of what constitutes health or the impact that
disease can have on people’s lives may change the way we measure
health.  The measures may then be capable of becoming genuinely
universal, rather than the imposed universe of well educated, wealthy,
white, middle class professionals from the US or other high- income
countries (Guyatt, 1993; Fox-Rushby and Parker, 1995).  Clearly this
would require a radical change in the thinking and practice of research
by those developing and using QALYs and DALYs.
6.2 Are DALYs better than QALYs as an outcome
measure in economic evaluation?
In addressing this question, it is important to clarify whether values are
likely to differ between the two approaches and to outline the mean-
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110 ing of ‘better’, which draws on:
● types of applications (e.g. estimations from literature; application
to evaluations of effectiveness);
● methodological issues (e.g. validity, reliability, sensitivity);
● inclusiveness (e.g. what is measured, whose values count).
The values given to disease states with DALYs and QALYs are like-
ly to differ.  Nord (personal communication) states that DALYs have
a much stronger upper end compression (values closer to full health)
than most versions of QALYs.  It can be seen, for example, that the
median values of the first four out of seven disability classes in Mark
2 DALYs (see Table 2 in Section 2.3.4) cover 30 percent of the scale,
with the bottom three disability classes spread across the remaining 70
percent of the scale.  Compare this with the EQ5D classification102,
where the first two out of three parts of the scale use 40 percent of the
valuation space between 0 and 1 and a quick calculation shows Nord
is correct.  Of course, this does not show which approach might be
‘right’, just that they are likely to give different values.  It is also the
case that the QALY approach allows for the possibility that health
states can be valued worse than dead whereas DALYs do not.  Finally,
as both the methods of valuation and the characteristics of the valuers
differ between the DALY and QALY approaches, there is evidence to
suggest that values are also likely to differ (Nord, 1992; Dolan et al.,
1996).
I found only one example of a microeconomic evaluation using
DALYs in a high-income country and this dealt with leishmaniasis
amongst immigrant populations in the US (Muenning et al., 1999).
Most evaluations using DALYs come from low-income countries and
are for interventions to reduce infectious disease.  The construction of
the DALY is having an impact on the outcome measures used in eco-
nomic evaluations from low- and middle-income countries.  For
example, in the period 1993-1996 only three academic papers report-
ed cost per DALY averted for interventions to control communicable
diseases (Walker and Fox-Rushby, 2000), whereas Appendix 5 shows
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the UK population (Dolan et al., 1996).
111that between 1997-2000 a further 11 papers using DALYs were pub-
lished and hence, where researchers once reported cost per death-
averted or life-year saved, there are now increasing reports of cost per
DALY averted (e.g. Marseille et al., 1998).  It is also clear that the cal-
culations of DALYs are all estimated, at least in part, using tables from
the burden of disease series (for the disability weight attached to dif-
ferent sequelae, for the time spent in the sequelae states, or for the dis-
ability weight attached to treated and untreated disease), see for exam-
ple Goodman et al. (1999).
One of the most significant explanations for the current pattern of
use of DALYs and QALYs is that the DALY has not yet been opera-
tionalised for evaluating the effectiveness of specified interventions.  It
has largely been a tool to estimate the potential impact of an unspeci-
fied intervention on a specific disease and the only way to access
DALY values is through the burden of disease group numbers.
However, as Fox-Rushby and Hanson (2001) highlight:
‘none of the estimates of disability provided in the current
Global Burden of Disease series relates to any specific inter-
vention.  This creates a problem for using DALYs in cost-effec-
tiveness analysis if researchers base their estimates on those pro-
vided in the Murray and Lopez (1996a-c)103 books because
there is no way of distinguishing alternative interventions [for
the same disease] using the existing disability weights’.
A second reason for the pattern is because QALY measures are
rarely translated for use in low- or middle-income countries and so
there is little that researchers in these settings can draw on for use in
cost-effectiveness/utility analysis.
When considering the comparable evidence concerning the
validity, reliability and sensitivity of DALYs versus QALYs, it is clear
that there is almost no published evidence for DALYs but an array of
data for QALYs104.  Indeed the lack of openness regarding the
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103 Same references as in this monograph.
104 See for example, copies of all the annual EuroQol plenary group conference issues
and listing of published papers, available from Frank de Charro, Business Manager of
the EuroQol group http://www.eurqol.org
112 design105 and measurement properties of DALYs is likely to be a sig-
nificant problem for researchers choosing outcome measures for eco-
nomic evaluations106.
Given that significant criticisms of the DALY have focussed on the
exclusive reliance on ‘experts’ to estimate changes in health state before
and after treatment, it is interesting to compare this with the sources
used to calculate QALYs.  In 1992, a literature review by Gerard
showed that 8 percent of papers used the researchers’ own values for
QALYs, 39 percent of studies used clinicians’ views and 41 percent the
views of the general community.  She also showed that 25 percent of
studies measured (rather than estimated) changes in health outcomes
following an intervention (Gerard, 1992).  More recently, it has been
shown that the number of studies not reporting the source of values
has fallen from 23 percent to 11 percent but that large proportions of
values are still coming from health professionals (16 percent) and
researchers (30 percent) (Gerard et al., 1999). Thus whilst QALY cal-
culations are more frequently based on community preferences than
DALYs, there are still many QALY values that are not.  Gerard et al.
(1999, p233) were highly critical of this and suggested that a study not
reporting community preferences was ‘probably not worth publish-
ing’.
There are problems of how inclusive DALYs can be in their cur-
rent state as an outcome indicator for economic evaluation.  For exam-
ple, they do not include side-effects, co-morbidity or ability to adapt
to conditions before and after treatments.  One of the questions on the
EQ5D questionnaire for measuring health-related quality of life asks
whether people have no problems, some problems or are unable to
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105 There is a paucity of data and explanation.  For example: what were the response
rates by question in the valuation exercise; how did the disability weights change after
each individual had deliberated on their value publicly within the focus group; what was
the distribution of values; and how would results have changed if weights given had
been divided into a six or eight disability classes instead of seven or if different size
intervals had been used (see Table 2 in Section 2.3.4)?
106 The most comprehensive evidence concerning reliability and validity of DALYs’
disease weights is presented by Stouthard et al. (1997), but this does not relate to the
estimates of the global burden of disease exercise.
113perform their usual activities.  The impact of side-effects and co-mor-
bidity are therefore subsumed within the answers.  As people adapt to
living with a disease they may adapt to their circumstance by, for
example, changing their expectation of what is considered usual or
what they feel to be important107.  In either case this could lead a per-
son stating that they have no problems in undertaking their usual
activities.  Because QALYs do allow for these issues, they are more
inclusive than DALYs108.  Theoretically, DALYs could include these if
either the focus were changed from disease to interventions and the
interventions were specified, or if a multi-dimensional measurement
tool were operationalised and tested so that disease-specific health
states tied to specific interventions could be measured or estimated109,
or if DALYs moved away from measuring disease to measuring health.
Section 4.2 listed a number of criticisms of DALYs concerning
their bias against particular populations.  Are QALYs considered to be
any less biased than DALYs?  Certainly there are several criticisms of
the in-built ageism of QALYs.  For example, Harris (1987) argued that
QALYs discriminate against older people because of their shorter life
expectancy.  More recently, Johanesson and Johansson (1997) have
suggested that as people value QALYs more if they gain them at
younger ages rather than at older ages, QALYs in fact discriminate
against the young by ignoring that factor.  There is no reason to expect
that the criticisms that using DALYs biases resources away from
women, unborn babies and the poor110 do not apply equally to
QALYs if, for example, the same type of gender-biased data are used,
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107 See for example Sprangers and Schwartz (1999), who outline a new theoretical
approach to examining change in health-related quality of life scores over time.  In
particular, they argue that experience of illness may change an individual’s internal
standards or conceptualisation of quality of life.
108 This is only the case for a questionnaire-based measure such as the EQ5D.  For a
scenario-based approach to QALY valuation, it would depend on what was written in
the scenario.
109 See Gerard et al. (1999) for an example of how women linked descriptions of
breast screening to EQ5D classifications and hence adopted the values provided by the
EuroQol group.  Kirsch and McGuire (2000) also elicit health state valuations from the
general population for the New York Heart Association classification.
110 See Sections 4.2.4 to 4.2.6 above.
114 or if the beginning of life is thought of in the same way, or if poor peo-
ple are less able or likely to return to full health.
Many of the criticisms of DALYs that are made by the disability
rights movement are also levelled at QALYs.  For example, Koch
(2000) equates DALYs and QALYs in their broad aims and criticises
both for disregarding the sanctity of human life.  Both, he argues,
would allocate funds away from people like Stephen Hawking and
Christopher Reeves, who face challenges of severe physical limitations,
if the only alternative was giving the same funds to perfectly healthy
people, because ‘prospective, health-related quality of life constructs –
and the culture that supports them – assume a restricted life is neces-
sarily less full than one lived in a state of physical normalcy irrespec-
tive of any other context or condition’ (Koch, 2000, p425).  Indeed
the core criticism, and centre of the legal case, that prevented the
introduction of the state of Oregon’s proposal for health care rationing
based on cost per QALY was that it discriminated against those who
were disabled and could not be returned to full health after life-saving
treatments111 (Ubel et al., 1999, p739).
The underlying problem that these criticisms highlight is that the
focus of decision-makers is drawn to maximising ‘health’, rather than
a more general definition of utility, and acceptance of the distribution
of resources across people.  This implies willingness to value ‘health’
above all other outcomes.  If the desired objective function is more
than just ‘health’, however, it implies that the best strategies for
improving utility and efficiency may be forfeited.  Moving to a broad-
er measurement of well-being and, as Broom (2001) suggests, distin-
guishing measured change from the value of that change would allow
clarification of the impact of alternative value bases and hence alter-
native distributions of well-being to be included.  As objective func-
tions are likely to differ from country to country, it suggests we should
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111 See also the open letter on the internet from the Consortium for Citizens with
Disabilities (17th July 2000, p4) to DeParle of the US Health Care Financing
Administration, that stated ‘both the QALY and DALY have serious flaws when .. (they
are)... premised on the antiquated notion that once disabled, quality of life is poor, when
in fact, with adequate health services, assistive technologies, and other supports, the
quality of life of a person with even a significant disability can be quite high’.
be particularly cautious about transferring such measurement tech-
nologies under the auspices of improving efficiency.
6.3 DALYs or QALYs in decision-making?
Decision-makers and their needs are not homogenous.  Therefore I con-
sider a variety of settings: at international, national and sub-national lev-
els; and in high-, middle- and low-income countries.  Specifically, I con-
sider how QALYs and DALYs may feed into decisions about where to
target expenditure in the health sector.  Decision-makers’ preferences for
QALYs or DALYs will depend on the way in which decisions are cur-
rently made in any setting, the availability of data, and views on the rel-
evance of burden of disease and cost-effectiveness in priority setting.
There are a number of actors at the international level interested in
using QALYs and DALYs for decision-making, including:
● international agencies, such as the World Bank and World Health
Organisation;
● multi-national multi-agency initiatives like the Global Alliance for
Vaccines Initiative (GAVI);
● non-governmental organisations, like Save the Children and
Oxfam;
● bilateral aid agencies, such as the UK Department for
International Development;
● multi-national pharmaceutical companies;
● international research organisations.
The common link is that each organisation is interested in fund-
ing, providing or influencing health care in several countries.
Comparison of the outcomes of intervening in disease areas can be
part of their decision-making and DALYs offer an easy route to this.
A vast amount of data on the burden of disease has been compiled
by the global burden of disease group, along with estimates of the
impact of treatment on DALYs.  A broad brush approach can quickly
assume what intervention might be used and estimates of effectiveness
made.  Indeed a cursory glance through the pages of Jamison et al.
(1993) will provide global estimates of the cost per DALY averted for
a range of named interventions.
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116 Compare this with data on cost per QALY gained and the differ-
ence is stark.  QALYs were developed to measure and value change
from interventions and not to assess burden of disease, and therefore
they have not been used widely in burden of disease studies.  Secondly
they have been developed and used predominantly in high-income
countries.  To date the EQ5D survey instrument has been translated
for use in 19 countries112, with the section on self-assessed health
translated most frequently for use in international clinical trials113.
However, even the EuroQol group is cautious about how comparable
results from new translations are across countries.  Therefore, for inter-
national agencies considering allocation of expenditure across low-
and middle-income countries, QALYs currently offer little help.
It is the case that, even when information is not available, decisions
still have to be made.  This is a key reason for the push to developing,
and continuing the use of, the DALY for decision-making by interna-
tional organisations.  It is also important to recognise that interna-
tional organisations have less incentive to respond to the needs of local
populations because not only are they interested in comparisons across
diverse populations but also because they are not held accountable to
local populations.  The role of the WHO and of the World Bank in its
lending for health sector development and sector-wide programme
planning is also key because the focus remains on ‘health’, rather than
a broader notion of well-being.
There is a disturbing focus on disease burden by international
agencies.  Burden of disease studies are really only helpful in knowing
the size of the problem.  They do not suggest what might be done or
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112 Languages into which the EQ5D instrument have been translated include:
Afrikaans, Catalan, Croatian, Czech, Danish, Dutch, Finnish, French, German,
Hungarian, Italian, Japanese, Norwegian, Polish, Spanish, Swedish, Turkish, UK
English.  Cultural adaptations have additionally been prepared for Argentina, Australia,
Austria, Canada, Mexico, Peru, South Africa, US and Venezuela.  Seventeen further
translations and adaptations are awaiting approval by the EuroQol group for use in
other countries. (Source: EuroQol website, http://www.euroqol.org reported on 20th
July 2000).
113 In order to get EQ5D scores and the facility to calculate QALYs from such
questionnaires it is necessary to adopt one of the valuation scoring systems produced
from existing valuation surveys, which are available only from a limited set of countries.
117where to start, or anything about the decision to provide care for one
disease in terms of what is lost in not providing care for another dis-
ease.  Knowing the size of the disease burden is helpful if a disease is
to be eradicated (e.g. polio) or to ascertain the size of current and
future resource use for palliative care given current practice.  However,
a choice to eradicate polio or continue palliative care also involves an
implicit choice not to put the resources somewhere else, for example
into reducing measles or promoting healthy life styles.  Should the
WHO’s Macroeconomic Commission on Health succeed in raising
sufficient global funding for health care in developing countries to tril-
lions rather than the millions of US$ currently allocated (Sachs,
2001), it may also help to know the size of the burden of disease (to
gain a sense of the possible orders of magnitude for change).
However, much of this data is now available and yet precious research
and planning resources continue to be channelled into burden of dis-
ease calculations rather than learning about the costs and effects of
health interventions.  Does this matter?
There is astonishingly little data available on the efficiency of
health interventions.  Walker and Fox-Rushby (2000) showed that
only 107 papers were published on communicable disease interven-
tions in developing countries in academic journals between 1984-
1997, which is an average of one per low- or middle-income country!
In addition, fewer than 35 percent of these used an outcome indicator
suitable for comparison across diseases (including a mix of death avert-
ed, DALYs or a monetary valuation) and only 7 percent of papers con-
sidered the generalisability of their findings to other contexts.
This rather frustrating situation for decision-makers clearly needs
to change.  It is important to direct research to decisional information
about which interventions are most efficient to provide, where and
when.  As all DALYs are calculated on the basis of estimation (rather
than direct measurement) it does suggest that DALYs might provide a
useful route to increasing the utility of existing economic evaluations
for international agencies – as long as these are tied to specific inter-
ventions and not just burden of disease.  Alternatively, researchers
might consider making similar kinds of estimations using an EQ5D
QALY based exercise but it is likely to take longer.  Those agencies dis-
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118 agreeing with the equity implications, the narrow disease focus or the
lack of consideration of context in calculating DALYs urgently need to
consider how to invest in changing this situation.  It also suggests that
evaluators need to develop techniques for assessing their findings in
the light of their spatial and temporal context, and to aim to find out
how and why costs and effects vary, to improve the validity of trans-
ferring or adapting results and models across countries.
Considerations for using DALYs and QALYs at the national level
need to take account of current approaches to decision-making in the
health sector, as there may or may not be a demand for outcome meas-
ures combining quantity and quality of life.  Where there is a demand,
its nature with respect to these specific tools is interesting to contem-
plate, as like much of health care, the suppliers and demanders are not
always distinct.  For example, academic advisors recommend use of
their own instruments and may also be employed by government min-
istries of health to conduct or advise on the evaluation of medical tech-
nologies.  Once these ministries or other organisations have invested
in the research and development or use of an instrument, there is like-
ly to be some unwillingness to change to using another type of out-
come measure to aid policy-making.
For decision-making concerning resource allocation, DALYs can
be considered a substitute for QALYs114.  The degree of substitutabil-
ity is likely to be related to the number of substitutes available (i.e. the
number of valid, reliable and culturally appropriate methods for com-
bining quantity and quality of life, in addition to the EQ5D) and the
speed with which one can be substituted for another.  Finally, the
tastes and preferences of decision-makers are also key.
Table 9 delineates potential scenarios of the demand for DALYs in
relation to QALYs.  It considers differences between high-, middle-
and low-income countries and why the demand for DALYs in deci-
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114 I distinguish this from the demand for DALYs as a research tool where, at least in
the short term, I think that DALYs and QALYs are more likely to be complements than
substitutes.  This is because testing the reliability and validity of new instruments is a
comparative process where the relative performance of new and old measures is
compared.  It will be particularly relevant should a questionnaire version for measuring
and valuing the ‘D’ part of DALYs become available.
119sion-making may be higher or lower relative to QALYs.  At present, it
would appear there is likely to be less demand for DALYs than for
QALYs by decision-makers in high-income countries.  This is because
there are a number of good quality and well-researched substitutes for
DALYs as a result of a substantial investment.  This considerable
knowledge will take a significant time to replicate in a new instru-
ment, both in terms of the measure itself and as a measure of the effec-
tiveness of various interventions.
The situation is very different in low-income countries, as they are
required to calculate DALYs averted as part of the process of applying
for health sector loans from the World Bank.  Should there be insuffi-
cient local expertise to carry out the calculations, external consultants
can be hired to help complete the procedure (this may even be part of
the loan).  Low-income countries have little research money and may
also represent poor potential markets for pharmaceutical companies.
Therefore it would seem unlikely that QALY based measures will
receive priority for development there.  Clearly if negotiating positions
between the World Bank and individual countries change, or the
World Bank chooses to develop other approaches, or if other organi-
sations sponsor the development of culturally relevant national tools,
then this situation might change.
Middle-income countries such as Mexico have the potential to
develop either or both of QALYs and DALYs.  Links with World Bank
funding have facilitated the calculation of DALYs.  Indeed, Mexico
has undertaken one of the most extensive analyses of burden of disease
and cost-effectiveness to date115.  However, it also has a number of
research projects developing QALYs and other quality of life outcome
measures, which may have the potential to develop alternative
approaches for resource allocation (see for example: de Icaza et al.,
1997; Caso- Marasco et al., 1996; Lara-Munoz et al., 1995).  Research
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115 It will be fascinating the see the impact of DALYs on decision-making in Mexico
as, at the time of writing (May 2002) the Minister of Health was Dr Julio Frenk, who
was the director of the Evidence and Information for Policy cluster at WHO until May
2001.  He was therefore responsible, with Dr Christopher Murray, for leading the
development of tools to assess the performance of health systems.
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income and potential private markets may have a significant impact
on research in such middle-income countries, in particular leading to
investigation of culturally appropriate national instruments.
DALYs have been used at the sub-national level to set priorities.
The only published examples I could find were from the UK (Bowie,
1998), Australia (Vos and Begg, 1999) and Tanzania (Finlay et al.,
1995; The Economist, 2002).  It is likely that the issues identified at
the national level, exemplified in Table 9, are similar and possibly
accentuated at this level.  For example, given that per capita spending
on health in Tanzania ranges between US$4-7 (Finlay, 1996, p7), it is
not surprising that the Tanzanian project was funded from money
external to the country (although, it is not clear how much of this
might be in the form of a repayable loan).
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122 In drawing conclusions about what DALYs have achieved and whatmight have been achieved without them, I draw on their four prin-
cipal uses as:
● a measure of the burden of disease;
● a director of research and development;
● a measure of effectiveness117; and
● a unit of benefit in cost-effectiveness analysis for micro and sec-
toral evaluations.
Finally I outline key research questions for the future.
The construction of DALYs has had a major impact on thinking
about the burden of disease across the globe.  It provided the first
estimates of the impact of disease on death and disability, using one
measure to combine both effects.  This had never before been done
across so many diseases or so many regions of the world.  The impact
was to highlight the burden of some diseases in a new way.  For exam-
ple the DALY estimates stressed the size of the burden of mental
health.  Results from the global burden of disease exercise have been
provided in an eminently usable way and the results have been cited
by a myriad of agencies, often calling for new resources to prevent,
treat or research a specific disease area.  However, the major problems
with the use of the DALY as a measure of the burden of disease are:
● the quality of the evidence;
● its inability to account for co-morbidity other than by adding up
the impact of each non-fatal disease in an individual;
● the implied equity weighting introduced by the ‘aspirational’ life
expectancy.
The first two concern the reliability of the data.  The first can be
dealt with to some extent by understanding the impact of data uncer-
tainty through sensitivity analysis.  The second is much harder to
account for within the current DALY framework because the focus is
on diseases rather than individuals or communities.  If the focus were
to change to individuals then, in theory, it would be possible to con-
sider the marginal effect of each disease, although in practice this
would be a difficult and costly exercise.
7  CONCLUSIONS
117 DALYs or disability adjusted life expectancy (DALE).
The third point, concerning equity weights is tricky, but relevant
for international comparisons.  Murray’s arguments concerning the
implication of not capturing an ideal length of life (i.e. undervaluing
lives in poor countries relative to richer countries because of differen-
tial life expectancies) are understandable, but Williams shows clearly
the impact of the implied equity weights and that they do not match
the stated desires (Williams, 1999).  It would therefore be better to
clarify the impact of the value system imposed by separating it out
from the estimation of quantity of life years and disability.  This would
also allow others the option to adopt different valuation approaches.
The value of burden of disease studies to decision-makers (and
ultimately to citizens) must be questioned.  They have been shown to
be costly endeavours that tie up scarce human resources.  Results of
DALY burden exercises tell us only about the size of the problem, and
have nothing to do with the solutions.  Indeed, to find solutions
(deciding which interventions should be funded) requires a complete
re-estimation of life expectancy with and without interventions, spe-
cific to the location of the intervention (and therefore without the
aspirational life tables used in DALYs), as well as knowledge of the set-
ting-specific costs.  The burden of disease data tell us nothing about
this and the business of ascertaining the useful information needs to
begin.
The startling paucity of data on cost-effectiveness of health inter-
ventions in developing countries, and the concerns voiced over trans-
ferring cost-effectiveness results across settings, have been used to
explain why burden of disease studies are used.  But why is the money
not being transferred to providing useful decisional information?
Why are some countries being required to undertake more burden of
disease studies prior to undertaking any analysis of the variations in
cost-effectiveness of alternative interventions?  There is an urgent need
for useful data on the costs and cost-effectiveness of alternative health
interventions.
There has been both less criticism of, and less work directed at, the
use of DALYs to help decide research agendas.  The calculation of
DALYs has helped change or cement decisions to invest in particular
areas, for example recommending moving some funding of research
123
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124 from HIV to TB.  However, the main problem with using DALYs in
this context is the focus on disease and not the treated person who may
experience side-effects (which could be worse than the disease itself ).
The Ad Hoc Committee on Health Research Relating to Future
Intervention Options (1996, p85) highlighted the need for more
information about the effectiveness of single, and packages of, health
interventions.  However, it only ranked the value of such information
(along with cost) as fifth of five priorities for future research118.
As a measure of effectiveness of health interventions, the develop-
ment of DALYs has encouraged a wide variety of governments across
the world to think about the impact of interventions on morbidity and
mortality, although in practice many low-income countries still only
use mortality and therefore only the YLL part of DALYs.  However,
the availability of disability weights does allow an easy route to esti-
mating YLDs.  All that is needed are estimates of prevalence, life
tables, the size of the population treated and consideration of the aver-
age life history of a patient with and without treatment, and DALYs
averted from an intervention can then be estimated.  The main prob-
lem with using this as decisional information is that none of the dis-
ability weights that have been created are related to any particular
intervention.  It therefore means that unless evaluators use different
DALY weights for different interventions, the only way of differenti-
ating the impact of alternative interventions for the same disease is
through the traditional epidemiological parameters (mortality and
morbidity) and the proportion of a population treated.
Murray argues that patient reported data are biased for a range of
reasons, e.g. adaptation to disease, and that patients are unable to
report the ‘truth’.  This is reflected both in the original development
of DALYs as a tool for estimation by health professionals rather than
for measurement in the population and the more recent direction of
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118 The four higher research priorities were: development of simple, affordable
methods of monitoring the status and trends of mortality and morbidity; development
of indicators of population health status that take into account morbidity, mortality and
disability; measurement of the degree to which research findings are implemented, why
and how to improve it; and development of cheap and reliable methods of monitoring
the patterns of use of health care services.
‘adjusting’ self-reports by ‘objective’ biological measures.  This is a
major departure from the alternative approaches that measure health-
related quality of life and QALYs.  It also serves to highlight some of
the values held within the estimation of disability encompassed in
DALYs.  The views of patients are excluded from the calculation of the
burden of disease and the impacts of interventions, as both are con-
sidered the preserve of the ‘expert’ professional.  This is a key criticism
upheld by a range of disability rights groups as well as by some of the
‘experts’ who were involved in the DALY valuation exercises.  The
main problems are that DALYs are too narrowly focussed, they do not
account for the context of illness and there are concerns about the
quality of data.  For this to change, DALYs have to move away from a
biomedical model of health, to one that is centred on people and not
only disease.
The ability to move away from a bio-medical model to a more
holistic, socialised and context oriented conception of health or well-
being that can be used to measure change from health interventions
across the world is, however, not easy.  There is no universal agreement
on what constitutes an adequate measure of health.  Given the process
of its development and the conception of health adopted, the WHO-
QOL instrument probably comes closest to this at present (WHO-
QOL, 1998a,b; Bowden and Fox-Rushby, in press) but unfortunately
it does not provide information that allows life years to be adjusted for
quality.  Whilst the EQ5D does allow this, there is concern about how
appropriate that instrument would be for populations in low- and
middle-income countries.  There are also increasing questions of how
culturally fair the assessment processes are.  The desire for interna-
tional comparisons could lead to one of several developments includ-
ing:
● translation and adaptation of instruments like the EQ5D, with
particular attention paid to evaluation of different types of equiv-
alence;
● development of the WHOQOL into an index suitable for quality
adjusting survival data (plus further translation and adaptation);
● development of different national questionnaires designed to tap
universally agreed dimensions of health (these may include very
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different questions across countries about pain, but presupposes
research on the universality of dimensions of ‘health’) which are
then valued on a utility scale;
● developing broader measures of well-being rather than just one
with a limited focus on health.
This range of suggestions indicates that the value of an opera-
tionalised DALY measurement tool is likely to be much less in those
countries that have already invested in QALY-type measures, e.g. the
UK, but also that much methodological development of an opera-
tionalised DALY would be needed in a very wide range of countries
before accepting results as valid, reliable or equivalent across coun-
tries.  The potential cost of developing such measures also explains, in
addition to requirements made by the World Bank, why low-income
countries are more likely to use DALYs.
The main value of DALYs is to organisations like the World Bank
and World Health Organisation that have to make international com-
parisons and decide which types of health services to fund or recom-
mend.  However, the calculation of DALYs exacts a toll.  Most priori-
tisation exercises in lower income countries, whether based on burden
of disease or cost-effectiveness, require foreign assistance in terms of
personnel and funding, and most take on the assumptions embodied
within the construction of DALYs.  At the national level the value for
decision-making of using DALYs relative to QALYs will depend on:
● the development of views about what constitutes an appropriate
approach to prioritising health care resources;
● a country’s need for funding by the World Bank; and
● the extent of current knowledge about QALYs and DALYs.
The use of DALYs as an outcome measure in cost-effectiveness
analysis raises further issues because of the implications for resource
allocation.  One of the main concerns that has arisen is the extent to
which specific assumptions are embroiled inextricably within the con-
struction of DALYs.  For example, the current methods and interpre-
tations lead valuers and decision-makers into discrimination against
those with disability when considering the value of life-enhancing
interventions, and therefore may increase inequities in health and
access to health care.
127Separating out the measurement and valuation aspects of DALYs
would provide two benefits: a measurement tool that could be devel-
oped and tested more easily; and an aid to assessment of the impact of
alternative approaches to valuation.  It would mean, for example,
using base case DALYs without weights for age or time preference, so
that different value systems that weight the distribution of potential
health gain and/or initial levels of health may be considered.  This
would also allow evidence to be built up and then added, for example
on time preference rates.  It might also encourage evaluators to exam-
ine the sensitivity of their results to uncertainties in the data.  Finally,
when the objective function of health spending differs between coun-
tries, this approach could also be used to compare the effect of differ-
ent national and international priorities.
The research agenda is large.  I would suggest that there is a press-
ing need to move away from funding more of the same burden of dis-
ease studies to instead funding cost-effectiveness analyses and for these
analyses to focus specifically on understanding the variation in cost-
effectiveness of health interventions across settings.  Clearly for this to
have an impact supposes that cost-effectiveness analyses have a value
through impact on decision-making.  Whether they do have such an
impact is an important question itself.  In the short term, in low- and
middle-income countries, the DALY could help as an outcome meas-
ure for this exercise but this must be accompanied by a focus on inter-
ventions rather than disease, and an operationalisation of methods to
allow for alternative valuations of the distribution of health gain across
populations.
In the medium term, better information is needed on the general-
isability of existing methods for measuring and valuing gains in health
and well-being from interventions across settings, rather than relying
on estimation by health professionals sitting in offices in Geneva or
elsewhere.
In the longer term (beginning now), we need to see a radical
change in the way that measures of health (or well-being) that claim
to be universal, or are used globally, are developed.  Starting with peo-
ple rather than disease is key.  This does not exclude disease but will
add to it the context in which diseases thrive and people live, and so is
7  CONCLUS IONS
128 more likely to provide usable interventions that people believe
improve their well-being.
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Method
The search for literature involved four methods: search of electronic data
bases; contact with researchers known to be working in the field; search of
the world wide web (on 31st March and 10th November 2000); and a
hand search of selected journals in year 2000 journals.
Databases searched: Medline (Jan1991- March 2000), Econlit (1969-
Dec 1999), Embase (1989 – Jan 2000), CINAHL (Nursing and Allied
Health) (1982 – Jan 2000), Psychological abstracts (1989 – Dec 1999),
SIGLE (Grey literature in Europe) (1980 – June 1999), Sociological
abstracts (1986 – Dec 1999), BIDS ISI (1999 – March 2000), Aslib Index
to Theses, and the world wide web.
Search terms used for all above: Disability Adjusted Life Yea**, DALY*
Authors searched: Murray C, Murray CJ, Murray CJL, Lopez A,
Lopez AD, Jamison D, Jamison DT, Vos T, Bevan G, Bonsel G.
Researchers contacted, and replied: Sadana R, Nord E, Bonsel G,
Bevan G, Evans D, Essink-Bott M-L, Hanson K, Musgrove P, Mathers C,
Wasserman D, Gold L, Robinson S.
Specific additional websites searched: World Bank, World Health
Organisation, Harvard University, London School of Economics.  Year
2000 journals included: Health Economics, Health Policy and Planning;
Social Science and Medicine, Bulletin WHO.
Papers selected
Papers were selected from the electronic search on the basis of a review of
abstracts or titles (where abstracts were not available).  Papers were exclud-
ed if not in English.  Of the total 912 references found in the search, 331
were selected after the following exclusions: 357 related to the wrong
authors (e.g. Daly) or to authors writing on other subjects and the remain-
der were duplicated references.  A further 83 were then rejected on review
as disability adjusted life years were not mentioned or mentioned only in
passing, or authors were writing on a related but not directly relevant sub-
ject.  The final bibliography for DALYs can be obtained directly from the
author at Julia.Fox-Rushby@LSHTM.ac.uk.  The bibliography is divided
into ten sections.  These are as follows (with the number of references read
in regular type, and number not found but judged relevant in italics and
* in the bibliography): journal papers (n= 142, 13), books (n=5), chapters
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in books (n=8, 1), letters in journals, book reviews/editorials (n=14, 1),
discussion/working papers (n=13, 3), reports (n=16, 7), items in newslet-
ters (n=8), items on websites (n=25, 3), and ‘other’ (n=8).
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Table A1 Results of the literature search
Total number of Total references 
references found selected for
(all abstracts or full review
titles reviewed)
Disability Adjusted Life Years 320 208
Specific authors 550 56
Websites Not recorded 25
Personal collection, not 9 9
available from other searches
From search of references 33 33
Total Not applicable 331
The EQ-5D is a generic instrument for describing, measuring andvaluing health outcomes that was originally designed for use along-
side other measures of health and disease in five countries (United
Kingdom, The Netherlands, Sweden, Norway and Finland).  The
EuroQol Group, an eclectic collection of academic researchers1 led ini-
tially by the University of York economist Professor Alan Williams2,
designed it.
The EuroQol website3 describes the EQ5D as applicable to a wide
variety of health conditions and treatments and providing a ‘simple
descriptive profile and a single index value for health status that can be
used in clinical and economic evaluation of health care as well as popula-
tion health surveys’.  The questionnaire is comprised of three main sec-
tions that can be used independently:
1. The descriptive health outcome measure
This is based on five dimensions of health (mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression), each with three levels of
severity (e.g. none, some/moderate, extreme/unable). It is designed to be
self-completed by respondents as a postal questionnaire, within clinics or
as part of an interview.  It takes about two minutes to complete.
The dimensions of EQ-5D were selected on the basis of a review of
other generic HRQOL measures at that time (EuroQol Group, 1991) and
the experiences of the EuroQol Group members. There was general agree-
ment that the following dimensions were included: mobility, daily activi-
ties and self-care, psychological functioning, social and role performance,
and pain or other health problems (Gudex, 1996).  The selection of levels
took place during Group discussions and involved on-the-spot transla-
tions by the developers for key words in all languages of development.
The levels were designed with the aim of covering a wide range of severi-
ty and to ensure ordinality (Gudex, 1996).  The first descriptive system
emerged in 1988 with six dimensions.  Following initial experimentation,
a large survey of lay concepts in the UK, and further deliberation about
the impact of dimensions and levels on the number of potential health
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AN INTRODUCTION TO EQ5D QALYS
1 Of whom I am one!
2 Williams has been instrumental in the development and promotion of QALYs for
health care decision-making in the UK.
3 http://www.euroqol.org/
states (and hence requirements for valuation), the current EQ-5D was
developed (Gudex, 1996).
2. The visual analogue rating scale
This is a vertical 20cm scale with end points labelled at ‘best/worst imag-
inable health’ with points numbered along its length between 0 and 100.
It takes about two minutes to complete, and it most often used along with
the descriptive health outcome measure above.
3. The valuation questionnaire
This part consists of a minimum of 14 health states that are valued, along
with the states dead and unconscious, using either a visual analogue scale
or the time trade-off approach.  It is not designed for use in clinical trials
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Table A2 EQ5D classification system and associated coefficients
Dimension Level Statement Coefficient
Mobility 1 No problems walking 0
2 Some problems walking about 0.069
3 Confined to bed 0.314
Self-care 1 No problems with self-care 0
2 Some problems washing or dressing self 0.104
3 Unable to wash or dress self 0.214
Usual 1 No problems with performing usual 0
activities activities (e.g. work, study, housework,
family or leisure activities)
2 Some problems performing usual 0.036
activities
3 Unable to perform usual activities 0.094
Pain/ 1 No pain or discomfort 0
discomfort 2 Moderate pain or discomfort 0.123
3 Extreme pain or discomfort 0.386
Anxiety/ 1 Not anxious or depressed 0
depression 2 Moderately anxious or depressed 0.071
3 Extremely anxious or depressed 0.269
Source: Adapted from Dolan et al. (1995).
or population surveys and is used only by researchers wishing to develop
valuations of health to create an index.  There currently exist 14 valuation
sets from eight different countries using samples of the general popula-
tion.
Most research only uses the first two parts of EQ5D.  Results from the
first part provide a profile of an individual’s health state.  The value for any
one state is ‘read off ’ using the results from one of the existing valuation
sets.  Hence the value of change between two states is also easily calculat-
ed.  Alternatively, using a specific valuation set in the UK, Dolan et al.
(1995) provided a formula to facilitate calculation, whilst at the same time
showing the basis from which the values had been calculated.
Table A2 shows a series of statements and a pattern of statements that
might have been ticked by a respondent in the questionnaire.  It also
shows the coefficients for each statement.  In this example, the health state
is known as 11223.
To calculate the index score for health state 11223, the following algo-
rithm is used: 
Full health = 1.0
Constant term – 0.081
Mobility (1) – 0
Self care (1) – 0
Usual activities (2) – 0.036
Pain/discomfort (2) – 0.123
Anxiety/depression (3) – 0.236
N3 – 0.269
Estimated value = 0.255
Three particular aspects to note are that: a constant is needed; the
coefficient for any dysfunction is subtracted from 1.0 and that an addi-
tional weighting (N3) is subtracted for any health state which includes a
level 3 severity.
The psychometric performance of the EQ5D has been compared with
other preference and non-preference based health-related quality of life
measures.  Essink-Bott et al. (1997) compared the Nottingham Health
Profile, the Medical Outcomes Study 36-item short form, and the
COOP/WONCA charts with the EQ5D in a group of migraine sufferers
and matched control group in the Netherlands.  They found that no one
instrument performed worse or better than any other.  Coons et al. (2000)
reviewed published evidence comparing the EQ5D with two other pref-
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erence-based measures (the quality of well-being index and health utilities
index) according to six criteria4.  With respect to reliability and validity
they concluded that, whilst the supporting evidence for the EQ5D’s reli-
ability and validity was acceptable, evidence from validity testing was
strongest for the quality of well-being index.  More recently Macran (in
press) has argued that in a group of arthritis sufferers and general popula-
tion sample in the UK the EQ5D exhibited acceptable measurement
properties over a three-month period and that the EQ VAS was sensitive
to self-reported clinical change.
The EQ-5D has been used in a range of studies including population
surveys, as a measure of change in patient health over time and as a meas-
ure of the impact of health interventions for use in economic analysis. In
addition to the five countries in which it was developed, the EQ-5D has
also been used in a variety of countries in Europe, Asia, Latin America,
Australasia and Africa.  Its use in an increasing number of settings is lead-
ing to greater questioning about what the EQ-5D is measuring in each
setting (e.g. Jelsma et al. 2000).
Further details of how to use the EuroQol can be gained from the
EuroQol business management through the website.
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4 Including: the conceptual and measurement model; reliability; validity; respondent
and administrative burden; alternative forms; and cultural and language adaptations.
The formulas here are taken from Murray (1996, pp65-6)5.
YLLs[r, K, ß] = KCera {e-(r+ß)(L+a)[-(r+ß)(L+a)-1] - e-(r+ß)a[-(r+ß)a - 1]}
(r+ß)2
+ (1 - K)(1- e-rL)
r
where:
K = age weighting modulation factor
C = constant
r = discount rate expressed as a decimal
a = age of death
ß = parameter from the age weighting function
L = standard expectation of life at age a
The formula for YLDs[r, K, ß] differs in the addition of D (the dis-
ability weight) and in different interpretations of a and L, and is shown
below:
YLDs[r, K, ß] = D{KCera {e-(r+ß)(L+a)[-(r+ß)(L+a)-1]
(r+ß)2
- e-(r+ß)a[ -(r+ß)a - 1]} + (1-K)(1- e-rL)}
r
where:
K = age weighting modulation factor
C = constant
r = discount rate expressed as a decimal
a = age of onset of disability
ß = parameter from the age weighting function
L = duration of disability
D = disability weight
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FORMULAS FOR CALCULATING DALYS
5 This broadly follows Murray’s recommended nomenclature of YLLs[r,K] in order to
ensure that DALYs are compared on a like basis.  However, given that anyone could
choose a different age weighting, I have added the rate of age-weighting.
With the discount rate set to zero and a uniform age weighting, the
length of life lost due to death at a particular age is L (i.e. the life expectan-
cy at age a) and the years of life lived with disability as a result of ill-health
commencing at age a is the product of the disability weight and the dura-
tion of disability at age a, that is DL.
155
APPE N DIX 3
A
ut
ho
rs
H
ol
lin
gh
ur
st
 e
t 
al
.
M
ar
a 
an
d 
Fe
ac
ha
m
M
at
he
rs
 e
t 
al
.
Ye
ar
 
20
00
19
99
19
99
A
im
 o
f 
pa
pe
r
To
 e
st
im
at
e 
th
e 
‘a
vo
id
ab
le
’6
(u
si
ng
 3
 a
pp
ro
ac
he
s 
to
To
 r
ea
pp
ra
is
e 
ag
in
g 
cl
as
si
fic
at
io
n 
of
 w
at
er
 a
nd
To
 c
al
cu
la
te
 t
he
 b
ur
de
n 
of
 d
is
ea
se
 in
de
fin
e 
th
is
) 
bu
rd
en
 o
f 
di
se
as
e 
as
 a
 p
ro
po
rt
io
n 
of
 t
ot
al
ex
cr
et
a 
re
la
te
d 
di
se
as
es
 g
iv
en
 n
ew
ly
 e
m
er
ge
nt
A
us
tr
al
ia
bu
rd
en
 o
f 
di
se
as
e
pa
th
og
en
s
D
is
ea
se
 f
oc
us
H
ea
rt
 d
is
ea
se
, s
tr
ok
e,
 c
at
ar
ac
t, 
be
ni
gn
 p
ro
st
at
ic
W
at
er
 a
nd
 e
xc
re
ta
 r
el
at
ed
 d
is
ea
se
s
17
6 
di
se
as
es
, i
nj
ur
ie
s 
an
d 
ri
sk
 f
ac
to
rs
hy
pe
rp
la
si
a,
 a
rt
hr
iti
s 
of
 t
he
 h
ip
, p
ep
tic
 u
lc
er
, d
ep
re
ss
iv
e
ill
ne
ss
In
te
rv
en
ti
on
s
A
 r
an
ge
 o
f 
tr
ea
tm
en
ts
N
ot
 a
pp
lic
ab
le
N
ot
 a
pp
lic
ab
le
co
ns
id
er
ed
G
eo
gr
ap
hi
ca
l
So
ut
h 
an
d 
W
es
t 
re
gi
on
 in
 E
ng
la
nd
G
lo
ba
l
A
us
tr
al
ia
fo
cu
s
Po
pu
la
ti
on
G
en
er
al
 p
op
ul
at
io
n 
in
 r
eg
io
na
l h
ea
lth
 a
ut
ho
ri
ty
A
ll 
ag
es
A
ll 
A
us
tr
al
ia
ns
 in
 1
99
6
co
ns
id
er
ed
(6
.3
 m
ill
io
n)
D
A
LY
 t
yp
e
A
 d
ev
el
op
m
en
t 
an
d 
va
ri
an
t 
of
 D
A
LY
s.
  N
ei
th
er
M
ar
k 
2
M
ar
k 
2
fo
rm
ul
a 
w
as
 u
se
d 
di
re
ct
ly
D
is
ab
ili
ty
 w
ei
gh
t
G
B
D
 w
ei
gh
ts
 f
or
 u
nt
re
at
ed
 c
on
di
ti
on
s 
fo
r 
so
m
e
0.
06
6
D
iff
er
en
t 
w
ei
gh
ts
 d
ep
en
di
ng
 o
n 
co
nd
it
io
n
an
d 
ot
he
r 
da
ta
 (
ci
te
d)
 t
o 
w
ei
gh
t 
or
 r
e-
w
ei
gh
t 
ot
he
r
co
nd
it
io
ns
A
ge
 w
ei
gh
t
N
o 
0.
04
N
o
D
is
co
un
t 
ra
te
3%
3%
3%
D
A
LY
s 
[0
.0
3,
1,
N
o 
Ye
s
N
o
0.
04
] 
pr
es
en
te
d?
156
APPENDIX 4
Ta
bu
la
r 
R
ev
ie
w
 o
f 
th
e 
U
se
 o
f 
D
A
LY
s 
in
 S
tu
di
es
 C
al
cu
la
ti
ng
 t
he
 B
ur
de
n 
of
 D
is
ea
se
W
hi
ch
 li
fe
82
.5
 (
fe
m
al
es
) 
80
 (
m
al
es
) 
SE
Y
LL
82
.5
 (
fe
m
al
es
) 
80
 (
m
al
es
)
81
.5
 f
or
 m
al
es
 a
nd
 8
5.
7 
fo
r 
fe
m
al
es
 a
t
ex
pe
ct
an
cy
?
bi
rt
h
P
re
se
nt
at
io
n
To
ta
l/
‘a
vo
id
ab
le
’ D
A
LY
s 
by
 d
is
ea
se
. A
vo
id
ab
le
To
ta
l D
A
LY
s,
 a
nd
  p
er
ce
nt
 c
on
tr
ib
ut
io
ns
Y
LL
 a
nd
 Y
LD
, a
ge
 s
ta
nd
ar
di
se
d,
 D
A
LY
s
of
 D
A
LY
s
D
A
LY
s/
 1
00
,0
00
 b
y 
ca
us
e 
an
d 
he
al
th
 a
ut
ho
ri
ty
fr
om
 w
at
er
/e
xc
re
ta
 r
el
at
ed
 D
A
LY
s 
pe
r 
1,
00
0 
by
 d
is
ea
se
, t
ot
al
 b
ur
de
n 
by
:
ge
nd
er
, a
ge
, s
oc
io
-e
co
no
m
ic
 g
ro
up
.
A
tt
ri
bu
ta
bl
e 
D
A
LY
s 
as
 a
 p
ro
po
rt
io
n 
of
to
ta
l D
A
LY
s
So
ur
ce
 o
f
G
B
D
 (
w
he
re
 p
os
si
bl
e)
G
B
D
 1
99
6
D
ut
ch
 D
is
ab
ili
ty
 W
ei
gh
ts
, a
nd
 if
 n
ot
di
sa
bi
lit
y 
w
ei
gh
ts
av
ai
la
bl
e 
th
en
 G
B
D
 w
ei
gh
ts
So
ur
ce
 o
f 
lif
e
G
B
D
G
B
D
 1
99
6
A
us
tr
al
ia
n 
C
oh
or
t 
Li
fe
 E
xp
ec
ta
nc
ie
s
ex
pe
ct
an
cy
fo
r 
19
96
So
ur
ce
 o
f
M
os
tly
 f
ro
m
 a
dd
it
io
na
lly
 c
it
ed
 e
vi
de
nc
e
G
B
D
 1
99
6
D
ut
ch
 s
tu
dy
 a
nd
 G
B
D
se
qu
el
ae
Se
ns
it
iv
it
y
Ye
s.
 D
is
co
un
t 
ra
te
, a
ge
 w
ei
gh
ti
ng
 a
nd
 t
he
 in
te
ra
ct
io
n
N
ot
 in
cl
ud
ed
 in
 t
hi
s 
pa
pe
r
D
is
co
un
t 
ra
te
an
al
ys
is
 o
n
be
tw
ee
n 
th
em
D
A
LY
as
su
m
pt
io
ns
?
Fu
nd
er
s
R
eg
io
na
l H
ea
lth
 A
ut
ho
ri
ty
 in
 t
he
 S
ou
th
 a
nd
N
ot
 s
ta
te
d
A
us
tr
al
ia
n 
In
st
it
ut
e 
of
 H
ea
lth
 a
nd
 W
el
fa
re
W
es
t 
of
 E
ng
la
nd
M
ai
n 
co
nc
lu
si
on
Pr
io
ri
ti
se
 t
re
at
in
g 
de
pr
es
si
on
 in
 g
en
er
al
 p
ra
ct
ic
e,
 a
nd
C
om
bi
ne
d 
cl
as
si
fic
at
io
ns
 o
f 
w
at
er
/e
xc
re
ta
-
Y
LL
s 
ac
co
un
t 
fo
r 
57
 p
er
ce
nt
 t
ot
al
 b
ur
de
n
R
&
D
 in
 p
re
ve
nt
in
g 
he
ar
t 
di
se
as
e 
in
 t
he
 e
ld
er
ly
.  
M
or
e
re
la
te
d 
di
se
as
es
 is
 m
or
e 
us
ef
ul
 b
ec
au
se
 o
f 
th
e
an
d 
51
 p
er
ce
nt
 in
 f
em
al
es
.  
D
ep
re
ss
io
n 
is
da
ta
 n
ee
de
d 
on
 s
ev
er
it
y
bi
-c
au
sa
l n
at
ur
e 
of
 m
an
y 
di
se
as
es
th
e 
le
ad
in
g 
ca
us
e 
of
 n
on
-f
at
al
 d
is
ea
se
 a
nd
is
ch
ae
m
ic
 h
ea
rt
 d
is
ea
se
 f
or
 t
ot
al
 b
ur
de
n.
Le
ad
in
g 
ri
sk
 f
ac
to
r 
is
 t
ob
ac
co
 s
m
ok
in
g.
M
or
e 
in
fo
rm
at
io
n 
on
 c
os
t-
ef
fe
ct
iv
en
es
s
ne
ed
ed
N
ot
e:
 G
B
D
 =
 g
lo
ba
l b
ur
de
n 
of
 d
is
ea
se
.
6
T
hi
s 
is
 a
 v
ar
ia
nt
 o
f 
th
e 
bu
rd
en
 o
f 
di
se
as
e 
by
 a
cc
ou
nt
in
g 
fo
r 
th
e 
pr
op
or
ti
on
 o
f 
tr
ea
tm
en
t 
de
em
ed
 s
uc
ce
ss
fu
l.
157
APPE N DIX 4
158
APPE N DIX 4
A
ut
ho
rs
G
w
at
ki
n 
et
 a
l.
M
el
tz
er
 e
t 
al
. 
St
ou
th
ar
d 
et
 a
l.
Ye
ar
 
19
99
19
98
19
97
A
im
 o
f 
pa
pe
r
To
 e
st
im
at
e 
th
e 
bu
rd
en
 o
f 
di
se
as
e 
am
on
g 
th
e
To
 c
al
cu
la
te
 D
A
LY
s 
lo
st
 t
o 
de
ng
ue
 d
ur
in
g
To
 in
ve
st
ig
at
e 
re
lia
bi
lit
y,
 v
al
id
ity
 a
nd
 u
sa
bi
lit
y 
of
ri
ch
es
t 
an
d 
po
or
es
t 
20
%
 o
f 
th
e 
gl
ob
al
 p
op
ul
at
io
n 
ep
id
em
ic
 a
nd
 n
on
-e
pi
de
m
ic
 y
ea
rs
th
e 
di
sa
bi
lit
y 
w
ei
gh
ti
ng
 m
et
ho
d.
  T
o 
de
ve
lo
p
(1
98
4-
94
)
an
d 
ap
pl
y 
a 
se
t 
of
 c
oh
er
en
t 
w
ei
gh
ts
D
is
ea
se
 f
oc
us
(N
on
) 
C
om
m
un
ic
ab
le
 d
is
ea
se
s 
an
d 
in
ju
ry
D
en
gu
e 
32
 in
di
ca
to
r 
co
nd
iti
on
s 
fr
om
 5
2 
di
ag
no
st
ic
 g
ro
up
s
+ 
ac
tiv
iti
es
 o
f d
ai
ly
 li
vi
ng
 li
m
ita
tio
ns
 in
 t
he
 e
ld
er
ly
In
te
rv
en
ti
on
s 
N
ot
 a
pp
lic
ab
le
N
ot
 a
pp
lic
ab
le
N
ot
 a
pp
lic
ab
le
G
eo
gr
ap
hi
ca
l
20
%
 r
ic
he
st
/p
oo
re
st
 c
ou
nt
ri
es
 (
av
er
ag
e 
pe
r 
Pu
er
to
 R
ic
o
T
he
 N
et
he
rl
an
ds
fo
cu
s
ca
pi
ta
 in
co
m
e 
ad
ju
st
ed
 f
or
 p
ur
ch
as
in
g 
po
w
er
)
Po
pu
la
ti
on
T
he
 p
oo
r
C
ou
nt
ry
 
45
 d
oc
to
rs
, 1
5 
la
y 
pe
op
le
 w
it
h 
ac
ad
em
ic
co
ns
id
er
ed
ba
ck
gr
ou
nd
 b
ut
 n
o 
m
ed
ic
al
 k
no
w
le
dg
e
D
A
LY
 t
yp
e
M
ar
k 
2
M
ar
k 
1
A
 v
ar
ia
nt
 o
f 
M
ar
k 
2
D
is
ab
ili
ty
 w
ei
gh
t
N
o 
di
sa
bi
lit
y 
w
ei
gh
ts
 u
se
d 
– 
on
ly
 d
ea
th
s 
w
er
e
0.
81
N
ew
 w
ei
gh
ts
 d
ev
el
op
ed
 f
or
 d
iff
er
en
t 
se
t 
of
co
nv
er
te
d 
to
 D
A
LY
s.
in
di
ca
to
r 
co
nd
it
io
ns
 m
or
e 
re
le
va
nt
 t
o 
D
ut
ch
 
po
pu
la
ti
on
2
A
ge
 w
ei
gh
t
N
ot
 s
ta
te
d
0.
04
N
ot
 a
pp
lic
ab
le
D
is
co
un
t 
ra
te
  
N
ot
 s
ta
te
d
3%
N
ot
 a
pp
lic
ab
le
D
A
LY
s 
[0
.0
3,
N
ot
 s
ta
te
d 
(a
lth
ou
gh
 d
id
 c
it
e 
G
B
D
 a
pp
ro
ac
h)
Ye
s
N
ot
 a
pp
lic
ab
le
1,
 0
.0
4]
pr
es
en
te
d?
W
hi
ch
 li
fe
C
oh
or
t
44
 y
ea
rs
, a
t 
ag
e 
of
 3
3
N
ot
 a
pp
lic
ab
le
 
ex
pe
ct
an
cy
?
Ta
bu
la
r 
R
ev
ie
w
 o
f 
th
e 
U
se
 o
f 
D
A
LY
s 
in
 S
tu
di
es
 C
al
cu
la
ti
ng
 t
he
 B
ur
de
n 
of
 D
is
ea
se
 (
co
nt
in
ue
d)
159
P
re
se
nt
at
io
n
Pe
rc
en
t 
of
 t
ot
al
 D
A
LY
 lo
ss
D
A
LY
s l
os
t /
 m
ill
io
n 
po
p 
fo
r 
ea
ch
 y
ea
r, 
us
in
g
Ju
st
 t
he
 d
is
ab
ili
ty
 w
ei
gh
ts
 w
er
e 
pr
es
en
te
d,
 
of
 D
A
LY
s
3 
ye
ar
 m
ov
in
g 
av
er
ag
e.
  M
ea
n,
 m
in
, m
ax
,
th
er
ef
or
e 
no
 D
A
LY
s
5t
h 
an
d 
95
th
 p
er
ce
nt
ile
s 
D
A
LY
s 
lo
st
 b
y
ye
ar
.  
Lo
g 
ba
se
 1
0 
of
 D
A
LY
s 
fo
r 
al
l d
is
ea
se
s
So
ur
ce
 o
f
N
ot
 a
pp
lic
ab
le
C
la
ss
 5
 o
f W
or
ld
 B
an
k 
cl
as
si
fic
at
io
n.
  
4 
gr
ou
p 
ex
er
ci
se
s
di
sa
bi
lit
y
N
um
be
r 
of
 d
ay
s 
in
 s
ev
er
it
y 
cl
as
s 
es
ti
m
at
ed
w
ei
gh
ts
fr
om
 li
te
ra
tu
re
 a
nd
 lo
ca
l s
ur
ve
ys
So
ur
ce
 o
f 
lif
e
U
N
 a
nd
 W
or
ld
 B
an
k 
so
ur
ce
s 
on
 li
fe
 e
xp
ec
ta
nc
y 
an
d
U
S 
B
ur
ea
u 
of
 C
en
su
s 
19
96
, S
ta
ti
st
ic
al
 
N
ot
 a
pp
lic
ab
le
ex
pe
ct
an
cy
nu
m
be
rs
 in
 p
op
ul
at
io
n 
co
ho
rt
s.
  L
ife
 e
xp
ec
ta
nc
y
A
bs
tr
ac
to
f 
th
e 
U
S 
19
96
co
nv
er
te
d 
to
 d
ea
th
 r
at
es
 v
ia
 li
fe
 t
ab
le
s 
an
d
‘a
dj
us
te
d’
 in
 li
ne
 w
it
h 
fig
ur
es
 in
 G
B
D
So
ur
ce
 f
or
N
ot
 a
pp
lic
ab
le
G
B
D
 a
nd
 a
dd
ed
 c
la
ss
ic
 d
en
gu
e,
 n
ot
 o
nl
y
Fu
ll 
di
se
as
e 
st
ag
in
g 
w
as
 g
iv
en
 t
o
se
qu
el
ae
de
ug
ue
 h
em
or
rh
ag
ic
 fe
ve
r 
(D
H
F)
 a
s i
n 
G
B
D
w
ei
gh
ti
ng
 p
an
el
s
Se
ns
it
iv
it
y
N
o 
D
is
ab
ili
ty
 w
ei
gh
t, 
ti
m
e 
lo
st
 b
y 
se
ve
ri
ty
95
 p
er
ce
nt
 c
on
fid
en
ce
 in
te
rv
al
s 
an
al
ys
is
 o
n
co
nd
it
io
n,
 m
ul
ti
pl
ic
at
io
n 
fa
ct
or
 u
se
d 
fo
r
pr
ov
id
ed
 f
or
 e
ac
h 
di
se
as
e 
w
ei
gh
t
D
A
LY
ca
se
 lo
ad
as
su
m
pt
io
ns
?
Fu
nd
er
s
W
or
ld
 B
an
k,
 G
lo
ba
l F
or
um
 f
or
 H
ea
lth
 R
es
ea
rc
h,
N
ot
 s
ta
te
d
D
ut
ch
 M
in
is
tr
y 
of
 H
ea
lth
, W
el
fa
re
 a
nd
G
ov
er
nm
en
ts
 o
f 
N
or
w
ay
 a
nd
 S
w
it
ze
rl
an
d,
 W
or
ld
Sp
or
ts
H
ea
lth
 O
rg
an
is
at
io
n
M
ai
n 
co
nc
lu
si
on
H
ea
lth
 p
ol
ic
y 
ba
se
d 
on
 a
ve
ra
ge
 e
st
im
at
es
 o
f 
G
B
D
U
si
ng
 o
nl
y 
D
H
F 
un
de
re
st
im
at
es
 t
he
W
ei
gh
ts
 f
or
 1
75
 d
is
ea
se
 s
ta
ge
s 
fr
om
 5
2
is
 li
ke
ly
 t
o 
sh
ift
 r
es
ou
rc
es
 a
w
ay
 f
ro
m
 p
oo
r 
to
 r
ic
h
bu
rd
en
 o
f 
di
se
as
e.
  C
la
ss
ic
 d
en
gu
e 
is
di
se
as
es
 p
ro
vi
de
d.
   
Te
st
in
g 
of
 r
el
ia
bi
lit
y/
co
un
tr
ie
s
th
e 
ca
us
e 
of
 g
re
at
es
t 
bu
rd
en
va
lid
it
y 
ne
ed
ed
N
ot
e:
 G
B
D
 =
 g
lo
ba
l b
ur
de
n 
of
 d
is
ea
se
.
2 
T
he
re
 w
er
e 
a 
nu
m
be
r 
of
 f
un
da
m
en
ta
l d
iff
er
en
ce
s:
 m
or
e 
an
d 
di
ff
er
en
t 
in
di
ca
to
r 
co
nd
it
io
ns
 w
er
e 
w
ei
gh
te
d;
 s
om
e 
‘c
on
di
ti
on
s’ 
ra
th
er
 t
ha
n 
di
se
as
es
 w
er
e 
w
ei
gh
te
d;
 d
is
ea
se
 s
ta
ge
 w
as
 d
es
cr
ib
ed
 in
te
rm
s 
of
 a
 v
ar
ia
nt
 o
f 
th
e 
E
Q
5D
 (
6 
di
m
en
si
on
s 
w
it
h 
3 
le
ve
ls
 p
er
 d
im
en
si
on
, i
nc
lu
di
ng
 a
n 
ad
di
ti
on
al
 c
og
ni
ti
ve
 d
im
en
si
on
);
 t
he
 a
dd
it
io
n 
of
 a
 r
at
in
g 
sc
al
e 
ex
er
ci
se
 f
ol
lo
w
in
g 
th
e 
pe
rs
on
 t
ra
de
-o
ff
 t
as
ks
;
th
e 
ai
m
 o
f 
di
sc
us
si
on
 o
f 
pe
rs
on
al
 v
al
ua
ti
on
s 
w
as
 n
ot
 t
o 
re
ac
h 
a 
co
ns
en
su
s 
bu
t 
to
 a
llo
w
 w
el
l-
co
ns
id
er
ed
 v
al
ua
ti
on
s;
 a
nd
 e
ve
nt
ua
lly
 1
1 
cl
as
se
s 
be
tw
ee
n 
0 
an
d 
1 
w
er
e 
ou
tli
ne
d.
APPE N DIX 4
160
A
ut
ho
rs
C
ha
n
M
ar
te
ns
 e
t 
al
.
Ye
ar
 
19
97
19
95
A
im
 o
f 
pa
pe
r
Q
ua
nt
ifi
ca
ti
on
 o
f 
th
e 
di
se
as
e 
bu
rd
en
 f
ro
m
 in
te
st
in
al
 n
em
at
od
e
To
 m
od
el
 t
he
 e
ff
ec
ts
 o
f 
pr
oj
ec
te
d 
ch
an
ge
s 
in
 t
em
pe
ra
tu
re
 a
nd
 
in
fe
ct
io
ns
, a
nd
 p
re
di
ct
in
g 
co
st
-e
ff
ec
ti
ve
ne
ss
 o
f 
tr
ea
ti
ng
 s
ch
oo
l c
hi
ld
re
n
pr
ec
ip
it
at
io
n 
on
 m
os
qu
it
o 
an
d 
pa
ra
si
te
 c
ha
ra
ct
er
is
ti
cs
 a
nd
 t
he
ir
po
te
nt
ia
l i
m
pa
ct
 o
n 
m
al
ar
ia
 r
is
k
D
is
ea
se
 f
oc
us
In
te
st
in
al
 n
em
at
od
e 
in
fe
ct
io
ns
 
M
al
ar
ia
In
te
rv
en
ti
on
 f
oc
us
Sc
ho
ol
 b
as
ed
 c
he
m
ot
he
ra
py
N
ot
 a
pp
lic
ab
le
G
eo
gr
ap
hi
ca
l f
oc
us
G
lo
ba
l e
st
im
at
es
, a
s 
w
el
l a
s 
co
ns
id
er
at
io
n 
of
 a
 h
yp
ot
he
ti
ca
l p
op
ul
at
io
n
G
lo
ba
l, 
pa
rt
ic
ul
ar
ly
 h
ig
h 
an
d 
lo
w
 e
nd
em
ic
 m
al
ar
io
us
 a
re
as
Po
pu
la
ti
on
A
 ‘h
yp
ot
he
ti
ca
l c
om
m
un
it
y,
 a
ss
um
ed
 t
o 
ha
ve
 a
 t
yp
ic
al
ly
 C
hi
ne
se
G
en
er
al
 p
op
ul
at
io
n 
in
 h
ig
h 
an
d 
lo
w
 e
nd
em
ic
 a
re
as
co
ns
id
er
ed
po
pu
la
ti
on
 d
is
tr
ib
ut
io
n’
D
A
LY
 t
yp
e
M
ar
k 
1
N
ot
 s
ta
te
d 
(p
ro
ba
bl
y 
M
ar
k 
1)
D
is
ab
ili
ty
 w
ei
gh
t
N
ot
 s
ta
te
d
0.
6,
 f
or
 7
 d
ay
s,
 t
w
ic
e 
a 
ye
ar
A
ge
 w
ei
gh
t
T
he
 G
B
D
 a
pp
ro
ac
h 
to
 D
A
LY
s 
is
 e
xp
la
in
ed
, a
lth
ou
gh
 it
 is
 n
ot
 c
le
ar
 f
or
Ye
s
th
e 
hy
po
th
et
ic
al
 e
xa
m
pl
e
D
is
co
un
t 
ra
te
  
T
he
 G
B
D
 a
pp
ro
ac
h 
to
 D
A
LY
s 
is
 e
xp
la
in
ed
, a
lth
ou
gh
 it
 is
 n
ot
 c
le
ar
 f
or
3%
th
e 
hy
po
th
et
ic
al
 e
xa
m
pl
e
D
A
LY
s 
[0
.0
3,
Ye
s 
fo
r 
gl
ob
al
 e
st
im
at
es
, u
nc
le
ar
 f
or
 h
yp
ot
he
ti
ca
l e
xa
m
pl
e
N
ot
 s
ta
te
d
1,
 0
.0
4]
] 
pr
es
en
te
d?
W
hi
ch
 li
fe
82
.5
 (
fe
m
al
es
) 
80
 (
m
al
es
) 
fo
r 
gl
ob
al
 e
st
im
at
es
, a
nd
 p
re
su
m
ab
ly
 e
st
im
at
es
Pr
es
en
t 
up
pe
r 
lif
e 
ex
pe
ct
an
cy
 f
or
 h
um
an
s
ex
pe
ct
an
cy
?
fr
om
 C
hi
na
 f
or
 t
he
 c
os
t-
ef
fe
ct
iv
en
es
s 
es
ti
m
at
es
P
re
se
nt
at
io
n 
of
D
A
LY
s 
lo
st
 p
er
 1
00
,0
00
 o
f 
th
e 
to
ta
l (
ad
ul
t 
an
d 
ch
ild
) 
po
pu
la
ti
on
D
A
LY
s 
pe
r 
1,
00
0 
po
pu
la
ti
on
D
A
LY
s
Ta
bu
la
r 
R
ev
ie
w
 o
f 
th
e 
U
se
 o
f 
D
A
LY
s 
in
 S
tu
di
es
 C
al
cu
la
ti
ng
 t
he
 B
ur
de
n 
of
 D
is
ea
se
 (
co
nt
in
ue
d)
APPE N DIX 4
161
APPE N DIX 4
So
ur
ce
(s
) 
of
G
B
D
 f
or
 g
lo
ba
l e
st
im
at
es
, u
nc
le
ar
 f
or
 h
yp
ot
he
ti
ca
l e
xa
m
pl
e
N
ot
 s
ta
te
d
di
sa
bi
lit
y 
w
ei
gh
ts
So
ur
ce
(s
) 
of
 li
fe
G
B
D
 f
or
 g
lo
ba
l e
st
im
at
es
, n
ot
 s
ta
te
d 
fo
r 
hy
po
th
et
ic
al
 e
xa
m
pl
e
N
ot
 s
ta
te
d,
 b
ut
 C
oa
le
 e
t 
al
. (
19
83
) 
in
 r
ef
er
en
ce
s
ex
pe
ct
an
cy
So
ur
ce
(s
) 
fo
r
A
da
pt
ed
 f
ro
m
 d
e 
Si
lv
a 
et
 a
l. 
(t
he
ir
 r
ef
 2
1)
 a
nd
 g
iv
en
 in
 d
et
ai
l i
n 
pa
pe
r
N
ot
 s
ta
te
d
se
qu
el
ae
Se
ns
it
iv
it
y 
an
al
ys
is
R
ef
er
en
ce
d 
an
ot
he
r 
pa
pe
r 
(d
e 
Si
lv
a 
et
 a
l.)
N
o,
 o
nl
y 
on
 c
lim
at
ic
 a
nd
 v
ec
to
r 
ch
ar
ac
te
ri
st
ic
s
on
 D
A
LY
as
su
m
pt
io
ns
?
Fu
nd
er
s
W
el
lc
om
e 
Tr
us
t, 
E
dn
a 
M
cC
on
ne
ll 
C
la
rk
 F
ou
nd
at
io
n
D
ut
ch
 N
at
io
na
l R
es
ea
rc
h 
Pr
og
ra
m
m
e 
on
 G
lo
ba
l A
ir
 P
ol
lu
ti
on
an
d 
C
lim
at
ic
 C
ha
ng
e
M
ai
n 
co
nc
lu
si
on
s
A
bi
lit
y 
to
 c
al
cu
la
te
 b
ur
de
n,
 c
os
ts
 o
f 
pr
ov
is
io
n 
ar
e 
im
po
rt
an
t 
to
 a
id
in
g
T
he
re
 is
 a
 r
ea
l r
is
k 
of
 r
ei
nt
ro
du
ci
ng
 m
al
ar
ia
 in
to
 n
on
m
al
ar
ia
l a
re
as
op
er
at
io
na
lly
 r
ea
lis
ti
c 
se
rv
ic
es
, w
he
n 
ch
ea
p 
co
st
-e
ff
ec
ti
ve
 d
ru
gs
 a
re
 a
va
ila
bl
e
an
d 
in
cr
ea
si
ng
 t
he
 in
ci
de
nc
e 
in
 m
al
ar
ia
 e
nd
em
ic
 a
re
as
, w
hi
ch
 w
ill
in
cr
ea
se
 t
he
 D
A
LY
s 
lo
st
N
ot
e:
 G
B
D
 =
 g
lo
ba
l b
ur
de
n 
of
 d
is
ea
se
.
162
APPENDIX 5
A
ut
ho
rs
G
oo
dm
an
 e
t 
al
.
M
ue
nn
ig
 e
t 
al
.
A
kh
av
an
 e
t 
al
.
Ye
ar
19
99
19
99
19
99
D
is
ea
se
 f
oc
us
M
al
ar
ia
In
te
st
in
al
 p
ar
as
it
es
M
al
ar
ia
In
te
rv
en
ti
on
s
A
lte
rn
at
iv
e 
m
et
ho
ds
 o
f: 
pr
ev
en
ti
on
 in
 c
hi
ld
ho
od
A
lb
en
da
zo
le
M
on
it
or
in
g 
+ 
st
ra
ti
fic
at
io
n 
of
 p
op
ul
at
io
n 
by
co
ns
id
er
ed
an
d 
pr
eg
na
nc
y;
 t
re
at
m
en
t
ri
sk
, n
ew
 d
ia
gn
os
is
 a
nd
 t
re
at
m
en
t 
pr
ot
oc
ol
s,
tr
ai
ni
ng
, s
up
pl
ie
s 
of
 a
nt
i-
m
al
ar
ia
ls
G
eo
gr
ap
hi
ca
l
Su
b-
Sa
ha
ra
n 
A
fr
ic
a
U
S
B
ra
zi
l
fo
cu
s
Po
pu
la
ti
on
Im
m
ig
ra
nt
s 
to
 U
S 
fr
om
 A
si
a,
 M
id
dl
e 
E
as
t, 
A
m
az
on
 b
as
in
 (
16
-1
8 
m
ill
io
n 
pe
op
le
)
co
ns
id
er
ed
su
b-
Sa
ha
ra
n 
A
fr
ic
a,
 E
as
te
rn
 E
ur
op
e,
La
ti
n 
A
m
er
ic
a 
an
d 
C
ar
ib
be
an
A
im
 o
f 
pa
pe
r
Pr
ov
id
e 
es
ti
m
at
es
 o
f 
th
e 
m
ai
n 
pr
ev
en
ti
on
 a
nd
C
om
pa
re
 w
at
ch
fu
l w
ai
ti
ng
 w
it
h 
un
iv
er
sa
l
Ev
al
ua
te
 t
he
 m
al
ar
ia
 c
on
tr
ol
 p
ro
je
ct
 d
ur
in
g
tr
ea
tm
en
t 
in
te
rv
en
ti
on
s 
in
 S
ub
-S
ah
ar
an
 A
fr
ic
a
tr
ea
tm
en
t 
w
it
h 
al
be
nd
az
ol
e 
fo
r 
5 
da
ys
th
e 
7 
ye
ar
s 
of
 t
he
 W
or
ld
 B
an
k 
lo
an
D
A
LY
 t
yp
e
M
ar
k 
2?
 (
if 
us
ed
 G
B
D
)
M
ar
k 
2
U
nc
le
ar
, b
ut
 p
ro
ba
bl
y 
M
ar
k 
2,
 a
s 
19
96
 is
ci
te
d 
fo
llo
w
in
g 
ag
e/
di
sc
ou
nt
in
g 
w
ei
gh
ts
D
is
ab
ili
ty
A
ct
ua
l w
ei
gh
ts
 n
ot
 s
ta
te
d
N
ot
 s
ta
te
d
P.
vi
va
x
– 
0.
22
w
ei
gh
t
P.
fa
lc
ip
ar
um
– 
0.
37
5
A
ge
 w
ei
gh
t 
N
o
N
o
0.
04
D
is
co
un
t 
ra
te
 
3%
3%
3%
D
A
LY
s 
[0
.0
3,
 1
,
0.
04
] 
pr
es
en
te
d?
N
o
N
o
Pr
es
um
ab
ly
, n
ot
 c
le
ar
W
hi
ch
 li
fe
W
es
t 
A
fr
ic
an
 li
fe
 t
ab
le
 w
it
h 
lif
e 
ex
pe
ct
an
cy
 a
t 
bi
rt
h
U
nc
le
ar
, b
ut
 p
os
si
bl
y 
sa
m
e 
as
 c
it
ed
80
ex
pe
ct
an
cy
?
of
 5
0 
ye
ar
s 
fo
r 
lo
w
- 
an
d 
m
id
dl
e-
in
co
m
e 
co
un
tr
ie
s
in
 M
ur
ra
y 
19
96
an
d 
a 
ge
ne
ra
l p
at
te
rn
 li
fe
 t
ab
le
 w
it
h 
lif
e 
ex
pe
ct
an
cy
at
 b
ir
th
 o
f 
65
 y
ea
rs
 f
or
 h
ig
he
r-
in
co
m
e 
co
un
tr
ie
s
Ta
bu
la
r 
R
ev
ie
w
 o
f 
th
e 
U
se
 o
f 
D
A
LY
s 
in
 C
os
t-
ef
fe
ct
iv
en
es
s 
A
na
ly
se
s
163
P
re
se
nt
at
io
n
C
os
t 
pe
r 
D
A
LY
 a
ve
rt
ed
D
A
LY
s 
av
er
te
d,
 c
os
t 
pe
r 
D
A
LY
D
A
LY
s 
pe
r 
ca
se
, t
ot
al
 D
A
LY
s,
 (
ne
t)
 c
os
t 
of
 D
A
LY
s
av
er
te
d
pe
r 
D
A
LY
So
ur
ce
 o
f
G
B
D
 1
99
6
M
ur
ra
y 
an
d 
Lo
pe
z 
19
96
N
ot
 s
ta
te
d
di
sa
bi
lit
y
w
ei
gh
ts
So
ur
ce
 o
f 
lif
e
U
N
 M
od
el
 L
ife
 t
ab
le
s 
fo
r 
de
ve
lo
pi
ng
 c
ou
nt
ri
es
Po
ss
ib
ly
 M
ur
ra
y 
19
96
Li
fe
 t
ab
le
s 
in
 M
ur
ra
y 
19
94
, f
or
 b
ur
de
n 
of
ex
pe
ct
an
cy
di
se
as
e
So
ur
ce
 o
f
G
B
D
 1
99
6
M
ur
ra
y 
19
96
 a
nd
 o
th
er
 c
it
ed
 r
ef
er
en
ce
s
M
ix
 o
f 
as
su
m
pt
io
ns
 f
ro
m
 li
te
ra
tu
re
se
qu
el
ae
Se
ns
it
iv
it
y
N
o
N
o
Ye
s,
 a
ge
 w
ei
gh
ti
ng
, d
is
co
un
ti
ng
, c
as
e
an
al
ys
is
 o
n
fa
ta
lit
y 
ra
te
s
D
A
LY
as
su
m
pt
io
ns
?
W
ha
t 
w
er
e
W
or
ld
 B
an
k’
s 
ra
ng
e 
of
 ‘g
oo
d 
bu
ys
’. 
 E
st
im
at
ed
 t
ot
al
C
os
ts
 o
f 
sm
ok
in
g 
ce
ss
at
io
n.
  C
os
t
C
os
t-
ef
fe
ct
iv
en
es
s 
of
 t
re
at
m
en
t 
an
d 
re
su
lt
s 
co
m
pa
re
d
co
st
 o
f 
fu
ll 
co
ve
ra
ge
 b
y 
in
te
rv
en
ti
on
s 
as
 a
 %
 o
f
pe
r 
D
A
LY
 b
y 
ar
ea
 o
f 
im
m
ig
ra
ti
on
.
pr
ev
en
ti
on
 s
tr
at
eg
ie
s 
in
 p
ro
je
ct
 c
om
pa
re
d.
  
to
?
pu
bl
ic
 h
ea
lth
 b
ud
ge
t 
(u
si
ng
 T
an
za
ni
an
 d
at
a)
. C
os
t
C
os
t 
of
 v
ac
ci
na
ti
ng
 a
ga
in
st
 H
ep
 A
C
os
t-
ef
fe
ct
iv
en
es
s 
ra
ti
os
 c
om
pa
re
d 
ov
er
 
pe
r 
D
A
LY
 a
ve
rt
ed
 f
or
 o
ra
l r
eh
yd
ra
ti
on
 t
he
ra
py
,
in
 h
ea
lth
 c
ar
e 
w
or
ke
rs
ti
m
e 
an
d 
w
it
h 
ra
ti
os
 p
re
se
nt
ed
 in
 1
99
3
m
ea
sl
es
 v
ac
ci
na
ti
on
, o
th
er
 in
te
rv
en
ti
on
s
W
or
ld
 D
ev
el
op
m
en
t 
R
ep
or
t
Fu
nd
er
s
W
or
ld
 B
an
k
N
ot
 s
ta
te
d
N
ot
 s
ta
te
d
M
ai
n 
co
nc
lu
si
on
A
ll 
in
te
rv
en
ti
on
s 
re
vi
ew
ed
 a
re
 c
os
t-
ef
fe
ct
iv
e 
w
ay
s 
of
W
at
ch
fu
l w
ai
ti
ng
 is
 m
or
e 
co
st
-
M
os
t 
D
A
LY
s 
av
er
te
d 
by
 p
re
ve
nt
in
g 
de
at
h.
re
du
ci
ng
 m
or
ta
lit
y 
fr
om
 m
al
ar
ia
ef
fe
ct
iv
e 
pe
r 
D
A
LY
 a
ve
rt
ed
M
os
t 
he
al
th
 g
ai
n 
is
 f
ro
m
 t
re
at
m
en
t, 
w
hi
ch
 is
ch
ea
pe
r 
th
an
 p
re
ve
nt
io
n,
 e
sp
ec
ia
lly
 w
he
re
P.
fa
lc
ip
ar
um
pr
ev
al
en
t
N
ot
e:
 G
B
D
 =
 g
lo
ba
l b
ur
de
n 
of
 d
is
ea
se
.
APPE N DIX 5
164
A
ut
ho
rs
C
ol
em
an
 e
t 
al
.
G
re
ik
sp
oo
r 
et
 a
l.
M
ar
se
ill
e 
et
 a
l.
Va
rl
ey
 e
t 
al
.
Ye
ar
 
19
99
19
99
19
99
19
98
D
is
ea
se
 f
oc
us
M
al
ar
ia
V
is
ce
ra
l L
ei
sh
m
an
ia
si
s
H
IV
-1
 
C
hi
ld
ho
od
 d
ia
rr
ho
ea
In
te
rv
en
ti
on
s
In
se
ct
ic
id
e 
tr
ea
te
d 
m
os
qu
it
o 
ne
ts
D
ia
gn
os
is
 a
nd
 t
re
at
m
en
t 
(w
it
h
H
IV
N
E
T
 0
12
 n
ev
ir
ap
in
e 
re
gi
m
en
H
ar
d/
so
ft
w
ar
e 
in
te
rv
en
ti
on
s 
co
ns
id
er
ed
(I
T
N
)
pe
nt
av
el
en
t 
an
ti
m
on
iu
m
) 
in
 h
os
pi
ta
l
to
 r
ed
uc
e 
m
ot
he
r/
ch
ild
fo
r 
w
at
er
 a
nd
 s
an
it
at
io
n
an
d 
he
al
th
 p
os
ts
 v
s 
no
 t
re
at
m
en
t
tr
an
sm
is
si
on
G
eo
gr
ap
hi
ca
l
Su
b-
Sa
ha
ra
n 
A
fr
ic
a
W
ar
-t
or
n 
ar
ea
 o
f W
es
te
rn
 U
pp
er
Su
b-
Sa
ha
ra
n 
A
fr
ic
a
Sl
um
/p
er
i-
ur
ba
n 
ar
ea
s 
w
it
h
fo
cu
s
N
ile
, S
ud
an
fe
w
 f
or
m
al
 s
er
vi
ce
s
Po
pu
la
ti
on
H
yp
ot
he
ti
ca
l p
op
ul
at
io
n 
of
 c
hi
ld
re
n
E
st
im
at
ed
 3
00
,0
00
 p
op
ul
at
io
n
H
yp
ot
he
ti
ca
l c
oh
or
t 
of
 2
0,
00
0
A
ss
um
ed
 a
 c
it
y 
of
 1
 m
ill
io
n 
co
ns
id
er
ed
<1
0 
ye
ar
s 
in
 S
ub
-S
ah
ar
an
 A
fr
ic
a
du
ri
ng
 1
99
0-
19
94
pr
eg
na
nt
 w
om
en
in
ha
bi
ta
nt
s
A
im
 o
f 
pa
pe
r
To
 a
sc
er
ta
in
 a
t 
w
ha
t 
le
ve
l o
f 
re
bo
un
d
To
 e
va
lu
at
e 
co
st
-e
ff
ec
ti
ve
ne
ss
 o
f
C
os
t-
ef
fe
ct
iv
en
es
s 
an
al
ys
is
 o
f: 
ta
rg
et
ed
C
os
t-
ef
fe
ct
iv
en
es
s 
an
al
ys
is
 o
f 
im
pr
eg
na
te
d 
ne
ts
 w
ou
ld
 n
o 
lo
ng
er
M
éd
ec
in
 S
an
s 
Fr
on
ti
er
s 
pr
og
ra
m
m
e
an
d 
un
iv
er
sa
l c
ov
er
ag
e 
w
ith
 H
IV
N
E
T
ha
rd
w
ar
e 
an
d 
so
ft
w
ar
e 
be
 c
os
t-
ef
fe
ct
iv
e 
or
 e
ff
ec
ti
ve
01
2;
 H
IV
N
E
T
 w
it
h 
ot
he
r 
sh
or
t-
pr
og
ra
m
m
es
 s
ep
ar
at
el
y 
an
d 
co
ur
se
 a
nt
i-
re
tr
ov
ir
al
 in
te
rv
en
ti
on
s
jo
in
tly
 u
si
ng
 f
in
an
ci
al
 c
os
ts
D
A
LY
 t
yp
e
M
ar
k 
2
M
ar
k 
2
N
ot
 c
le
ar
M
ar
k 
2
D
is
ab
ili
ty
 w
ei
gh
t
N
ot
 s
ta
te
d
N
ot
 u
se
d 
(o
nl
y 
Y
LL
)
N
on
e 
ci
te
d 
– 
ju
st
 Y
LL
s 
0.
6
A
ge
 w
ei
gh
t
N
o
0.
04
N
ot
 s
ta
te
d
0.
04
D
is
co
un
t 
ra
te
 
3%
3%
3%
3%
D
A
LY
s 
[0
.0
3,
 1
,
N
o
Ye
s
N
ot
 c
le
ar
Ye
s
0.
04
] 
pr
es
en
te
d?
L
if
e 
ex
pe
ct
an
cy
 
50
, a
t 
bi
rt
h
80
44
 
80
P
re
se
nt
at
io
n 
of
D
A
LY
s 
av
er
te
d 
pe
r 
ch
ild
 a
ge
d 
1-
11
9
A
ve
ra
ge
/m
ar
gi
na
l c
os
t 
pe
r 
D
A
LY
C
os
t 
pe
r 
D
A
LY
 a
ve
rt
ed
,
C
os
t 
pe
r 
D
A
LY
 s
av
ed
, f
ro
m
D
A
LY
s
m
on
th
s,
 c
os
t 
pe
r 
D
A
LY
s 
av
er
te
d
av
er
te
d,
 t
ot
al
 D
A
LY
s 
av
er
te
d
D
A
LY
s 
sa
ve
d
de
at
hs
 /
 m
or
bi
di
ty
Ta
bu
la
r 
R
ev
ie
w
 o
f 
th
e 
U
se
 o
f 
D
A
LY
s 
in
 C
os
t-
ef
fe
ct
iv
en
es
s 
A
na
ly
se
s 
(c
on
ti
nu
ed
)
APPE N DIX 5
165
So
ur
ce
 o
f
M
ur
ra
y 
an
d 
Lo
pe
z,
 1
99
6,
 a
nd
 o
th
er
N
ot
 a
pp
lic
ab
le
N
ot
 a
pp
lic
ab
le
U
se
d 
in
fo
rm
at
io
n 
fr
om
 D
A
LY
 
di
sa
bi
lit
y
st
ud
ie
s 
ci
te
d
gr
ou
p
w
ei
gh
ts
So
ur
ce
 o
f 
lif
e
U
N
 s
ta
nd
ar
d 
W
es
t 
A
fr
ic
an
 li
fe
C
oa
le
 a
nd
 D
em
en
y’
s 
ta
bl
e 
fr
om
H
au
b 
an
d 
C
or
ne
liu
s 
(1
99
8)
U
se
d 
in
fo
rm
at
io
n 
fr
om
 D
A
LY
 
ex
pe
ct
an
cy
ta
bl
e 
fo
r 
w
om
en
M
ur
ra
y 
19
96
. A
ls
o 
m
od
el
 li
fe
W
or
ld
 P
op
ul
at
io
n 
D
at
a 
Sh
ee
t
gr
ou
p
ta
bl
e 
So
ut
h 
le
ve
l 8
 a
nd
 1
2,
 in
= 
av
er
ag
e 
lif
e 
ex
pe
ct
an
cy
 f
or
 1
8
se
ns
it
iv
it
y 
an
al
ys
is
co
un
tr
ie
s 
of
 E
as
t 
A
fr
ic
a
So
ur
ce
 o
f
M
ur
ra
y 
an
d 
Lo
pe
z,
 1
99
6,
 a
nd
N
ot
 a
pp
lic
ab
le
C
hi
n 
(1
98
9)
U
se
d 
in
fo
rm
at
io
n 
fr
om
 D
A
LY
se
qu
el
ae
ot
he
r 
st
ud
ie
s 
ci
te
d 
gr
ou
p
Se
ns
it
iv
it
y
Ye
s,
 f
or
 in
ci
de
nc
e,
 s
eq
ue
la
e,
 c
ha
ng
e
Ye
s,
 f
or
 li
fe
 e
xp
ec
ta
nc
y 
an
d 
ca
se
Ju
st
 li
fe
 e
xp
ec
ta
nc
y
C
ov
er
ed
 c
ha
ng
in
g 
th
e 
ca
se
 
an
al
ys
is
 o
n 
D
A
LY
in
 m
or
ta
lit
y
fa
ta
lit
y 
ra
te
fa
ta
lit
y 
ra
te
 a
nd
 in
ci
de
nc
e
as
su
m
pt
io
ns
?
W
ha
t 
w
er
e
C
ut
-o
ff
 p
oi
nt
s 
by
 W
or
ld
 B
an
k 
fo
r
C
ut
-o
ff
 p
oi
nt
s 
re
co
m
m
en
de
d 
by
W
or
ld
 B
an
k 
co
st
 p
er
 D
A
LY
 c
ut
C
os
t 
pe
r 
ca
se
 /
 d
ea
th
 a
ve
rt
ed
re
su
lt
s
co
st
 p
er
 D
A
LY
 a
ve
rt
ed
 e
st
im
at
es
W
or
ld
 B
an
k 
an
d 
co
st
 p
er
 D
A
LY
of
f 
po
in
t. 
 C
os
t 
pe
r 
D
A
LY
 a
ve
rt
ed
co
m
pa
re
d 
to
?
av
er
te
d 
fo
r 
ot
he
r 
in
te
rv
en
ti
on
s 
in
fo
r 
ot
he
r 
in
te
rv
en
ti
on
s 
in
 S
T
D
s 
an
d
ot
he
r 
co
un
tr
ie
s
di
se
as
es
 w
it
h 
hi
gh
 c
hi
ld
 m
or
ta
lit
y
Fu
nd
er
s?
W
H
O
, D
fI
D
 
N
ot
 s
ta
te
d
N
IA
ID
/N
IH
 a
nd
 N
IM
H
 
U
SA
ID
M
ai
n 
co
nc
lu
si
on
A
ge
 r
an
ge
 o
f 
re
bo
un
d 
cr
uc
ia
lly
It
 w
as
 a
 m
os
t 
co
st
-e
ff
ec
ti
ve
N
IV
N
E
T
 0
12
 r
eg
im
en
 c
an
 b
e
In
ve
st
in
g 
in
 s
of
tw
ar
e 
is
 a
s 
af
fe
ct
s 
co
st
-e
ff
ec
ti
ve
ne
ss
.  
If
 it
 
in
te
rv
en
ti
on
hi
gh
ly
 c
os
t-
ef
fe
ct
iv
e 
in
 h
ig
h
co
st
-e
ff
ec
ti
ve
 a
s 
or
al
 
fa
lls
 a
m
on
gs
t 
3-
6 
ye
ar
s 
ol
ds
, I
T
N
se
ro
-p
re
va
le
nc
e 
se
tt
in
gs
re
-h
yd
ra
ti
on
, e
sp
ec
ia
lly
 w
he
re
m
ay
 n
o 
lo
ng
er
 b
e 
co
st
-e
ff
ec
ti
ve
. 
ha
rd
w
ar
e 
ex
is
ts
Lo
ng
 t
er
m
 s
ur
ve
ill
an
ce
 c
ru
ci
al
N
ot
e:
 N
IA
ID
 =
 N
at
io
na
l I
ns
ti
tu
te
 o
f 
A
lle
rg
y 
an
d 
In
fe
ct
io
us
 D
is
ea
se
.
APPE N DIX 5
166
A
ut
ho
rs
V
ic
to
ra
 a
nd
 v
an
 H
ae
ck
e
M
ar
se
ill
e 
et
 a
l.
M
ill
er
Ye
ar
 
19
98
19
98
19
98
D
is
ea
se
 f
oc
us
V
it
am
in
 K
 d
ef
ic
ie
nc
y
H
IV
H
ae
m
op
hi
lu
s 
In
flu
en
za
e 
(H
ib
) 
as
 a
 c
au
se
of
 b
ac
te
ri
al
 m
en
in
gi
ti
s
In
te
rv
en
ti
on
s
R
an
ge
 o
f 
pr
op
hy
la
xi
s 
an
d 
br
ea
st
fe
ed
in
g 
pr
om
ot
io
n
D
o 
no
th
in
g,
  3
 d
iff
er
en
t 
re
gi
m
en
s 
of
 s
ho
rt
-
Ty
pe
 b
 c
on
ju
ga
te
 v
ac
ci
ne
co
ns
id
er
ed
co
ur
se
 a
nt
iv
ir
al
 r
eg
im
en
G
eo
gr
ap
hi
ca
l
N
o 
on
e 
co
un
tr
y 
– 
gl
ob
al
 p
ol
ic
y
Su
b-
Sa
ha
ra
n 
A
fr
ic
a
A
si
a
fo
cu
s
Po
pu
la
ti
on
Le
ss
 d
ev
el
op
ed
 c
ou
nt
ri
es
 a
s 
a 
w
ho
le
A
 c
oh
or
t 
of
 1
00
 w
om
en
Su
rv
iv
in
g 
in
fa
nt
s 
in
 e
ac
h 
bi
rt
h 
co
ho
rt
co
ns
id
er
ed
ac
co
rd
in
g 
to
 c
ou
nt
ry
-s
pe
ci
fic
 p
op
ul
at
io
n
an
d 
co
ve
ra
ge
 r
at
es
 f
or
 2
3 
A
si
an
 c
ou
nt
ri
es
A
im
 o
f 
pa
pe
r
C
os
t-
ef
fe
ct
iv
en
es
s 
an
d 
ne
ed
 f
or
 p
ro
ph
yl
ax
is
 t
o 
re
du
ce
To
 a
ss
es
s 
co
st
-e
ff
ec
ti
ve
ne
ss
 o
f 
sh
or
t 
co
ur
se
 
A
ss
es
se
s 
po
te
nt
ia
l o
f 
ne
w
 H
ib
 v
ac
ci
ne
 f
or
vi
ta
m
in
 K
 d
ef
ic
ie
nc
y
tr
ea
tm
en
ts
 t
o 
re
du
ce
 m
ot
he
r 
to
 c
hi
ld
A
si
a 
an
d 
ba
rr
ie
rs
 t
o 
it
s 
in
tr
od
uc
ti
on
tr
an
sm
is
si
on
 o
f 
H
IV
D
A
LY
 t
yp
e
M
ar
k 
1
M
ar
k 
2
M
ar
k 
1
D
is
ab
ili
ty
 w
ei
gh
t
50
%
 in
 g
ra
de
 3
, 5
0%
 in
 g
ra
de
 4
0.
12
3 
fo
r 
H
IV
 a
nd
 0
.5
05
 f
or
 A
ID
S
D
is
ab
ili
ty
 a
dj
us
tm
en
t 
of
 2
5%
 f
or
 e
ac
h
ye
ar
 a
ft
er
 r
ec
ov
er
y
A
ge
 w
ei
gh
t
N
ot
 m
en
ti
on
ed
0.
04
N
ot
 s
ta
te
d
D
is
co
un
t 
ra
te
 
N
ot
 m
en
ti
on
ed
5%
 a
nd
 3
%
N
ot
 s
ta
te
d
D
A
LY
s 
[0
.0
3,
 1
,
U
nl
ik
el
y
Ye
s
N
ot
 c
le
ar
0.
04
] 
pr
es
en
te
d?
L
if
e 
ex
pe
ct
an
cy
?
N
ot
 s
ta
te
d
B
as
ed
 o
n 
an
 a
ve
ra
ge
 li
fe
 s
pa
n 
of
 5
2.
5 
ye
ar
s
N
ot
 s
ta
te
d
(m
id
po
in
t b
et
w
ee
n 
th
e 
lif
e 
ex
pe
ct
an
ci
es
 a
t b
ir
th
fo
r 
m
en
 a
nd
 w
om
en
 in
 S
ub
-S
ah
ar
an
 A
fr
ic
a)
Ta
bu
la
r 
R
ev
ie
w
 o
f 
th
e 
U
se
 o
f 
D
A
LY
s 
in
 C
os
t-
ef
fe
ct
iv
en
es
s 
A
na
ly
se
s 
(c
on
ti
nu
ed
)
APPE N DIX 5
167
P
re
se
nt
at
io
n
To
ta
l a
nd
 p
er
ce
nt
 D
A
LY
s 
lo
st
 b
y 
ge
nd
er
 a
nd
 3
 le
ve
ls
D
A
LY
s 
av
er
te
d 
pe
r 
av
er
te
d 
in
fe
ct
io
n,
C
os
t 
pe
r 
D
A
LY
, c
os
t 
pe
r 
D
A
LY
 a
s 
pe
rc
en
t
of
 D
A
LY
s
of
 in
ci
de
nc
e.
 C
os
t 
pe
r 
D
A
LY
 s
av
ed
co
st
 p
er
 D
A
LY
 a
ve
rt
ed
G
N
P 
pe
r 
ca
pi
ta
So
ur
ce
 o
f
A
ss
um
pt
io
n
G
B
D
Sc
hi
lli
ng
er
 e
t 
al
. i
n 
G
B
D
 s
er
ie
s
di
sa
bi
lit
y
w
ei
gh
ts
So
ur
ce
 o
f 
lif
e
T
ha
i s
tu
dy
 a
nd
 m
et
a 
an
al
ys
is
.  
Po
ss
ib
ly
 1
99
3 
W
D
R
19
96
 W
or
ld
 P
op
ul
at
io
n 
D
at
a 
Sh
ee
t,
N
ot
 s
ta
te
d
ex
pe
ct
an
cy
to
o 
(i
.e
. J
ap
an
es
e 
lif
e 
ex
pe
ct
an
cy
) 
bu
t 
un
cl
ea
r
Po
pu
la
ti
on
 R
ef
er
en
ce
 B
ur
ea
u
So
ur
ce
 o
f
A
ss
um
pt
io
ns
, o
ne
 s
tu
dy
 f
ro
m
 T
ha
ila
nd
 a
nd
 a
 m
et
a
C
it
ed
 2
 p
ap
er
s 
as
 ju
st
ifi
ca
ti
on
 f
or
N
ot
 s
ta
te
d
se
qu
el
ae
an
al
ys
is
as
su
m
pt
io
ns
Se
ns
it
iv
it
y
N
o
Ye
s,
 d
is
co
un
t 
ra
te
N
o
an
al
ys
is
 o
n 
D
A
LY
as
su
m
pt
io
ns
?
W
ha
t 
w
er
e
W
or
ld
 B
an
k 
‘c
ut
-o
ff
’ p
oi
nt
s.
  C
os
t-
ef
fe
ct
iv
en
es
s 
of
D
ec
is
io
n 
br
an
ch
es
 f
ro
m
 t
he
 m
od
el
.
C
os
t 
pe
r 
lif
e 
sa
ve
d 
w
it
h 
an
d 
w
it
ho
ut
 
re
su
lt
s 
co
m
pa
re
d
ot
he
r 
in
te
rv
en
ti
on
s 
fr
om
 a
ro
un
d 
th
e 
w
or
ld
 t
o
R
es
ul
ts
 f
ro
m
 o
th
er
 c
os
t-
ef
fe
ct
iv
en
es
s
tr
ea
tm
en
t 
co
st
 s
av
in
gs
.  
C
ha
ng
in
g 
pr
ic
e 
of
 
to
?
re
du
ce
 v
it
am
in
 K
 d
ef
ic
ie
nc
y
an
al
ys
is
 in
 lo
w
 a
nd
 h
ig
h 
m
or
ta
lit
y
va
cc
in
e.
  A
ve
ra
ge
 c
os
t 
pe
r 
fu
lly
 v
ac
ci
na
te
d 
ar
ea
s
ch
ild
Fu
nd
er
s
U
N
IC
E
F 
ev
al
ua
ti
on
 a
nd
 r
es
ea
rc
h 
of
fic
e
U
N
A
ID
S
N
ot
 s
ta
te
d
M
ai
n 
co
nc
lu
si
on
In
te
rv
en
ti
on
 is
 ‘m
od
er
at
el
y 
co
st
-e
ff
ec
ti
ve
’. 
 I
t 
sh
ou
ld
A
nt
iv
ir
al
 t
he
ra
py
 m
ay
 b
e 
co
st
-
C
ou
nt
ri
es
 w
he
re
 H
ib
 v
ac
ci
ne
 m
os
t 
lik
el
y
be
 r
ec
om
m
en
de
d 
in
 d
ev
el
op
ed
 c
ou
nt
ri
es
ef
fe
ct
iv
e 
co
m
pa
re
d 
w
it
h 
ot
he
r 
he
al
th
to
 b
e 
ef
fic
ie
nt
 a
re
 le
as
t 
lik
el
y 
to
 b
e 
ab
le
 t
o 
in
te
rv
en
ti
on
s 
if:
 H
IV
 p
re
va
le
nc
e 
is
af
fo
rd
 it
.  
C
os
t-
ef
fe
ct
iv
en
es
s 
is
 c
ri
ti
ca
lly
 
hi
gh
; c
lin
ic
al
 t
ri
al
s 
co
nf
ir
m
 e
st
im
at
ed
de
pe
nd
en
t 
on
 p
ri
ce
 o
f 
va
cc
in
e
ef
fic
ac
ie
s;
 d
ru
g 
pr
ic
es
 a
re
 r
ed
uc
ed
N
ot
e:
 G
B
D
 =
 g
lo
ba
l b
ur
de
n 
of
 d
is
ea
se
.
APPE N DIX 5
168
A
ut
ho
rs
T
ha
in
eu
a 
et
 a
l.
G
ils
on
 e
t 
al
.
M
ar
se
ill
e
Ye
ar
 
19
98
19
97
19
96
D
is
ea
se
 f
oc
us
H
IV
ST
D
s
C
at
ar
ac
ts
In
te
rv
en
ti
on
s
Sh
or
t 
co
ur
se
 Z
id
ov
ud
in
e 
(Z
D
V
) 
to
 r
ed
uc
e 
m
ot
he
r-
Im
pr
ov
ed
 m
an
ag
em
en
t 
of
 S
T
D
s 
by
 p
ri
m
ar
y
O
ut
-p
at
ie
nt
 (
ey
e 
ho
sp
it
al
/c
am
p)
 c
at
ar
ac
t 
co
ns
id
er
ed
ch
ild
 t
ra
ns
m
is
si
on
he
al
th
 c
ar
e 
w
or
ke
rs
su
rg
er
y 
w
it
h 
lo
ca
l a
na
es
th
et
ic
, 7
 d
ay
s
fo
llo
w
-u
p 
an
d 
ap
ha
ki
c 
sp
ec
ta
cl
es
G
eo
gr
ap
hi
ca
l
N
or
th
er
n 
T
ha
ila
nd
M
w
an
za
 r
eg
io
n,
 T
an
za
ni
a
N
ep
al
fo
cu
s
Po
pu
la
ti
on
Pr
eg
na
nt
 w
om
en
 w
it
h 
H
IV
 a
nd
 p
op
ul
at
io
n 
of
R
an
do
m
 c
oh
or
t 
of
 1
,0
00
/1
2,
53
7 
ad
ul
ts
2 
m
ill
io
n 
pe
op
le
 in
 L
um
bi
ni
 Z
on
e,
 s
ou
th
-
co
ns
id
er
ed
51
7,
00
0 
in
ha
bi
ta
nt
s 
in
 P
ha
ya
o 
pr
ov
in
ce
ag
ed
 1
5-
54
ce
nt
ra
l N
ep
al
 s
er
ve
d 
by
 a
 U
S/
C
an
ad
ia
n
no
n-
go
ve
rn
m
en
ta
l o
rg
an
is
at
io
n
A
im
 o
f 
pa
pe
r
D
el
in
ea
te
 t
he
 im
pl
em
en
ta
ti
on
 is
su
e 
of
 a
 s
ho
rt
 c
ou
rs
e
To
 a
ss
es
s 
im
pa
ct
, c
os
t 
an
d 
co
st
-e
ff
ec
ti
ve
ne
ss
To
 c
om
pa
re
 c
os
t-
ef
fe
ct
iv
en
es
s 
of
 c
at
ar
ac
t 
Z
D
V
 t
re
at
m
en
t 
pr
og
ra
m
m
e
of
 a
ve
rt
in
g 
H
IV
-1
 in
fe
ct
io
n 
w
it
h 
ne
w
su
rg
er
y 
ve
rs
us
 n
o 
ca
ta
ra
ct
 s
ur
ge
ry
pr
og
ra
m
m
e
D
A
LY
 t
yp
e
M
ar
k 
1
M
ar
k 
1
U
se
d 
ow
n 
fo
rm
ul
a 
to
 c
al
cu
la
te
 D
A
LY
s
D
is
ab
ili
ty
 w
ei
gh
t
U
nc
le
ar
, p
os
si
bl
y 
on
ly
 Y
LL
s
0.
1 
fo
r 
lim
it
ed
 m
or
bi
di
ty
 a
nd
 0
.9
 f
or
 s
ev
er
e
0.
39
 f
or
 b
lin
dn
es
s 
an
d 
0.
87
 f
ol
lo
w
in
g 
m
or
bi
di
ty
su
rg
er
y
A
ge
 w
ei
gh
t
N
ot
 s
ta
te
d
0.
04
N
ot
 m
en
ti
on
ed
D
is
co
un
t 
ra
te
 
N
ot
 s
ta
te
d
3%
3%
D
A
LY
s 
[0
.0
3,
 1
,
N
ot
 c
le
ar
Ye
s
N
o
0.
04
] 
pr
es
en
te
d?
L
if
e 
ex
pe
ct
an
cy
A
ve
ra
ge
 li
fe
 e
xp
ec
ta
nc
y 
of
 6
9 
ye
ar
s
40
.7
 a
nd
 5
3.
9
N
ot
 s
ta
te
d
Ta
bu
la
r 
R
ev
ie
w
 o
f 
th
e 
U
se
 o
f 
D
A
LY
s 
in
 C
os
t-
ef
fe
ct
iv
en
es
s 
A
na
ly
se
s 
(c
on
ti
nu
ed
)
APPE N DIX 5
169
P
re
se
nt
at
io
n
C
os
t 
pe
r 
D
A
LY
 a
ve
rt
ed
D
A
LY
s 
pe
r 
in
fe
ct
io
n 
av
er
te
d,
 in
cr
em
en
ta
l
(D
is
co
un
te
d)
 C
os
t 
pe
r 
D
A
LY
of
 D
A
LY
s
co
st
 p
er
 D
A
LY
 s
av
ed
So
ur
ce
 o
f
N
ot
 s
ta
te
d
U
ns
ur
e,
 p
os
si
bl
y 
M
ul
de
r 
19
96
Sa
ck
et
t 
an
d 
To
rr
an
ce
 1
98
7.
 (
U
n)
pu
bl
ish
ed
di
sa
bi
lit
y
st
ud
ie
s 
on
 v
is
ua
l a
cu
it
y 
fo
llo
w
in
g
w
ei
gh
ts
tr
ea
tm
en
t 
an
d 
ra
te
s 
of
 lo
st
/b
ro
ke
n 
gl
as
se
s
So
ur
ce
 o
f 
lif
e
N
ot
 g
iv
en
Ta
nz
an
ia
n 
de
m
og
ra
ph
ic
 d
at
a 
an
d 
W
D
R
 1
99
3
A
nn
ua
l 1
98
0 
m
or
ta
lit
y 
ra
te
 a
m
on
g
ex
pe
ct
an
cy
no
n-
bl
in
d 
N
ep
al
es
e 
fo
r 
po
pu
la
ti
on
 w
it
h
sa
m
e 
ag
e-
se
x 
st
ru
ct
ur
e 
as
 c
at
ar
ac
t 
ba
ck
lo
g.
 
N
at
io
na
l B
lin
dn
es
s 
Su
rv
ey
 a
nd
 o
th
er
s
So
ur
ce
 o
f
N
ot
 m
en
ti
on
ed
U
ns
ur
e,
 p
os
si
bl
y 
M
ul
de
r 
19
96
B
lin
dn
es
s 
is
 a
 s
te
ad
y 
st
at
e,
 o
nl
y 
m
or
ta
lit
y 
se
qu
el
ae
ch
an
gi
ng
.  
Fo
llo
w
in
g 
tr
ea
tm
en
t 
co
ns
id
er
ed
da
ta
 f
ro
m
 v
ar
io
us
 f
ol
lo
w
-u
p 
st
ud
ie
s
Se
ns
it
iv
it
y
N
o
Ye
s,
 d
is
co
un
t 
ra
te
, l
ife
 e
xp
ec
ta
nc
y
Ye
s,
 u
ti
lit
y 
va
lu
e 
an
d 
m
or
ta
lit
y 
ra
te
 w
it
h
an
al
ys
is
 o
n 
D
A
LY
bl
in
dn
es
s,
 a
nd
 d
is
co
un
t 
ra
te
as
su
m
pt
io
ns
?
W
ha
t 
w
er
e
C
os
t 
pe
r 
D
A
LY
 f
or
 a
nt
en
at
al
 a
nd
 d
el
iv
er
y 
ca
re
.  
C
os
t
C
os
t-
ef
fe
ct
iv
en
es
s 
fo
r 
ot
he
r 
pu
bl
ic
 h
ea
lth
C
os
t 
pe
r 
D
A
LY
 f
or
 o
th
er
 in
te
rv
en
ti
on
s 
re
su
lt
s 
co
m
pa
re
d
pe
r 
ca
pi
ta
 p
er
 y
ea
r. 
 S
iz
e 
of
 h
ea
lth
 s
ec
to
r 
bu
dg
et
in
te
rv
en
ti
on
s 
in
 lo
w
 in
co
m
e 
co
un
tr
ie
s 
an
d
fr
om
 o
th
er
 c
ou
nt
ri
es
 a
s 
w
el
l a
s 
W
or
ld
to
?
of
 ‘m
in
im
um
 e
ss
en
ti
al
 c
lin
ic
al
 s
er
vi
ce
s’
B
an
k 
es
ti
m
at
es
 o
f 
co
st
-e
ff
ec
ti
ve
ne
ss
Fu
nd
er
s
N
ot
 s
ta
te
d
A
ID
S 
ta
sk
 f
or
ce
 o
f 
E
U
, U
K
 O
ve
rs
ea
s
N
ot
 s
ta
te
d
D
ev
el
op
m
en
t 
A
dm
in
is
tr
at
io
n,
 G
er
m
an
C
en
tr
e 
fo
r 
In
te
rn
at
io
na
l M
ig
ra
ti
on
, U
K
M
ed
ic
al
 R
es
ea
rc
h 
C
ou
nc
il
M
ai
n 
co
nc
lu
si
on
It
 is
 p
os
si
bl
e 
to
 in
te
gr
at
e 
a 
sh
or
t 
co
ur
se
 Z
D
V
 in
to
C
os
t-
ef
fe
ct
iv
en
es
s 
of
 t
hi
s 
in
te
rv
en
ti
on
 
C
at
ar
ac
t 
su
rg
er
y 
ev
en
 m
or
e 
co
st
-e
ff
ec
ti
ve
ro
ut
in
e 
m
ot
he
r 
an
d 
ch
ild
 h
ea
lth
 s
er
vi
ce
s
co
m
pa
re
s 
fa
vo
ur
ab
ly
 w
it
h 
ch
ild
ho
od
th
en
 p
re
vi
ou
sl
y 
re
po
rt
ed
.  
It
 is
 o
ne
 o
f 
th
e
im
m
un
is
at
io
n
m
os
t 
co
st
-e
ff
ec
ti
ve
 p
ub
lic
 h
ea
lth
in
te
rv
en
ti
on
s
APPE N DIX 5
170
A
ut
ho
rs
H
or
to
n 
et
 a
l. 
Po
lit
i 
et
 a
l.
Sh
ep
ar
d
Ye
ar
 
19
96
19
95
19
94
D
is
ea
se
 f
oc
us
D
ia
rr
ho
ea
l d
is
ea
se
A
fr
ic
an
 G
am
bi
ne
se
 T
ry
pa
no
so
m
ia
si
s
M
ea
sl
es
In
te
rv
en
ti
on
s
B
re
as
t 
fe
ed
in
g 
pr
om
ot
io
n
A
lte
rn
at
iv
e 
dr
ug
 t
he
ra
pi
es
 
E
ar
ly
 o
ne
 d
os
e 
va
cc
in
e
co
ns
id
er
ed
G
eo
gr
ap
hi
ca
l
B
ra
zi
l, 
H
on
du
ra
s,
 M
ex
ic
o
U
ga
nd
a
V
ar
ie
d 
an
d 
w
or
ld
w
id
e
fo
cu
s
Po
pu
la
ti
on
Po
pu
la
ti
on
s 
se
rv
ed
 b
y 
2 
ho
sp
it
al
s 
in
 e
ac
h 
co
un
tr
y 
1,
00
0 
hy
po
th
et
ic
al
 p
at
ie
nt
s 
H
yp
ot
he
ti
ca
l c
oh
or
t 
of
 1
,0
00
 c
hi
ld
re
n 
co
ns
id
er
ed
fr
om
 b
ir
th
 t
o 
ag
e 
59
A
im
 o
f 
pa
pe
r
C
os
t-
ef
fe
ct
iv
en
es
s 
an
al
ys
is
 o
f 
3 
br
ea
st
fe
ed
in
g
C
os
t-
ef
fe
ct
iv
en
es
s 
an
al
ys
is
 o
f 
sw
it
ch
in
g 
dr
ug
s
To
 d
is
cu
ss
 a
llo
ca
ti
on
 o
f 
re
so
ur
ce
s 
pr
om
ot
io
n 
pr
og
ra
m
m
es
 w
it
h 
ot
he
r 
he
al
th
in
 t
re
at
in
g 
la
te
 s
ta
ge
 s
le
ep
in
g 
si
ck
ne
ss
am
on
g 
im
pl
em
en
ta
ti
on
, o
pe
ra
ti
on
s 
in
te
rv
en
ti
on
s
re
se
ar
ch
 a
nd
 v
ac
ci
ne
 r
es
ea
rc
h
D
A
LY
 t
yp
e
M
ar
k 
1 
(b
ut
 o
nl
y 
Y
LL
s)
M
ar
k 
1
M
ar
k 
1
D
is
ab
ili
ty
 w
ei
gh
t
N
ot
 s
ta
te
d
N
ot
 s
ta
te
d
N
ot
 s
ta
te
d 
– 
po
ss
ib
ly
 n
on
e
A
ge
 w
ei
gh
t
N
ot
 s
ta
te
d 
bu
t 
pr
es
um
ab
ly
 0
.0
4 
be
ca
us
e 
ci
te
d
N
ot
 s
ta
te
d
N
o
19
93
 W
D
R
D
is
co
un
t 
ra
te
 
3 
pe
rc
en
t
N
ot
 s
ta
te
d
N
ot
 s
ta
te
d
D
A
LY
s 
[0
.0
3,
 1
,
U
nc
le
ar
N
ot
 c
le
ar
N
o
0.
04
] 
pr
es
en
te
d?
L
if
e 
ex
pe
ct
an
cy
80
SE
Y
LL
 (
81
 y
ea
rs
 a
t 
bi
rt
h)
N
ot
 s
ta
te
d
P
re
se
nt
ia
to
n 
of
C
os
t 
pe
r 
D
A
LY
 a
ve
rt
ed
C
os
t 
pe
r 
D
A
LY
 a
ve
rt
ed
, a
dd
it
io
na
l D
A
LY
s
D
A
LY
s 
av
er
te
d,
 c
os
t 
pe
r 
D
A
LY
 a
ve
rt
ed
D
A
LY
s
av
er
te
d
Ta
bu
la
r 
R
ev
ie
w
 o
f 
th
e 
U
se
 o
f 
D
A
LY
s 
in
 C
os
t-
E
ff
ec
ti
ve
ne
ss
 A
na
ly
se
s 
(c
on
ti
nu
ed
)
APPE N DIX 5
171
So
ur
ce
 o
f
N
o 
w
ei
gh
ti
ng
 f
or
 d
is
ab
ili
ty
 
U
nc
le
ar
 –
 p
os
si
bl
y 
on
ly
 m
or
ta
lit
y 
N
ot
 a
pp
lic
ab
le
di
sa
bi
lit
y
w
ei
gh
ts
So
ur
ce
 o
f 
lif
e
W
D
R
 1
99
3,
 a
nd
 V
ic
to
ra
 e
t 
al
. 1
98
7+
19
89
 a
nd
 o
th
er
W
D
R
U
nc
le
ar
ex
pe
ct
an
cy
lit
er
at
ur
e
So
ur
ce
 o
f
U
nc
le
ar
U
nc
le
ar
U
nc
le
ar
se
qu
el
ae
Se
ns
it
iv
it
y
N
o
N
o
N
o
an
al
ys
is
 o
n
D
A
LY
as
su
m
pt
io
ns
?
W
ha
t 
w
er
e
C
os
t 
pe
r 
de
at
h 
av
er
te
d 
fo
r 
m
ea
sl
es
, r
ot
av
ir
us
 a
nd
W
or
ld
 B
an
k’
s 
ra
ng
e 
of
 ‘g
oo
d 
bu
ys
’. 
Po
te
nt
ia
l
W
or
ld
 B
an
k 
cu
t-
of
f 
po
in
ts
re
su
lt
s 
co
m
pa
re
d
ch
ol
er
a 
im
m
un
is
at
io
n,
 o
ra
l r
e-
hy
dr
at
io
n 
th
er
ap
y,
fin
an
ce
s 
av
ai
la
bl
e 
fo
r 
fu
nd
in
g
to
?
hy
gi
en
e 
pr
om
ot
io
n 
an
d 
fo
rm
ul
a 
fe
ed
.  
C
os
t 
pe
r
D
A
LY
 e
st
im
at
es
 f
ro
m
 1
99
3 
W
D
R
Fu
nd
er
s
U
SA
ID
W
H
O
W
H
O
 a
nd
 R
oc
ke
fe
lle
r 
Fo
un
da
ti
on
M
ai
n 
co
nc
lu
si
on
B
re
as
tf
ee
di
ng
 s
ho
ul
d 
be
 p
ro
m
ot
ed
 in
 c
ou
nt
ri
es
 w
he
re
M
el
ar
so
po
l s
av
es
 li
ve
s 
at
 lo
w
 c
os
t, 
bu
t 
w
it
h
G
re
at
er
 %
 o
f 
ex
is
ti
ng
 r
es
ou
rc
es
 s
ho
ul
d
it
 is
 n
ot
 w
id
el
y 
pr
ac
ti
se
d 
in
 e
ar
ly
 m
on
th
s 
an
d 
w
he
re
si
de
 e
ff
ec
ts
.  
W
ill
in
ge
ss
 o
f 
do
no
rs
/g
ov
er
nm
en
t
go
 o
n 
R
C
T
s,
 t
o 
va
cc
in
e 
de
ve
lo
pm
en
t
m
os
t 
w
om
en
 g
iv
e 
bi
rt
h 
in
 h
ea
lth
 f
ac
ili
ti
es
to
 p
ay
 a
ff
ec
ts
 c
ho
ic
e 
of
 in
te
rv
en
ti
on
fo
r 
ea
rl
y 
m
ea
sl
es
 v
ac
ci
ne
s 
an
d 
be
fo
re
/a
ft
er
 
st
ud
ie
s 
of
 e
xi
st
in
g 
st
ra
te
gi
es
N
ot
e:
W
D
R
 =
 W
or
ld
 D
ev
el
op
m
en
t 
R
ep
or
t.
APPE N DIX 5
172
Interpreting and Addressing Inequalities in Health: from Black to Acheson to Blair
to…?
by Robert Evans, 2002 (price £7.50)
The Life Cycle of Pharmaceuticals: a Cross-national Perspective
by Patricia Danzon and Jeong Kim, 2002 (price £10.00)
Health Economics: An Introduction to Economic Evaluation (2nd edition)
by Gisela Kobelt, 2002 (price £5.00)
The Links of Public Health and Economic Development
by Professor Jeffrey Sachs, 2001 (price £5.00)
Applied Econometrics for Health Economists – a Practical Guide
by Andrew Jones, 2001 (price £10.00)
Consolidation and Competition in the Pharmaceutical Industry
ed. Hannah Kettler, 2001 (price £10.00)
Don’t Look Back? Voluntary and Charitable Finance of Hospitals in Britain, Past and
Present
by John Mohan and Martin Gorsky, 2001 (price £10.00)
Capturing the Unexpected Benefits of Medical Research
ed. Clive Pritchard, 2001 (price £10.00)
The Economics of the Private Finance Initiative in the NHS
by Jon Sussex, 2001 (price £10.00)
Why Care about Health Inequality?
by Adam Oliver, 2001 (price £7.50)
Health Care Without Frontiers? The Development of a European Market in Health
Services?
by Lyndsay Mountford, 2000 (price £10.00)
Productivity Costs: Principles and Practice in Economic Evaluation
by Clive Pritchard and Mark Sculpher, 2000 (price £10.00)
Improving Population Health in Industrialised Nations
ed. Jon Sussex, 2000 (price £10.00)
RECENT OHE PUBLICATIONS
